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Medicine is not only a science; it is also an art. 
It does not consist of compounding pills and 
plasters; it deals with the very processes of life, 
which must be understood before they may be guided. 
 
-Paracelsus 
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ABSTRACT 
Obesity is one of the biggest health risks of our society today; however, 
treatment options are sparse and most pharmaceutical manipulations result in 
suboptimal weight-loss outcomes. The development of more effective treatment 
options for this disease is therefore crucial. The glucagon-like peptide-1 (GLP-1) 
receptor (GLP-1R) agonist liraglutide was recently approved for the treatment 
of obesity in the US. GLP-1, and synthetic analogues of the peptide, reduce 
body weight by suppressing food intake and food reward through actions on 
GLP-1Rs in the central nervous system. The regulation of homeostatic feeding 
by GLP-1 was previously thought to be mediated through actions within the 
hypothalamus, while its effects on food reward were attributed to actions within 
the limbic system. Our studies challenge this view and demonstrate novel central 
areas which mediate the effects of GLP-1R stimulation on food intake and 
reward. 
Using standard food intake and body weight measurements, in addition to tests 
of reward behavior, such as the operant conditioning and conditioned place 
preference tests, we demonstrate that GLP-1R stimulation, using the GLP-1R 
agonist exendin-4 (Ex4), reduces food intake and food reward behavior through 
actions in the nucleus of the solitary tract (NTS) and lateral hypothalamus (LH). 
Using a transgenic mouse line expressing fluorescent YFP-preproglucagon 
neurons, NTS GLP-1 neurons were found in close proximity to noradrenergic 
neurons, providing a potential connection to the mesolimbic system. Intra-NTS 
Ex4 injection also led to an increase in dopamine-related genes in the ventral 
tegmental area; further suggesting a link between the NTS and the reward 
system in which GLP-1 can alter reward-related behavior. In addition, the 
parabrachial nucleus (PBN) was identified as a novel area mediating the anorexic 
effects of GLP-1R stimulation. 
Sex differences have been implicated in the regulation of reward, and the 
sensitivity of several ingestive hormones has been shown to differ between 
 males and females. However, potential differences in the actions of GLP-1 on 
food reward were previously unknown. Central GLP-1R stimulation led to 
increased suppression in food-motivated behavior in females compared to 
males. In addition, central estrogen blockade, and blockade of estrogen 
receptor-α (ERα) specifically, attenuated the effects of Ex4 on food reward, but 
not food intake. Therefore, these data suggest that central ERα signaling is 
necessary for the actions of GLP-1 on food-reward behavior in both sexes, 
while females display a much higher sensitivity to the food reward impact of 
central GLP-1R activation. Moreover, we also show that the actions of intra-LH 
GLP-1R stimulation on food-reward behavior are regulated in a sex divergent 
manner, where GLP-1R stimulation is sufficient to reduce food-motivated 
behavior in both sexes, but only necessary in males. In addition to food reward, 
Ex4 treatment in the LH also induced a robust reduction in food intake and 
body weight in a sex-dependent manner; chronic knockdown of LH GLP-1Rs, 
using an adeno-associated virus (AAV)-short hairpin RNA targeting GLP-1R 
transcripts, increased ingestive behavior and body weight in both sexes, but only 
increased food-motivated behavior in males. 
In conclusion, the effects of GLP-1, and its synthetic agonists, on food intake 
and food reward are not bound to actions on GLP-1R exclusively within 
homeostatic or hedonic feeding centers, respectively. In contrast, GLP-1 can 
also exert its actions on food reward by acting in classic homeostatic centers, 
such as the NTS and the LH. In addition, a novel site of action was identified 
for GLP-1’s actions on food intake: the PBN. Furthermore, GLP-1-mediated 
food reward, but not food intake, suppression is dependent on estrogen 
signaling, with a higher sensitivity to its actions in females. However, GLP-1 
may also act differently within specific brain nuclei to regulate food-motivated 
behavior, as LH GLP-1R stimulation is sufficient to reduce food-reward in both 
sexes, while it only seems to be necessary for its actions in males.  
Keywords: Glucagon-like peptide-1, Food reward, Food intake, Sex differences. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Övervikt och fetma är växande folkhälsoproblem, både i Sverige och i resten 
utav världen. Tillståndet är även ofta associerad med andra åkommor, såsom en 
ökad risk för hjärt- och kärlsjukdomar, typ 2 diabetes, och särskilda 
cancerformer. Trots att andelen överviktiga nästan fördubblats under de senaste 
20 åren finns ännu ingen effektiv behandling mot denna sjukdom. 
År 2014 godkändes läkemedlet liraglutide för behandling av övervikt i USA på 
grund av dess aptitdämpande och viktminskande effekter. I Sverige, och övriga 
delar av världen, används det främst för behandling av typ II diabetes på grund 
av dess blodsockerreglerande egenskaper. Liraglutide är en syntetisk variant av 
det kroppsegna hormonet glucagon-like peptide-1 (GLP-1), som frisätts från 
tarmen vid födointag och bidrar till en ökad mättnadskänsla genom att verka på 
det centrala nervsystemet. GLP-1 kan även produceras lokalt i hjärnan, främst i 
nucleus of the solitary tract (NTS). 
Utöver dess aptitdämpande effekt, har GLP-1 även visat sig kunna inverka på 
hjärnans belöningssystem för att minska den belönande upplevelsen av föda, 
särskilt vid intag av kaloririka livsmedel med hög andel fett och socker. Trots att 
läkemedel som innehåller syntetiska varianter av detta hormon används flitigt 
runtom i världen, är mekanismerna bakom dess aptit- och belöningsdämpande 
effekter ännu inte fullt utredda. Dessutom har dess effekter och specifika 
mekanismer ej utretts i honor/kvinnor, trots indikationer att kvinnor reglerar 
både födointag och belöning på ett annorlunda sätt än män. Vår forskning 
ämnade därför utreda de specifika hjärnområdena och mekanismer som ligger 
bakom de aptit- och belöningsdämpande effekterna av GLP-1 och GLP-1-
baserad behandling, samt undersöka potentiella könskillnader i dessa effekter. 
Dessa punkter studerades med hjälp av djurexperimentella modeller. 
Med hjälp av det GLP-1-baserade läkemedlet exendin-4 (Ex4) identifierade vi 
två nya hjärnområden som förmedlar hormonets/läkemedlets effekter på födo-
associerad belöning: NTS och lateral hypothalamus (LH), samt ett nytt område 
som reglerar dess matintagsdämpande effekter: parabrachial nucleus (PBN). 
NTS och LH är klassiska födointagsrelaterande center, men GLP-1s 
belöningsreducerande effekt i dessa områden var tidigare okända. För att 
undersöka hormonets påverkan på dessa effekter använde vi oss utav två 
klassiska belöningstest: operant betingning (operant conditioning) och 
konditionerad plats preferens (conditioned place preference; CPP). Testen mäter 
motivation för att erhålla en belöning (i detta fallet belönande föda), samt 
utvärderar drogens förmåga att påverka matens belönande egenskaper. 
Dessutom mättes djurens kroppsvikt och födointag av vanlig och belönande 
föda i respons till Ex4 behandling. Genom att använda oss av transgena möss 
kunde vi även påvisa förekomsten av GLP-1 fibrer i dessa områden, vilket tyder 
på att förutom läkemedel, kan kroppseget GLP-1 även verka i områdena. Man 
 fann även att GLP-1 nervceller i NTS med stor sannolikhet är kopplat till, och 
påverkar, belöningssystemet.  
GLP-1s effekter på födo-associerad belöning visade sig även vara beroende av 
könshormonet östrogen. Östrogen bildas i könskörtlarna hon kvinnor 
(äggstockarna) och män (testiklarna), samt i hjärnan. GLP-1 behandling verkade 
belöningsdämpande i både honor och hanar, dock i högre grad i honor; denna 
effekt visade sig även förmedlas via östrogen receptor alpha (Erα). Man fann 
inga skillnader i Ex4s effekter på födointag. Vidare fann man även att GLP-1s 
belöningshämmande effekter på mat regleras annorlunda i honor och hanar 
specifikt i hjärnområdet LH. Stimulering av GLP-1 receptorer i LH reducerade 
födoämnesbelöning i båda könen; dock är hormonets effekter på det här 
beteendet nödvändig i hanar och blockering av de här receptorerna påverkar 
därför inte födoämnesbelöning i honor. Man fann inga könsskillnader på 
matintag efter Ex4 behandling i LH. 
Sammanfattningsvis identifierar forskningen i denna avhandling två nya 
områden som medverkar i de reducerande effekterna av GLP-1 på födointag 
och födoassocierad belöning: NTS och LH, samt ett område som förmedlar 
hormonets effekter på matintag: PBN. Forskningen ökar även kunskapen om ett 
flertal mekanismer genom vilka GLP-1 kan förmedla dess kroppsviktsreglerande 
effekter. Dessutom fann vi även könskillnader i hormonets effekt på 
födoämnesbelöning, medan regleringen av matintag inte påverkades av kön, 
eller könshormonet östrogen. Våra fynd bidrar därmed till utvecklingen av mer 
effektiva behandlingsmetoder mot övervikt, samt bättre insyn i de mekanismer 
som existerande GLP-1-baserade behandlingar verkar igenom. Fynden tyder 
även på att läkemedel av denna sort kan behöva anpassas beroende på kön för 
att säkerställa effektiv behandling samt undvika onödiga biverkningar.
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OVERWEIGHT AND OBESITY 
Obesity is a chronic medical condition that currently kills more people 
worldwide than underweight and undernutrition. The condition also increases 
the risk for other serious diseases such as type II diabetes, cardiovascular 
diseases and cancer. According to the World Health Organization (WHO) more 
than 1.9 billion adults were overweight worldwide in 2016, and over 650 million 
were obese. 
Obesity is primarily attributed to excessive energy intake, often through the 
intake of high-fat/high-sugar foods, which exceeds energy expenditure. Excess 
energy is stored as lipids in the adipose tissue in various fat depots around the 
body, and its regulation and organization can differ based on sex. 
Energy intake refers to the amount of energy that we ingest through food (in 
the form of proteins, carbohydrates and fat), and is commonly measured in 
calories (cal) or joule (J). The standard daily recommended energy intake for 
women is 2000 kcal (8400 kJ), and 2500 kcal (10500 kJ) for men. Energy 
expenditure is determined mainly by the energy required to uphold our resting 
metabolic rate, and the energy that we expend through physical activity. 
An individual’s body mass state can roughly be determined using the body mass 
index (BMI), which is calculated by dividing an individual’s body weight in 
kilograms (kg) by the square of their height in meters (m; BMI (kg/m2) = mass/ 
height2). Commonly, an individual with a BMI lower than 18.5 kg/m2 is 
considered underweight, between 18.5 and 25 kg/m2 normal weight, 25-30 
kg/m2 overweight and >30 kg/m2 obese. 
Energy intake is driven by our feeding behavior, which is controlled by the 
homeostatic and hedonic food intake regulating systems. These systems are 
coordinated through an intricate interplay of anorexic and orexigenic peptides 
which act within the gut, as well as in the central nervous system (CNS). 
Central targets for the effects of glucagon-like peptide-1 on food intake and reward 
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FOOD INTAKE AND BODY WEIGHT 
REGULATION 
THE HOMEOSTATIC SYSTEM 
Appetite and body weight are regulated by two intertwined neural pathways: 
homeostatic and hedonic (Berthoud, 2011; Saper et al., 2002). The homeostatic 
system ensures that energy balance is maintained; i.e. eating when energy stores 
are depleted, and refraining from eating when adequate energy is present. This 
process is regulated by an intricate array of anorexigenic (e.g. leptin, insulin, 
glucagon-like peptide-1 (GLP-1), estradiol) and orexigenic (e.g. ghrelin, 
neuropeptide-Y (NPY), agouti-related peptide (AgRP)) molecules produced in 
the periphery and within the central nervous system (CNS) (Figure 1). These 
peptides will be discussed briefly below. 
 Representative image of peripheral signals and brain areas involved in the homeostatic regulation of food Figure 1.
intake. PYY = peptide YY, CCK = cholecystokinin, GLP-1 = glucagon-like peptide-1, PVN = paraventricular 
nucleus, LH = lateral hypothalamus, VMH = ventromedial hypothalamus, DMH = dorsomedial hypothalamus, 
PBN = parabrachial nucleus, NTS = nucleus of the solitary tract. Image modified after composing illustrations 
from Wikimedia Commons and Public Domain Files. 
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MOLECULES INVOLVED IN FOOD INTAKE 
REGULATION 
GHRELIN 
Ghrelin, “the hunger hormone”, was discovered in 1999 by Kojima et al. 
(Kojima et al., 1999). Circulating ghrelin levels are high during fasting, and levels 
rise in response to weight loss (Ariyasu et al., 2001; Cummings et al., 2004; 
Yoshimoto et al., 2002).  
Ghrelin is produced in the stomach; it is released in the hunger state and 
stimulates feeding by acting on its receptor, the growth hormone secretagogue 
receptor (GHS-R) located within the arcuate nucleus (ARC), on NPY/AgRP 
neurons. These neurons are inhibitory and synapse on POMC neurons which 
inhibit food intake through the synthesis of melanocortin peptides; ghrelin 
therefore acts to promote feeding by removing these inhibitory signals 
(Nakazato et al., 2001) (Figure 2). In addition to stimulating food intake in 
response to hunger, ghrelin has also been suggested to play a role in stress-
induced feeding. Rodents with increased caloric intake, due to chronic social 
defeat, display increased plasma ghrelin concentrations, and ghrelin secretion in 
humans is also increased in individuals prone to stress-induced feeding 
(Patterson et al., 2013; Raspopow et al., 2010, 2014). The increased caloric 
intake in response to stress is driven selectively by an increase in the intake of 
high carbohydrate-containing foods (Patterson et al., 2013; Schele et al., 2016). 
In addition to appetite, ghrelin also reduces fat utilization and increases 
adiposity (Tschop et al., 2000).  
 Schematic scheme of the regulation of food intake through the actions of hormones ghrelin, leptin and Figure 2.
insulin on NPY/AgRP and POMC neurons. NPY = neuropeptide Y, AGRP = agouti-related peptide, POMC 
= proopiomelanocortin, DMH = dorsomedial hypothalamus LH = lateral hypothalamus, NTS = nucleus of the 
solitary tract, PBN = parabrachial nucleus, PVN = paraventricular nucleus, VMH = ventromedial 
hypothalamus. 
Central targets for the effects of glucagon-like peptide-1 on food intake and reward 
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LEPTIN 
Leptin is a hormone secreted by the adipose tissue; it plays a key role in energy 
balance regulation by informing the brain of the body’s energy storage level, as 
leptin is proportionately secreted in regard to body fat mass. It acts in a 
regulatory manner on body weight by limiting energy intake and promoting 
energy expenditure when adiposity is high (high circulating leptin), and 
promoting food intake, reducing energy expenditure and increasing fat 
accumulation when leptin levels are low (Cohen et al., 2001; Morton et al., 2006; 
Zhang et al., 1994). 
Leptin regulates energy balance by acting on its receptor, OB-R, which is 
located within the hypothalamus, in areas such as the lateral hypothalamus (LH), 
paraventricular nucleus (PVN), ventromedial hypothalamus (VMH),  and ARC 
(Morton et al., 2006). As for ghrelin, many of leptin’s effects are mediated by 
actions on its receptors on NPY/AgRP and POMC neurons. However, contrary 
to ghrelin, leptin suppresses the activity of NPY/AgRP neurons and increases 
the activity of POMC neurons; increased synthesis of melanocortin peptides by 
POMC neurons therefore results in a reduction in food intake (Morton et al., 
2006).  
Besides the hypothalamus, leptin also acts within the hindbrain (in the nucleus 
of the solitary tract; NTS), and within several structures of the limbic system, 
such as the hippocampus, amygdala, ventral tegmental area (VTA) and LH to 
reduce food intake (Figlewicz et al., 2003; Kanoski et al., 2011b; Leinninger and 
Myers, 2008; Leshan et al., 2006; Suarez et al., 2019). 
INSULIN 
Insulin is secreted from pancreatic β-cells and is crucial in the regulation of 
energy and glucose homeostasis (Prentki et al., 2013). In addition to its 
peripheral effects on hepatic glucose production and secretion, insulin also acts 
within the brain to regulate glucose and energy homeostasis (Belgardt and 
Bruning, 2010). Like leptin, insulin is an anorexigenic hormone that acts within 
the brain to convey the body’s adiposity level (Kennedy, 1953). 
The effects of insulin on food intake and body weight are mainly attributed to 
its actions on insulin receptors located within the hypothalamus (Bruning et al., 
2000; McGowan et al., 1992; Obici et al., 2002; Strubbe and Mein, 1977). Insulin 
receptor expression is high in the ARC, and its receptors can be found on both 
NPY/AgRP and POMC neurons (Benoit et al., 2002; Carvalheira et al., 2005). 
Leptin and insulin have been shown to act in concert to inhibit NPY/AgRP 
neurons and therefore reduce food intake. 
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CCK 
CCK was the first anorexigenic gut hormone discovered (Gibbs et al., 1973). 
The hormone is secreted from cells within the duodenum and small intestine; it 
binds to CCK receptors on the vagus nerve terminal, which relays the 
information to the hypothalamus via the NTS and parabrachial nucleus (PBN) 
(Liddle et al., 1985). There are two different subtypes of CCK with distinct 
locations of expression; CCK-A is primarily expressed in the gastrointestinal 
tract, while CCK-B is primarily expressed in the CNS (Wank, 1995). Central 
CCK receptors can be found within the hippocampus, cerebral cortex, and 
striatum, in addition to the NTS (Beinfeld, 2001). The central actions of CCK 
on food intake are mainly attributed to its effects on receptors within the 
brainstem (Aja et al., 2001). 
PEPTIDE YY3-36 (PYY3-36) 
PYY is co-secreted with GLP-1 in the intestinal L-cells in response to food 
intake; it is rapidly metabolized in the circulation to PYY3-36 by dipeptidyl 
peptidase IV (DPP-IV), and acts to reduce food intake and body weight 
(Batterham et al., 2002). The effects of PYY3-36 on food intake are mainly 
attributed to the actions of the hormone within the hypothalamus; peripheral 
injection of PYY3-36 induces neuronal activation in the ARC, and decreases the 
expression of hypothalamic NPY mRNA. Furthermore, intra-ARC injection of 
PYY3-36 directly inhibits food intake by inhibiting NPY/AgRP neurons (Michel 
et al., 1998). Besides ARC, the PYY3-36 receptor, Y2, is also expressed in the 
preoptic nucleus, dorsomedial hypothalamus (DMH), amygdala, substantia 
nigra, PBN and NTS (Dumont et al., 1998; Gustafson et al., 1997). 
In addition to the food intake regulating hormones and molecules above, the 
anorexigenic peptide GLP-1 is also an important regulator of food intake and 
body weight. The role of GLP-1 in energy homeostasis will be discussed in 
further detail below. 
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BRAIN AREAS INVOLVED IN FOOD INTAKE 
REGULATION 
Two of the classic brain areas involved in homeostatic food intake regulation, 
the hypothalamus and the brainstem, are located in close proximity to the 
brain’s ventricles, which contain cerebrospinal fluid (CSF), and receive 
peripherally transferred food intake-regulating signals via areas characterized by 
more permeable blood-brain barriers, called circumventricular organs. 
HYPOTHAMALUS 
The hypothalamus has long been depicted as “the feeding center”. Early studies 
by Anand and Brobreck demonstrated that lesioning the VMH led to a 
significant increase in food intake, while lesioning the ventral LH led to 
starvation and malnutrition (Anand and Brobeck, 1951a, b). 
The LH is one of the most interconnected areas of the hypothalamus, receiving 
and sending projections to and from many important food intake regulating 
areas, such as the NTS, amygdala and nucleus accumbens (NAc), in addition to 
other hypothalamic nuclei (Berk and Finkelstein, 1982; Elias et al., 1999; Elias et 
al., 1998; Ricardo and Koh, 1978; Simerly, 1995; Ter Horst et al., 1989; Ter 
Horst and Luiten, 1987). 
The LH contains three distinct neuronal cell types known to regulate food 
intake behavior: orexin/hypocretin, melanin-concentrating hormone (MCH) 
and neurotensin neurons. The LH is the sole area in the CNS that synthesizes 
and releases the orexigenic neuropeptide orexin; orexin increases food intake 
through its actions within the brain (Harrison et al., 1999; Sakurai, 1999). The 
effects of orexin are thought to be mediated partly through actions on its 
receptors in hypothalamic subregions, such as the DMH, and within the LH 
itself (Dube et al., 1999; Sweet et al., 1999). Orexin neurons also project to 
several other food intake-regulating areas, which also contain orexin receptors, 
such as the NTS (Hervieu et al., 2001; Marcus et al., 2001; Peyron et al., 1998; 
Zheng et al., 2005). Injection of orexin into the hindbrain has been shown to 
increase meal size, and intra-NTS injection selectively increases the intake of 
high-fat foods (Baird et al., 2009; Kay et al., 2014; Parise et al., 2011). The LH 
also contains MCH producing neurons, which project to a wide array of central 
areas, such as the striatum, thalamus, cerebral cortex, midbrain and brainstem 
(Bittencourt et al., 1992; Broberger et al., 1998). MCH is an orexigenic hormone; 
central injection of the peptide increases food intake and body weight (Qu et al., 
1996). Furthermore, overexpression of MCH leads to hyperphagia and 
subsequently obesity, while knockout of the peptide leads to reduced food 
intake (Alon and Friedman, 2006; Shimada et al., 1998). Neurotensin neurons 
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also reside within the LH, and have been hypothesized to play role in energy 
balance regulation. Both peripheral and central administration of neurotensin 
reduce food intake; in addition, ablation of these neurons, or knockout of its 
receptor, leads to hyperphagia and obesity (Cooke et al., 2009; Kim et al., 2008; 
Leinninger et al., 2011). 
The LH integrates a wide array of molecular signals that regulate food intake, 
such as glucose, insulin, leptin, ghrelin, GLP-1 and PYY3-36 (Berthoud and 
Munzberg, 2011). 
Subsequent research has identified several other important food intake 
regulating hypothalamic nuclei, such as the ARC, PVN and DMH. As 
mentioned above ARC contains NPY/AgRP and POMC neurons, which act to 
stimulate, or inhibit, food intake through the actions of various hormones. The 
PVN also contains POMC neurons, and destruction of this area leads to 
overeating (Leibowitz et al., 1981). Furthermore, deletion of the hypothalamic 
nucleus DMH reduces food intake (Bellinger and Bernardis, 2002). 
NTS 
The NTS is located in the caudal brainstem, ideally positioned to mediate food 
intake regulating signals between the periphery and the CNS. The rostral region 
of the NTS sends gustatory signals to the forebrain, facilitating taste recognition, 
while the caudal NTS integrates viscerosensory information (Travagli et al., 
2006). It receives afferent connections from the vagal nerve which innervates 
most of the gastrointestinal system, making it possible for the NTS to sense 
gastric distension, and rapidly release anorexic signals (such as leptin, CCK and 
GLP-1) in response to food intake (Andresen and Kunze, 1994; Cassidy and 
Tong, 2017).  
The NTS contains several different neuronal cell types involved in food intake 
regulation, for instance catecholamine, POMC and GLP-1 neurons (Rui, 2013). 
NTS catecholamine neurons respond to anorexigenic and orexigenic hormones 
from the periphery, such as CCK, which activates these neurons to reduce food 
intake, and ghrelin, which inhibits catecholamine neurons to stimulate food 
intake (Appleyard et al., 2007; Cui et al., 2011). In addition to catecholaminergic 
neurons, CCK can also act on POMC neurons within the NTS to reduce food 
intake (Fan et al., 2004). The NTS is also the major CNS producer of GLP-1; 
which, apart from the NTS, is only produced in a small population of 
interneurons in the olfactory bulb and in the intermediate reticular nucleus 
(Merchenthaler et al., 1999; Thiebaud et al., 2016; Vrang and Larsen, 2010). The 
actions of GLP-1 on food intake will be discussed in further detail below. 
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As an important integrator of peripheral and central signals, the NTS mediates 
the energy balance effects of a wide array of vagal and endocrine signals and, in 
addition to integrating them, relays them to other important central food intake 
regulating areas, such the hypothalamus and PBN. In addition it also projects to 
reward-related areas such as the NAc and the VTA, both through direct 
projections or via the hypothalamus (Alhadeff et al., 2012; Travagli et al., 2006), 
which creates a neuroanatomical pathway for direct brainstem influence on 
reward behaviors. 
PBN 
Of the many brain areas which receive connections from the NTS, the PBN is 
one of its major targets, relaying information to other food intake regulating 
brain areas, such as the hypothalamus and amygdala (de Araujo, 2009; Herbert 
and Saper, 1990; Jhamandas and Harris, 1992; Palmiter, 2018; Wu et al., 2012). 
The PBN, located within the dorsolateral pons, integrates viscerosensory 
information, such as satiety, malaise and taste (Berridge and Pecina, 1995; 
Palmiter, 2018; Swank and Bernstein, 1994; Yamamoto, 2006).  
Several neuropeptides act in this area to regulate feeding; for example, injection 
of melanocortin or prostaglandin agonists in the PBN leads to a reduction in 
food intake behavior (Skibicka et al., 2011a; Skibicka and Grill, 2009), while 
injection of cannabinoid or µ-opioid agonists increases feeding (DiPatrizio and 
Simansky, 2008; Wilson et al., 2003). In addition, disturbed balance of PBN 
input signals of γ-aminobutyric acid (GABA) and glutamate, the major 
excitatory and inhibitory neurotransmitters in the brain leads to starvation in 
mice (Carter et al., 2013; Wu et al., 2009; Wu and Palmiter, 2011; Wu et al., 
2013).  
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SEX DIFFERENCES IN FOOD INTAKE 
REGULATION 
More women than men are overweight and obese worldwide (Chooi et al., 
2019). In addition, men and women have differential patterns of body fat 
distribution. While men primarily tend to accumulate fat viscerally, within the 
abdominal cavity, women commonly accumulate fat subcutaneously, around the 
buttocks, thighs and hips (Demerath et al., 2007; Kotani et al., 1994). This 
difference is abolished through ovariectomy, the removal of the ovaries; the 
main source of steroidal sex hormones in females (Simpson, 2003). In addition 
to a shift in the location of fat storage, removal of the ovaries also leads to a 
marked increase in adipose tissue, an effect mainly attributed to the reduction of 
the hormone estrogen (Stotsenburg, 1913). 
Steroid hormones, such as estrogen, progesterone and testosterone, are all 
produced from cholesterol. Both men and women produce steroid hormones, 
albeit at different levels, and these hormones mediate various physiological 
functions in both sexes, such as reproduction, inflammation and metabolism. 
The gonads are the major source of these hormones; where the ovaries are the 
primary production site in females, and the testes the primary source in men 
(Baggett et al., 1959; Brook, 1999). 
In women, the levels of specific gonadal steroid hormones vary over the course 
of approximately 28 days. This cycle, the menstrual cycle, is divided into 3 
phases: follicular, periovulatory and luteal (Figure 3). The follicular phase begins 
with menstruation, where the levels of all four of the main female gonadal 
hormones, luteinizing hormone (LuH), follicle-stimulating hormone (FSH), 
estradiol and progesterone, are low. However the level of estradiol, the main 
estrogen, begins to rise during this cycle phase, reaching its peak in the 
periovulatory phase, where it dramatically drops, almost to baseline. The 
periovulatory phase is characterized by a surge in FSH and LuH, where the 
sudden surge in LuH is necessary for ovulation (the release of the egg or ovum) 
to occur. Following the LuH and FSH surges, estradiol and progesterone levels 
begin to rise, but decline again if fertilization hasn’t occurred (the fusion of the 
egg and sperm) (Hawkins and Matzuk, 2008). 
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 Representative plots of the human menstrual cycle and rat estrous cycle phases. Each phase is characterized by Figure 3.
different levels of the gonadal hormones estradiol, progesterone, luteinizing hormone (LuH) and follicle-stimulating hormone 
(FSH). Figure derived from (Donner and Lowry, 2013). 
In rodents, the estrous cycle is comprised of 4 cycle phases: diestrus (or diestrus 
II), proestrus, estrus and metaestrus (or diestrus I), which take place during a 4-5 
day time period (Figure 3). As in the human follicular phase, the levels of 
estradiol, LuH and FSH are low in diestrus; however, in rodents, progesterone 
levels are high at the beginning of diestrus, and lfall prior to proestrus. Estradiol 
levels are also on the rise during this phase. All four hormones reach their peak 
in proestrus, and subsequently fall to baseline in the estrus phase, during which 
ovulation occurs. The levels of estradiol, progesterone and FSH slowly begin to 
rise again during metaestrus (Asarian and Geary, 1999).  
While the steroidal hormones involved in reproduction are mainly produced in 
the gonads, these hormones can also be produced in several other areas, such as 
the adipose tissue and within the brain (Mellon et al., 2001). Brain derived 
hormones are commonly referred to as neurosteroids and are involved in several 
biological functions, such as neural plasticity, learning, memory, and 
psychological disorders e.g. anxiety and depression (Engel and Grant, 2001).  
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Neurosteroids have been shown to alter feeding behavior, and estrogens play a 
key role in the regulation of food intake and body weight. As mentioned above, 
removal of the ovaries leads to a marked increase in body weight, an effect 
which can be counteracted by the injection of the estrogen β-estradiol (Drewett, 
1973; Simpson, 2003; Wade, 1975). In addition to body weight, estrogens have 
also been shown to directly regulate food intake. Food intake varies due the 
fluctuating levels of estradiol during the ovarian cycle, with reduced food intake 
in cycle phases where estrogen signaling is high (Czaja and Goy, 1975; Eckel, 
2004; Gong et al., 1989; Houpt et al., 1979). Estrogens’ effects on food intake 
and body weight are mediated by actions on the estrogen receptor (ER). There 
are two main types of nuclear estrogen receptors: estrogen receptor-α (ERα) and 
estrogen receptor-β (ERβ) (Deroo and Korach, 2006; Nilsson and Gustafsson, 
2011). Activation of nuclear ER leads to binding of estrogen-response elements, 
which further bind to DNA to affect gene expression; a process which can take 
hours to days (Cheskis et al., 2007; Heldring et al., 2007). In addition, ERs can 
also be expressed outside the nucleus, on the cell membrane (Mendelsohn and 
Karas, 2010; Vasudevan and Pfaff, 2007). ER signaling kinetics can react to 
incoming stimuli from paracrine, autocrine and endocrine signals. 
ERs play an important role in the homeostatic regulation of body weight. Whole 
body knock-out of ERα leads to increased body weight in both male and female 
mice (Heine et al., 2000). Moreover, specific knock-down of ERα in the VMH 
leads to increased body weight, hyperphagia, glucose intolerance and reduced 
energy expenditure (Musatov et al., 2007). 
Estrogens can also affect food intake and body weight by interacting with other 
neuropeptides. For instance, females display increased sensitivity to the anorexic 
actions of leptin, an effect mainly attributed to the actions of estrogens (Clegg et 
al., 2006; Clegg et al., 2003). In addition, ghrelin increases food intake 
significantly more in males and ovariectomized females, than in intact females or 
females receiving estrogen replacement therapy, suggesting an inhibitory effect 
of estrogen on the actions of ghrelin (Clegg et al., 2007; Lopez-Ferreras et al., 
2017). However, site specific injection of ghrelin in the LH increases body 
weight only in females, though food intake is increased in both sexes, indicating 
site-specific sex differences in the regulation of ghrelin’s effects on food intake 
and body weight regulation (Lopez-Ferreras et al., 2017). Estrogen has also been 
shown to modulate the effects of CCK by increasing CCK-mediated satiation in 
intact females in phases of the estrous cycle with high circulating estrogen levels 
(Asarian and Geary, 1999, 2002; Eckel and Geary, 1999; Wager-Srdar et al., 
1987). 
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THE HEDONIC SYSTEM 
In addition to the homeostatic system, the body maintains an additional system 
to ensure that an individual strives to consume an adequate amount of food and 
nutrients: the hedonic system. While reward-driven eating was initially crucial 
for our survival, it has in recent decades become a problem due to the increasing 
accessibility of palatable, highly-caloric foods. Disinhibited intake of these food 
types can lead to overconsumption, weight gain and obesity. Food reward 
behavior is typically divided into two components: “liking” and “wanting”, 
originally described by Berridge et al. (Berridge, 1996; Berridge et al., 2009). 
Liking is associated with the palatability of the food, and the immediate 
response to their consumption, while wanting is associated with the motivation 
to obtain a certain type of food. 
THE MESOLIMBIC SYSTEM 
The reward system drives us to pursue behaviors that result in rewarding and 
pleasurable feelings; these behaviors provide positive reinforcement, increasing 
the likelihood that the behavior will be repeated.  Initial experiments by Olds 
and Milner identified several brain reward areas. When electrical probes were 
placed in distinct brain nuclei, animals would continuously self-stimulate, 
suggesting a rewarding effect of the stimulation in these areas  (Olds and Milner, 
1954). The mesolimbic pathway is a fundamental part of the reward system; it 
originates in the VTA, an area within the midbrain which sends dopaminergic 
projections to several areas within the limbic forebrain, such as the NAc, 
amygdala and hippocampus, in addition to the prefrontal cortex (PFC) 
(Dahlstrom and Fuxe, 1964; Koob, 1992; Nestler, 2004; Swanson, 1982) (Figure 
4). In turn, the PFC sends projections to the NAc and VTA, creating a 
possibility for a loop-like feedback system (Scofield and Kalivas, 2014).  
The NAc is a heterogenous structure; its two major subregions include the shell 
and the core, which have been shown to play dissociable roles in food reward 
regulation (West and Carelli, 2016; Zahm and Brog, 1992). Both structures 
receive dopaminergic inervation from the VTA, but project to different central 
areas. While the core mainly projects to motor structures, such as the cingulate 
motor areas and the premotor cortex, the shell mainly projects to other reward-
associated structures such as the amygdala and LH, in addition to the brainstem 
(Salgado and Kaplitt, 2015). Moreover, while the NAc core seems to play an 
important role in reward learning, the shell plays an important role in the 
control of food reward (Kelley, 2004). 
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 Representative image of the limbic system, and peripheral signals which alter food reward. Dopaminergic neurons Figure 4.
project from the ventral tegmental area (VTA) to the nucleus accumbens (NAc), amygdala, hippocampus and prefrontal 
cortex. The VTA and nucleus accumbens receive returning projections from the prefrontal cortex. The nucleus of the solitary 
tract (NTS) projects to the two major reward areas, the VTA and the NAc. Image modified; original image acquired from 
Wikimedia Commons. 
Initial studies on the reward system focused on its role in drug addiction (Berke 
and Hyman, 2000; Wise, 1996). However, later studies have shown that food 
and drugs affect many of the same reward areas. In fact, both drugs of abuse 
and palatable foods increase dopamine release in the brain reward system 
(Volkow et al., 2013). Dopamine is a catecholaminergic neurotransmitter 
involved in a variety of different physiological functions; in addition to reward it 
also plays a role in movement and emotional regulation. It is produced in the 
VTA, the midbrain and within the ARC, from the amino acid tyrosine, an 
enzyme derived from the liver. After synthesis, tyrosine is transported to 
dopaminergic neurons in the brain where it is converted to dopamine through 
several steps. The rate-limiting step is dependent on the actions of the enzyme 
tyrosine hydroxylase (TH) which converts tyrosine to L-dihydroxyphenylalanine 
(L-DOPA). L-DOPA is then converted to dopamine (Molinoff and Axelrod, 
1971). Dopamine’s role in food reward is based on original studies evaluating 
the effects of depletion of dopaminergic neurons using the neurotoxin 6-
hydroxydopamine; depletion of these neurons led to a reduction in food intake 
and body weight in the animals (Ungerstedt, 1968, 1971; Zigmond and Stricker, 
1972). In addition, dopamine receptor blockade using the antipsychotic drug 
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pimozide attenuates reward-driven food intake (Wise and Colle, 1984; Wise et 
al., 1978a; Wise et al., 1978b). Furthermore, genetic deletion of TH leads to 
hypophagia; an effect which can be counteracted by daily injections of L-DOPA 
(Zhou and Palmiter, 1995). 
Apart from affecting the dopaminergic pathway, through taste or palatable food 
cues, food can also affect food reward through the actions of various hormones 
and signals secreted from the gastrointestinal tract in response to food intake 
(Alonso-Alonso et al., 2015). In fact, several of the hormones that participate in 
the homeostatic regulation of food intake also act on the reward system to alter 
food reward behavior. 
MOLECULES INVOLVED IN FOOD REWARD 
REGULATION 
LEPTIN AND GHRELIN 
Leptin and ghrelin both act on the dopaminergic system to modulate food 
reward in an opposing manner. For instance, leptin administration in the VTA 
decreases firing of dopaminergic neurons in NAc, which leads to reduced food 
reward, and OB-R knock-down in the VTA increases dopamine release and 
sucrose preference (Hommel et al., 2006; Krugel et al., 2003). In contrast, 
ghrelin administration in the VTA or NAc increases food reward (Egecioglu et 
al., 2010; King et al., 2011; Perello et al., 2010; Skibicka et al., 2011b; Skibicka et 
al., 2012). 
INSULIN 
Insulin also alters dopamine release in the NAc; its effects are bidirectional, 
increasing dopamine release at low concentrations, while inhibiting release at 
higher concentrations (Potter et al., 1999). Furthermore, intraventricular insulin 
administration reduces the motivation to work for sucrose in rats (Figlewicz et 
al., 2006). 
PYY3-36 
Though the effects of PYY3-36 on food intake are thought to be mediated by 
receptors within the ARC, receptors are also found throughout other areas of 
the brain, including reward related structures, such as the PFC, VTA and 
amygdala (Batterham et al., 2007). In addition, PYY3-36 has been shown to 
modulate resting activity in the brain reward system in humans, and co-
administration of the peptide with GLP-1 additively reduces BOLD signal in 
response to food intake pictures in the amygdala and NAc in nonobese subjects 
(Batterham et al., 2007; De Silva et al., 2011). The effects of PYY3-36 on food 
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reward appear to be independent of actions of the peptide on Y2 receptors in 
the ARC. Systemic PYY3-36 administration reduces high-fat food seeking; a 
behavior which is unchanged after intra-ARC PYY3-36 administration (Ghitza et 
al., 2007). In addition, PYY3-36 may play a role in the development of obesity, as 
postprandial levels of the peptide are lower in obese individuals, which may lead 
to reduced satiety and increased food intake (le Roux et al., 2006). 
LH AND MOTIVATED BEHAVIOR 
In addition to the NAc and VTA, the LH was identified long ago as an 
important regulator of motivated behavior. In fact, the LH is the most potent 
self-stimulation center in the brain. In regard to food reward, neuronal 
activation within the LH stimulates food intake and food seeking, even in 
satiated rats (Miller, 1960). Furthermore, hungry or food restricted rats self 
stimulate more than fed rats, suggesting a role for the LH in the interaction 
between metabolic status and reward (Blundell and Herberg, 1968; Margules and 
Olds, 1962). The LH also contains several receptor populations for important 
food intake regulating hormones and peptides, for example ghrelin, leptin and 
GLP-1; potential roles for these molecules on food reward in the LH are 
however largely unexplored (Berthoud, 2011; Berthoud and Munzberg, 2011). 
NTS AND FOOD REWARD 
Though not commonly considered a reward area, the NTS receives a number of 
peripheral and central signals affecting food reward. For example leptin, which 
has previously been shown to reduce food reward through its actions on the 
mesolimbic system, reduces the rewarding effects of food by acting on receptors 
in the medial NTS (Kanoski et al., 2014). In addition, orexin may be released in 
the NTS to increase food reward (Kay et al., 2014; Peyron et al., 1998; Zheng et 
al., 2005). The NTS is also the primary source of production of the hormone 
GLP-1, which has previously been implicated in food reward regulation. 
However, potential effects of GLP-1 on food reward in this area were 
previously unknown. 
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SEX DIFFERENCES IN FOOD REWARD 
In addition to sex differences in food intake, differences have also been 
implicated in food reward. For instance, women have been shown to have more 
difficulty inhibiting their desire to eat when elicited by a food stimulus, and have 
an increased tendency to overeat when presented with palatable foods (Hays 
and Roberts, 2008; Wang et al., 2009). 
Besides “homeostatic areas” regulating food intake, ERs can also be found in 
regions involved in reward regulation, such as the VTA and NAc, and estrogens 
have previously been shown to act within these areas to regulate reward 
(Shughrue et al., 1997). In the VTA, estrogens have been shown to cause 
functional changes in GABAergic neurons, and estrogen treatment leads to 
enhanced striatal dopamine release (Becker, 1990; Becker and Ramirez, 1981; 
Becker and Rudick, 1999; Dazzi et al., 2007; Febo and Segarra, 2004; McEwen 
and Alves, 1999; Zhang et al., 2008). Although little is known of the effects of 
estrogens on food reward behavior, sex and estrogens have previously been 
shown to play a role in the rewarding effects of drugs of abuse. For instance, 
estrogen administered in ovariectomized rats increases dopaminergic cocaine 
sensitivity, and estradiol administration during the follicular phase increases the 
subjective effects of amphetamine in women (Justice and De Wit, 2000; Zhang 
et al., 2008). Dopamine levels, levels of its metabolites and synthesizing 
enzymes, and amphetamine -induced dopamine release vary based on ovarian 
cycle phase (Becker, 1990; Becker et al., 1984). In addition, women progress 
faster to cocaine dependence, and display higher preference for cocaine rewards, 
effects potentially mediated by the actions of estrogens (Kerstetter et al., 2012; 
Kerstetter and Kippin, 2011). 
Taken together, since estrogens modulate food intake, ERs are expressed in key 
reward-regulating areas, and there are sex differences in reward-regulated 
behaviors, we hypothesized that estrogen may also play a role in the regulation 
of the rewarding effects of food, specifically by modulating the rewarding 
effects of the peptide GLP-1. 
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CURRENT WEIGHT-LOSS TREATMENT 
OPTIONS 
Obesity treatment primarily involves the application of lifestyle changes, 
including dietary changes, increased physically activity and behavioral therapy. 
These recommendations are often difficult to maintain and adherence to this 
treatment regimen is low, resulting in no more than 5-10% body-weight loss 
(Wadden et al., 2012). 
Bariatric surgery, which is currently the most effective treatment for obesity, 
includes gastric bypass (Roux-en-Y), gastric banding or gastric sleeve, which 
involve reducing the size of the stomach mechanically or surgically. These 
procedures lead to a reduction in the capacity of the stomach, reducing the 
amount of food that can be consumed, in addition to decreasing energy and 
nutrient absorption. Gastric bypass results in an initial weight-loss of 30% 
within the first year, with 20% maintained weight loss up to 10 years after 
surgery (Maciejewski et al., 2016). However, bariatric surgery is invasive, and can 
result in acute or life-long side-effects, including bleeding, abdominal pain, 
chronic nausea and/or vomiting, excess loose skin, bowel destruction, ulcers 
and anastomotic stricture (Karmali et al., 2010). In addition, the treatment poses 
substantial economic costs on both the individual and society, making it a 
suboptimal treatment choice for obese individuals in general. 
Apart from bariatric surgery, a number of pharmaceutical treatments can be 
prescribed for weight-loss. The following are the most commonly prescribed 
weight loss treatments available: 
Orlistat (Xenical) acts locally within the gut to inhibit fat by binding to the 
enzyme lipase, thereby reducing lipid hydrolysis and absorption. Orlistat 
treatment results in an approximate 5% weight loss and potential side-effects 
include: increased flatulence, urgent bowel movements, inability to control 
bowel movements, stomach pain, rectal pain, nausea and vomiting (Jain et al., 
2011).  
Centrally acting pharmacological treatments include: Lorcaserin (Belvic), a 
serotonin 2C receptor agonist, phentermine-topiramate (Qsymia), the exact 
mechanism of which is unknown though it includes activation of hypothalamic 
noradrenergic neurons, and naltrexone-bupropion (Contrave), which reduces 
food intake by acting on POMC neurons in the hypothalamus. These drugs 
result in an approximate 5% reduction in body weight, and include a variety of 
side-effects ranging from gastrointestinal to psychological issues (Apovian et al., 
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2013; Aronne et al., 2014; Greenway et al., 2009; Shin and Gadde, 2013; 
Thomsen et al., 2008). In addition, the synthetic GLP-1R agonist liraglutide 
(Saxenda) was also recently approved for weight-loss treatment. While the 
weight loss effects of this drug are slightly larger than orlistat or lorcaserin, 
liraglutide treatment only results in a 5-10% reduction in body weight (Mehta et 
al., 2017). Possible side effects of liraglutide treatment include nausea, diarrhea, 
constipation, abdominal pain, headaches and increased pulse. The effects of 
liraglutide on food intake and reward are mediated through actions on GLP-1Rs 
within the brain; however, the exact brain areas involved, and the mechanisms 
mediating these effects, are not fully known. 
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GLP-1 IN FOOD INTAKE AND REWARD 
As mentioned above, GLP-1 has the ability to affect body weight regulation by 
acting on both the homeostatic and hedonic systems. 
GLP-1 is a peptide hormone composed of 30 amino acids, produced and 
secreted in the intestinal L-cells. It is synthesized through enzymatic cleavage of 
preproglucagon (PPG), by prohormone convertase, in response to food intake 
(Donnelly, 2012; George et al., 1985; Mojsov et al., 1990; Novak et al., 1987). 
GLP-1 mediates its effects by binding to its receptor, the GLP-1R, a G-coupled 
receptor widely expressed throughout the periphery and the brain (Dunphy et 
al., 1998; Holst, 2007).  
GLP-1 was first described as an incretin, stimulating insulin release and 
inhibiting glucagon secretion to regulate blood glucose (Kreymann et al., 1987; 
Orskov et al., 1988); it also acts in the gut to inhibit gastric emptying (Flint et al., 
1998). Due to its glucoregulatory ability, synthetic GLP-1R agonists have been 
developed for the treatment of type II diabetes (Holst, 2004). Synthetic variants, 
such as exendin-4 (Ex4), liraglutide and dulaglutide, are resistant to degradation 
by GLP-1’s primary metabolizer DPP-IV. By augmenting the site of cleavage, or 
using exendin-based treatments, the half-life of these GLP-1R acting 
compounds is significantly increased compared to endogenous GLP-1, which is 
degraded in a matter of minutes in the periphery (Vilsboll et al., 2003). 
In addition to its role in blood glucose regulation, GLP-1 also has anorexigenic 
properties, as both central and peripheral administration of the peptide, or its 
synthetic variants, have been shown to reduce food intake and subsequently 
body weight (Abbott et al., 2005; Chelikani et al., 2005; Kanoski et al., 2011a; 
Tang-Christensen et al., 1996; Turton et al., 1996). Due to the weight-loss 
effects of GLP-1, GLP-1R agonist liraglutide was recently approved for weight 
management treatment for obese individuals (Mehta et al., 2017). 
In addition to the gut, GLP-1 is also produced in the brain, primarily within the 
NTS as mentioned above (Merchenthaler et al., 1999). Centrally, GLP-1 acts to 
promote satiety by acting on GLP-1Rs in various brain regions. The effects of 
GLP-1 on satiety were initially attributed to the stimulation of GLP-1Rs in the 
hypothalamus, as site-specific injections of GLP-1 within this area decreases 
food intake, and peripheral injection of GLP-1R agonist has been shown to 
stimulate neuronal activity within the hypothalamus (Barrera et al., 2009; Goke 
et al., 1995; McMahon and Wellman, 1997, 1998; Pannacciulli et al., 2007; 
Turton et al., 1996). Hypothalamic nuclei that mediate GLP-1’s effects on food 
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intake include the ARC, PVN, VMH, DMH and LH (McMahon and Wellman, 
1998; Sandoval et al., 2008; Schick et al., 2003). 
Besides the hypothalamic nuclei, GLP-1 has been shown to reduce food intake 
by acting on several other brain areas. For instance, GLP-1 is able to act locally 
within its central site of production: the NTS. GLP-1Rs are expressed 
throughout the NTS and site-specific injection of GLP-1 has been shown to 
reduce food intake (Hayes et al., 2009; Hayes et al., 2008). In addition, the PBN 
has been shown to contain GLP-1Rs and GLP-1 mRNA has been found in this 
area (Merchenthaler et al., 1999), however whether these receptors are 
important for food intake regulation was previously unknown. 
Apart from homeostatic food intake regulation, GLP-1 has also been implicated 
in the regulation of food reward. Both systemic and central injection of GLP-1R 
agonist Ex4 reduces food reward behavior (Dickson et al., 2012). More 
specifically, GLP-1 has been shown to directly affect reward-related regions. 
GLP-1 neurons project from the NTS to the VTA and NAc, and GLP-1Rs are 
also expressed in these areas (Alhadeff et al., 2012; Goke et al., 1995; 
Merchenthaler et al., 1999; Rinaman, 2010). Moreover, GLP-1R agonist 
injection directly into the VTA and NAc inhibits food reward, and more 
specifically motivated behavior for palatable food (Dickson et al., 2012). In 
regard to the NAc, the effects of GLP-1 on food reward seem to be driven 
largely by its actions on GLP-1Rs in the NAc shell, while GLP-1Rs in the core 
only affect food intake regulation (Dickson et al., 2012; Dossat et al., 2011). 
GLP-1R stimulation in the NAc core does however influence palatability and 
the hedonic value of food, as blockade of GLP-1Rs in this area increases 
sucrose solution intake without affecting the intake of a non-nutritive saccharin 
solution (Dossat et al., 2013). Interestingly, GLP-1R stimulation in the VTA 
seems to specifically reduce the intake of rewarding foods, when both a 
palatable food choice and standard food choice (chow) are presented 
simultaneously (Alhadeff et al., 2012; Mietlicki-Baase et al., 2013). In addition to 
reward-regulating areas such as the NAc and the VTA, the LH is also innervated 
by GLP-1 neurons originating from the NTS, and contains GLP-1Rs 
(Merchenthaler et al., 1999). Interestingly, despite its strong connection with 
reward behavior, and its role in feeding behavior, whether GLP-1 acts within 
the LH to alter food reward was previously unknown. 
Therefore, while initial studies of GLP-1’s effects on food reward mainly 
focused on classic reward-regulating areas, the rewarding effects of the peptide 
on other central GLP-1R populations, and potential sex differences, were largely 
unexplored; these are two important topics which were investigated in this 
thesis. 
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AIMS 
The overall aim of this thesis was to investigate a potential role for GLP-1 on 
food reward in extra-mesocorticolimbic areas, and to investigate sex-dependent 
differences on the peptide’s reward-regulating effects. 
SPECIFIC AIMS 
I. To investigate if GLP-1 can alter food reward by acting on GLP-1Rs 
directly within its primary CNS source of production: the NTS. 
 
II. To explore if GLP-1 acts in the lateral PBN, a key nucleus in food 
intake control, to regulate the intake of standard and/or palatable 
foods, in addition to altering body weight. 
 
III. To determine if there are sex-specific differences in the actions of 
GLP-1 on food reward behavior, and whether these differences are 
due to the actions of the steroid hormone estrogen. 
 
IV. To investigate if GLP-1R stimulation within the LH, an important 
mediator of homeostatic and hedonic feeding behavior, is critical for 
body weight control, and if there are differences in the actions of LH-
acting GLP-1 between males and females. 
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ETHICS 
All studies were carried out with ethical permissions from the Animal Welfare 
Committee of the University of Gothenburg (Decree 86/609/EEC). All efforts 
were made to minimize animal suffering. 
ANIMALS 
SPRAGUE DAWLEY RATS 
Male (Paper I and II), or male and female (Paper III and IV), Sprague-Dawley 
rats were used in all behavioral experiments (purchased from Charles River, 
Germany). All animals were housed in a 12 hour light/dark cycle with ad libitum 
access to standard chow and water, unless otherwise specified. 
YFP-PPG MICE 
For GLP-1 detection studies (Paper I and II), adult male and female mGLU-124 
Venus yellow fluorescent protein transgenic mice (YFP-PPG mice; University of 
Cambridge, United Kingdom) were used. Transgenic mice are mice in which 
their genome has been altered, often to better mimic a human state or disease. A 
new gene can be inserted or an existing gene knocked out, down, or up, to 
investigate its function. In this specific case a fluorescent gene was inserted to 
allow visualization of PPG-expressing cells. As mentioned in the introduction, 
PPG is the precursor peptide which is enzymatically cleaved to GLP-1 in 
response to food intake (Donnelly, 2012; George et al., 1985; Mojsov et al., 
1990; Novak et al., 1987). PPG is also cleaved to other proteins, such as 
glucagon. However, glucagon expression in the brain is sparse compared to 
GLP-1, indicating that PPG cells most likely contain GLP-1 and not glucagon. 
In addition, cells were located in areas previously shown to contain GLP-1 
neurons.  
To generate the YFP-PPG mouse, a construct was first made in which the PPG 
promotor gene was coupled to a fluorescent gene (YFP). The genetic construct 
was then injected into a mouse embryo and integrated into the genome; YFP is 
then co-expressed in PPG-containing cells, making it possible to visualize the 
cell bodies and projecting fibers. 
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DRUGS 
GLP-1 AND EX4 
Endogenous GLP-1 has a very short half-life, lasting only a few minutes in 
plasma (Vilsboll et al., 2003). To bypass the potential short-lived effects of 
administration of the peptide (in contrast to physiologically produced and 
released endogenous GLP-1 which can be released for a longer time period), we 
used the synthetic GLP-1R agonist (Ex4) with considerably longer half-life. Ex4 
is a compound originating from the saliva of the gila monster, a poisonous lizard 
which resides in New Mexico and Arizona. Endocrinologist Dr. John Eng 
discovered the peptide hormone in 1992 and was intrigued by its abilities to 
trigger insulin synthesis and release from the pancreatic β-cells (Eng et al., 1992). 
Ex4 shares 53% of sequence homology with human GLP-1; however Ex4 has 
an altered amino-acid in position two which renders the peptide resistant to the 
actions of DPP-IV (its primary metabolizer), giving it a half-life of several hours. 
In addition, GLP-1 itself was used in select experiments (Paper I). Selected 
doses were chosen based on their ability to reduce food intake and reward in 
previous studies, without altering the general condition of the animal, e.g. 
reduced locomotor activity or malaise (Alhadeff et al., 2012; Dickson et al., 
2012; Dossat et al., 2011). In Paper I, 0.05 and 0.1 µg of Ex4 were used for 
intra-NTS injections in initial experiments; since the lower dose was sufficient to 
alter ingestive behavior the lower concentration was used for the remainder of 
the experiments. This dose was adapted from (Alhadeff et al., 2012). A dose of 
0.1, 0.3 or 1 µg was used in Paper II for intra-PBN injections; the effects of Ex4 
on this nucleus were previously unexplored, therefore several doses were used 
initially before finding an appropriate concentration. Paper III targeted the 
lateral ventricle, where 0.1 or 0.3 µg of Ex4 were applied; doses modified from 
(Dickson et al., 2012). Lastly, in Paper IV, 0.05 or 0.15 µg of Ex4 was applied to 
the LH. 
EXENDIN-3(9-39) 
To investigate the effects of endogenously acting GLP-1 we used a highly 
selective GLP-1R antagonist: exendin-3(9-39; Ex9), another compound 
discovered in the venom of the gila monster (Thorens et al., 1993). A dose of 20 
µg of Ex9 was administered to the PBN in Paper II and 10 µg of Ex9 to the 
LH; doses modified from (Hayes et al., 2009). 
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ICI 182, 780 (ICI) 
ICI is a highly selective estrogen receptor antagonist (Howell et al., 2000; 
Wakeling et al., 1991). It is used in the clinic as a treatment for certain types of 
breast cancer. A dose of 10 µg was injected into the lateral ventricle in Paper III; 
dose adapted from (Rivera and Eckel, 2010). 
MPP DIHYDROCHLORIDE (MPPd) 
MPPd is a highly selective ERα antagonist; it has a >200-fold selectivity for ERα 
over ERβ (Sun et al., 2002). Intraventricular injection of 1.4 µg was utilized in 
Paper III; dose adapted from (Martinez de Morentin et al., 2014). 
All drugs were diluted in artificial CSF (aCSF), with the exception of ICI and 
MPP which were dissolved in 10 and 20% dimethyl sulfoxide (DMSO; a 
powerful dissolvent), respectively. The use of DMSO is not ideal; it has been 
suggested in numerous studies to produce toxic and/or adverse effects in vivo. 
However, it has been demonstrated that small volumes, of up to 75% DMSO, 
do not produce any aversive affects, or affect feeding behavior, after CNS 
injection (Blevins et al., 2002). In addition, aCSF with 10 or 20% DMSO was 
used as vehicle in these specific experiments, to reduce the risk of mistaking any 
potential effects on food reward, on the solvent. 
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EXPERIMENTAL PROCEDURES 
CANNULA IMPLANTATION 
To investigate the effects of a drug on the CNS, or within a specific brain area, 
guide cannulas were implanted in the area of interest through stereotaxic 
surgery. Briefly, rats were anesthetized using a ketamine/xylazine mix (3:1); the 
volume of the mix was administered as x = 1.5 x body weight in kg for females 
and 2 x body weight in kg for males. The rodents were then fixed to the 
stereotaxic frame. Guide cannulas (26 gauge; Plastics One, Roanoke, VA) were 
inserted into the area of interest using coordinates derived from a rat brain atlas 
(Paxinos & Watson). The following coordinates, presented as anterior/posterior 
(AP) to bregma, medial/lateral (ML) to midline and dorsal/ventral (DV) to 
skull, were used for each selected brain area:  
 Lateral ventricle (Paper I, II and III): AP -0.9 from bregma, 
ML ±1.6 from midline and DV -2.0 (Paper I and III)/ -2.5 
(Paper II) mm from skull, with injector aimed -4.0/4.5 mm 
ventral to skull.  
 NTS (Paper I): AP on occipital suture/-4.9mm from bregma, 
ML ±0.75 from midline and DV -4.9 mm from skull, with 
injector aimed 6.9 mm ventral to skull. 
 Lateral PBN (lPBN; Paper II): AP -9.5, ML ±2.0 from midline 
and DV -4.5 mm from skull, with injector aimed 6.5 mm 
ventral to skull. 
 LH (Paper IV): AP -2.8, ML ±1.5 from midline, DV -, and -
6.8 mm from the skull, with injector aimed 8.8 mm ventral to 
skull. 
After being positioned according to the coordinates, the cannulas were fixed to 
the skull using jeweler’s screws and dental cement, and closed with an obturator. 
PLACEMENT CONFIRMATION 
LATERAL VENTRICLE – ANGIOTENSIN II DRINKING TEST 
Angiotensin II is a powerful stimulator of thirst; it induces immediate water 
intake (even in well-hydrated rats) when injected into certain brain regions, e.g. 
the third or lateral ventricle (Fitzsimons, 1976, 1998). In Paper I, II and III 20 
ng/2 µL of angiotensin II was injected into the lateral ventricle. Rats were 
required to make contact with their water bottle within 5 minutes, and drink a 
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minimum of 5 mL of water within the 30 minutes following the injection for the 
cannula to be included in the study. 
lPBN, LH AND NTS – HISTOLOGIC PLACEMENT 
CONFIRMATION USING INDIA INK 
For cannulas targeting the lPBN, LH and NTS in Papers I, II and IV, cannula 
placement was verified post mortem by injecting India ink, in the same volume as 
for drug injections, into each area. After euthanization, the brains were 
collected, stored and sliced using a cryostat; placement was later examined using 
a microscope. 
NTS – GLYCEMIC RESPONSE TEST 
Initial verification of NTS cannula placement took place one week after 
stereotaxic surgery. Injection of 5-thio-D-glucose (5TG) into the caudal 
hindbrain causes hyperglycemia (Ritter et al., 1981). Sympathoadrenal-mediated 
glycemic response after microinjection of 5TG (24 μg/0.3μl) was therefore  
measured by collecting blood from the tip of the tail 30, 45, 50, 60, 70, 90 and 
110 minutes after injection. An increase in blood glucose >100% increase was 
required for subject inclusion in the study. 
VIRAL KNOCK DOWN OF GLP-1RS 
To knock down the expression of GLP-1Rs in the LH in Paper IV, a short 
hairpin RNA (shRNA) targeting GLP-1R transcripts, developed by Schmidt et 
al. was used (Schmidt et al., 2016). 
Following guide cannula implantation, the virus was injected bilaterally into the 
LH (0.5 µL per hemisphere). Injections were carried out using a micropump at a 
rate of 0.1 µL/minute (for 5 minutes); the injector was left in place for an 
additional 10 minutes to allow for diffusion away from the injection site. The 
knock down was later confirmed post mortem using RT-PCR. 
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BEHAVIORAL PROCEDURES 
FOOD INTAKE AND BODY WEIGHT 
MEASUREMENTS 
The effects of GLP-1 and its synthetic agonists on food intake and body weight 
are well known; however, which brain areas mediate these effects have not been 
fully investigated.  
Paper I: food intake was measured 1 and 22 hours post injection; body weight 
change was measured at the 22 hour time point. 
Paper II: the aim was to determine whether intra-PBN GLP-1R activation 
contributes to a reduced intake of different foods with varying caloric and 
palatable properties. The intake of chocolate pellets, liquid saccharine and 
standard chow was therefore measured at different time points after injection. 
Chocolate pellet consumption was measured 0.5, 1 and 2 hours after injection. 
Saccharine, a non-caloric sweetener, was used to measure the effects of GLP-1R 
stimulation in the PBN on palatability, without the influence of caloric content. 
Liquid saccharine intake was measured 4 hours after injection. To exclude the 
possibility that potential changes in intake are due to differences in food type 
(liquid vs solid), or potential effects on water homeostasis, water intake was also 
measured during this time period. Chow intake was measured 24 hours after 
injection. Body weight was measured immediately before and 24 hours after 
injection. For GLP-1R blockade experiments, food was removed 5 hours prior 
to injection (60 minutes before the dark cycle) to ensure equal levels of satiety. 
Chow intake was measured 1, 2, 3 and 24 hours after Ex9 injection. Body 
weight change was also measured at the 16-hour time point. 
Paper III: Intake of chow and peanut butter was evaluated in non-deprived or 
overnight food-restricted rats. Peanut butter consumption was measured 1 hour 
after injection, and chow was offered for the remainder of the 24 hour time 
period. This experimental scheme was also used to investigate the effects of 
GLP-1R blockade in the PBN. The latter experiment was however only carried 
out in food restricted rats. 
Paper IV: Chow intake was measured 1 and 24 hours after Ex4 or Ex9 
injection. Prior to Ex4 experiments, rats were restricted to 50% of their normal 
intake overnight. For Ex9 experiments, rats were fasted overnight, and then 
given a 20-minute pre-meal of chow for 20 minutes before injection. This 
experimental design was modified from (Hayes et al., 2009) to elicit endogenous 
Jennifer Richard 
35 
 
GLP-1 release to a controlled meal. For GLP-1R knock down studies, food 
intake and body weight were measured daily for the entire duration of the 
experiment. 
PALATABLE FOOD CHOICE TEST 
To investigate if GLP-1R stimulation affects the intake of specific food types we 
utilized the palatable food choice test in Paper I. Preference for a palatable food 
(peanut butter) or chow was determined by offering the two foods 
simultaneously on the test day. In order to determine the effect of NTS GLP-1R 
activation on the palatable food choice, food presentation was preceded by 
intra-NTS microinjection of Ex4 or aCSF, and the amount of chow and peanut 
butter consumed was measured 1, 3 and 6 hours after injection. Variations in 
consumption due to neophobia, a fear of novel items, were reduced by 
familiarizing all the rats with peanut butter on at least one occasion prior to the 
test day. 
PICA TEST 
Nausea is one of the most common side-effects for individuals receiving 
synthetic GLP-1R agonist treatment (DeFronzo et al., 2005). Since rodents are 
not capable of emesis, the presence of nausea after treatment is measured using 
pica: the consumption of non-nutritive substances. Intake of kaolin, a form of 
white clay, was therefore measured in relation to food intake after Ex4 injection 
in Paper I. Rats were allowed to sample kaolin for at least 3 days before the Ex4 
injection to avoid association of kaolin with Ex4 injections. Kaolin and chow 
intake were measured at 1, 3, 6 and 24 hours after injection in mildly food-
restricted rats (10g of chow available overnight). 
OPERANT CONDITIONING 
Through operant conditioning, an individual makes an association between a 
particular behavior and a consequence, for example conducting a behavior to 
receive a reward (e.g. a sucrose pellet or electrical stimulation in a central reward 
area) or a punishment (e.g. foot shock). In regard to food reward, operant 
conditioning is commonly used to investigate the “wanting” component of food 
reward, i.e. the motivation to obtain a rewarding food.  
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To investigate the rewarding effects of palatable foods, rats in this study learned 
to press a lever in order to obtain a sucrose pellet (45 mg). The method was 
initially developed by Burrhus Frederic Skinner (Skinner, 1938), who developed 
a special box, the Skinner box, to study food-motivated behavior (Figure 5). The 
Skinner box, or operant conditioning box, main components include a signal 
light, one or two levers (one active), and a pellet dispenser. 
 Rodent using a Skinner box, a tool to measure operant conditioning behavior. This box is equipped with a Figure 5.
signal light and one active lever. Boxes used in the present studies included two levers, whereas only one was active, 
indicated by a lit signal light. Boxes used in these studies also include a pellet dispenser and food tray which allows the 
rat to obtain a pellet in response to pressing the active lever. 
The rats were trained and tested in operant conditioning boxes from Med-
Associates. Training was conducted in four stages; rats were first trained on the 
fixed ratio 1 (FR1) schedule (a single press on the active lever results in the 
delivery of one sucrose pellet), followed by FR3 and FR5 (3 and 5 presses per 
pellet respectively). A minimum of 30 (Paper III and IV) or 50 (Paper I) 
responses per session on the active lever was required for the advancement to 
the next schedule. Training culminates with progressive ratio conditioning, 
where the number of presses on the active lever required to obtain one pellet 
increases exponentially according to the following equation: Pellets obtained = 
5e0.2 x lever presses – 5. Progressive ratio training is carried out until stable 
responding was achieved (number of pellets earned per session did not vary 
more than 15% for three consecutive sessions). All operant response testing was 
performed after the responses stabilized. The duration of FR sessions is 30 
minutes and progressive ratio 60 minutes. 
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CONDITIONED PLACE PREFERENCE (CPP) 
CPP is a learned behavior that occurs when a subject comes to prefer one place 
more than another due to the association of the given location with previously 
rewarding events. The CPP test is used to investigate the reinforcing effects of 
natural and pharmacological stimuli, including drugs of addiction. In this 
context a palatable food choice is paired to one of the chambers prior to 
injection of Ex4 or control. 
The CPP test was performed in rats using an apparatus that is comprised of two 
connected chambers with distinct visual and tactile qualities (Med-Associates). 
CPP testing is carried out in three phases: habituation, conditioning and 
preference testing. During the habituation phase the preference for either 
chamber was assessed over the course of two days (20 minutes/day). The least 
preferred compartment (the compartment in which each rat spent the least 
amount of time during the two pretest days) was determined. Subsequently the 
least preferred compartment was paired with 4g of palatable food (chocolate or 
peanut butter). The conditioning phase consisted of 16 days of conditioning 
sessions (2 sessions per day). One day following the last conditioning session the 
rats received an intra-NTS Ex4 or aCSF injection, 30 minutes before CPP 
testing. The rats had free access to both compartments during testing, which 
took place in absence of the palatable food. The behavior of the animals was 
detected by infrared beams in each chamber and time spent in each 
compartment was determined. Time spent in each compartment reflects how 
rewarding the animal finds the substance/food that was paired to that specific 
compartment, and if the drug (Ex4) affects the rewarding properties of the 
palatable food.  
To assure that all palatable food was consumed during the training sessions the 
rats had restricted access to chow in their home-cages (70% of normal daily 
chow intake) throughout the CPP experiment. 
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BIOCHEMICAL PROCEDURES 
IMMUNOHISTOCHEMISTRY (IHC) 
IHC is a microscopy-based technique for visualizing cellular components, such 
as proteins or other macromolecules, in tissue samples. It utilizes the specificity 
of antibodies binding to an antigen. 
Antibodies, or immunoglobulins (Ig), are a large Y-shaped proteins synthesized 
by B-cells. There are five classes of antibodies: IgA, IgD, IgE, IgG and IgM, 
where IgG is most commonly used in immunohistochemistry. Antibodies are 
typically composed of two large heavy chains, and two small light chains. The 
two tips of the Y-shaped structure contain the antigen-binding sites which only 
bind to a specific antigen, in a lock and key manner. The tail, called the Fc 
fragment, has one binding site, which permits binding of other antibodies; an 
essential component in multistep immunohistochemistry (Ramos-Vara, 2005). 
Figure 6. Representative image of the antibody structure. The antibody consists of two light chains and two heavy 
chains. The tips of the Y-shape contain an antigen-binding site which binds to a specific antigen in a lock-and-
key manner. The antibody also has an Fc-fragment, which is critical for binding of other antibodies. Image 
modified from Wikimedia commons. 
Antibodies used in immunohistochemistry are made by immunizing animals 
with the antigen of interest. The animal’s immune system then responds by 
producing specific antibodies directed toward the antigen. Two types of 
antibodies are produced: polyclonal and monoclonal. Polyclonal antibodies bind 
to multiple sites on the antigen, but also to other epitopes depending on the 
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previous immune experience of the animal; therefore only a small fraction of the 
produced antibodies may actually bind to the actual site of interest on the 
targeted antigen. To minimize the risk of unspecific binding the collected 
antibodies therefore undergo affinity purification. Monoclonal antibodies are 
yielded by directly collecting B-cells from the spleen of an immunized animal. 
The B-cells producing only the antibody of interest are then fused with 
myeloma cells, carcinogenic plasma cells; the B-cell line therefore becomes 
immortal and divides continuously. Since these cells only produce the antibody 
of interest, monoclonal antibodies are therefore considered more specific than 
polyclonal; however they have lower sensitivity since they only bind to a single 
site of the antigen. 
The antigen-antibody compound is visualized using a reporter molecule, often a 
fluorescent tag, which is bound directly or indirectly to the antibody. In this 
thesis, experiments utilized an indirect reporter molecule; staining therefore 
takes place through the following two steps: 1) Binding of an antibody (the 
primary antibody) specific to the antigen of interest, and 2) Binding of a 
secondary antibody to the primary; the secondary antibody also contains a 
fluorescent tag, which allows for detection of the antigen-antibody complex 
using a microscope (Figure 7). 
Figure 7. Illustration of the immunohistochemistry method using a labelled secondary antibody. The primary 
antibody binds to the antigen of interest. In a second step, a secondary antibody, attached to a fluorescent tag, 
binds to the primary antibody. The antigen-antibody complex can then be visualized using a microscope. 
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GENERAL 
In Papers I and II, we utilized YFP-PPG mice for central GLP-1 detection; 
these mice already co-express PPG (the GLP-1 precursor) and YFP (the 
fluorescent protein) and need no further staining for visualization. However, to 
be able to visualize the presence of GLP-1 in relation to other molecules, such 
as TH (Paper I) or CGRP (Paper II), collected tissues require the use of 
immunohistochemistry to view the other molecular cell types. 
TISSUE PREPERATION 
The mice were anaesthetized with ketamine/xylazine solution and perfused 
transcardially with heparinized saline followed by fresh fixative solution 
(paraformaldehyde (PFA, 4%) in 0.1 M phosphate buffer. Briefly, the peritoneal 
cavity was exposed and a cut was made, parallel to the spine, to reveal the 
abdominal wall. The abdominal wall was carefully opened and the diaphragm 
cut open to reveal the heart. A 25 gauge needle, attached to a peristaltic pump, 
was inserted into the left ventricle and clamped in place. Heparinized saline was 
pumped through until clear solution flowed from the rodent and was followed 
by PFA perfusion which continued 10 minutes following contractions. Solutions 
were administered with a flow rate of 25 rpm. 
Following perfusion, the brains were collected, and cut into coronal 25 μm 
sections using a cryostat; sections were then collected into tubes containing 
tissue storage solution. The tissue storage solution consisted of 50 ml glycerin, 
50 ml ethylene glycol and 100 ml 0.1 M phosphate buffer (pH 7.5). Sections 
were then stored until use at 4°C.  
IHC STAINING 
The sections were first washed (3 x 15 min) in TNT with Triton-X (0.1%) 
(Sigma-Aldrich St.Louis, MO, USA).  
Paper I: For TH visualization, the sections were incubated for two days in TNB 
blocking solution (Perkin Elmer, Akron, Ohio, USA) with 1:2000 Goat 
polyclonal antibody to TH (ab6211, Abcam, Cambridge, UK). The sections 
were washed in TNT with Triton-X (0.1%) and incubated in TNB blocking 
solution with 1:1000 Donkey anti-goat Alexa Fluor 568 (ab36001, Abcam). 
Paper II: For CGRP visualization, the sections were incubated for 2 days in 
TRIS NaCl Boehringer Milk Powder-buffer (TNB-buffer) blocking solution 
(PerkinElmer) with 1:2000 goat polyclonal antibody to CGRP (ab36001; 
Abcam). The sections were then washed in TNT with Triton X-100 (0.1%) and 
incubated in TNB blocking solution with 1:1000 Donkey antigoat Alexa Fluor 
568 (ab36001; Abcam). 
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The cell nuclei were stained with DAPI (1:5000; Life Technologies). The 
sections were then washed in TNT (2 × 15 min), submerged in 0.1 M phosphate 
buffer (PB), and mounted on microscope slides (Superfrost Plus; Menzel) 
together with ProLong Gold Antifade (Life Technologies). 
NEUROANATOMICAL TRACING 
Traditional neuronal tracing methods rely on axonal transport; the transport of 
molecules or organelles through the axon. Axonal transport can either be 
anterograde (forward; from cell body to axon terminals) or retrograde 
(backwards; from axon terminals to cell body). Retrograde tracing is used to 
investigate neuronal connections between a specific neuronal population and 
their inputs through various areas of the CNS. 
Cholera Toxin Subunit B (CTB) is a nontoxic fragment from the cholera toxin 
secreted by the Vibrio cholera bacteria. Bacterial toxins have a high affinity to 
bind to specific sugars; after binding, the toxins are internalized by active 
transport via the nerve terminals and transported within the dendrites and axon 
to the cell body in the anterograde direction (Shehab et al., 2003). CTB binds 
specifically to the pentasaccharide chain of monosialotetrahexosyl ganglioside 
(its receptor), which makes it highly sensitive with minimal diffusion from 
labelled neurons (Lencer and Tsai, 2003). 
TRACING OF LH-VTA PROJECTING NEURONS 
Rats were anesthetized with a mix of ketamine, xylazine and acepromazine. A 
stereotax was used to target the VTA using the following coordinates: AP -5.0 
mm, ML +1.0 mm and DV -7.6 based on zeroing for DV at the skull at -0.9 AP 
and +4.8 ML. Fluorescently labeled CTB (CTB-488, Invitrogen C22841) was 
injected using a micro-infusion pump (Harvard Apparatus) connected to a 33-
gauge microsyringe injector attached to a PE20 catheter and Hamilton syringe. 
The compound was delivered with a flow rate of 5 µl/minute, and the injector 
was left in place 2 minutes after injection to allow for diffusion away from the 
injector before removal. Rats were sutured and allowed to recover and incubate 
with the virus for 10 days prior to sacrifice.  
TISSUE PREPARATION 
Rats were anesthetized and sedated with a mix of ketamine, xylazine and 
acepromazine; they were then transcardially perfused with 0.9% sterile saline 
(pH 7.4), followed by 4% paraformaldehyde in 0.1 M borate buffer (pH 9.5). 
Brains were collected and stored for later processing; they were then coronally 
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sliced in 20 µm sections using a cryostat, placed in a 0.02 M KPBS solution and 
mounted on slides which were placed into a vacuum chamber overnight. 
Sections were postfixed in 4% paraformaldehyde in 0.1 M borate buffer (pH 
7.4) for 1.75 hours, followed by 5 washes in KPBS. The sections were then 
pretreated by incubating them at 37 °C in pretreatment buffer (100 mM Tris 
buffer and 50 mM EDTA in distilled deionized water, pH 8) with 0.001% 
Proteinase K (Sigma P2308) for 30 minutes. This was followed by a 3 minute 
wash in incubation buffer and a 3 minute rinse in 100 mM Triethanolamine in 
water (pH 8). Sections were then incubated with 0.25% acetic anhydride in 100 
mM triethanolamine for 10 minutes at room temperature followed by 2x2 
minute washes in saline-sodium citrate buffer (1% citric acid trisodium/2% 
sodium chloride in water (pH 7.0)). Slides were then dehydrated in ethanol 
solutions in the following sequence: 50%, 70%, 95%, 100%, for 3 
minutes/concentration and air-dried prior to hybridization.  
FLUORESCENT IN SITU HYBRIDIZATION (FISH) 
FISH is a technique used to localize specific segments of nucleic acid within a 
histologic section. It is based on the pairing of a specific sequence of nucleic 
acids with a complementary strand of DNA, which can be detected by attaching 
a reporter molecule (e.g. a fluorophore). This method is therefore distinct from 
IHC, since it detects a specific RNA or DNA sequence in a tissue, while IHC 
localizes proteins within a tissue. 
VISUALIZATION OF GLP-1R EXPRESSING NEURONS 
A hydrophobic barrier was drawn around each section and 3-4 drops of a probe 
targeting GLP-1R mRNA (GLP-1R, Advanced Cell Diagnostics 315221) was 
placed on each tissue section. The slides were incubated with the probe at 40 °C 
for 3 hours in a HybEz oven (Advanced Cell Diagnostics). Sections were 
washed with wash buffer (RNAscope®, Advanced Cell Diagnostics 320058) for 
2 minutes. Reagents from RNAscope® Fluorescent Multiplex Detection 
Reagent Kit (Advanced Cell Diagnostics, 320851) were applied in order to 
amplify the probe signal: AMP1 was applied for 45 minutes, AMP2 for 30 
minutes, AMP 3 for 45 minutes, and AMP4 for 30 minutes. Incubation steps 
occurred at 40 °C and each amplification step was followed by a 2 minute wash. 
Slides were mounted using ProLong® Gold Antifade mounting medium (Cell 
Signaling, 9071S) and a coverslip was placed over the sections.  
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CONFOCAL MICROSCOPY 
Confocal microscopy is used to visualize a single plane of a tissue, increasing the 
optical resolution of the image; it is an important tool for determining potential 
co-localization between two or more molecular structures. By eliminating areas 
situated on top or below of the area of interest, it is possible to visualize, for 
example, if two proteins are expressed within the same neuron.  
Focusing on one plane, or a thin optical section, is enabled by a pinhole placed 
in front of the detector; the pinhole allows the light to be focused in the specific 
plane only, within a range of only a few µm. Laser lights are then emitted 
separately at different wavelengths to excite the different fluorescent tags. 
Wavelengths used are within the fluorophores excitatory range, but that do not 
overlap with each other, to avoid leakage in between channels. 
For IHC, fluorophore Alexa Fluor 568 (ab36001, Abcam) was used in both 
Paper I and Paper II for visualization of TH and CGRP respectively. Alexa 
Fluor 568 is an orange/red-fluorescent dye; excited by the 568 nm laser. YFP, 
the yellow/green fluorescent tag expressed in PPG cells in YFP-PPG mice, can 
be excited within a range of 490 to 510 nanometers; a lower wavelength within 
the span was chosen to avoid the risk of signal leaking from another 
fluorophore (for example Alexa Fluor 568). Diamidino-2-phenylindole (DAPI) 
is a blue fluorescent DNA stain which enables visualization of the cell nucleus, 
and is excited using a 405 nm laser. 
Triple channel confocal images were acquired from 25 µm sections by 
alternating between lasers of different wavelengths. High resolution images were 
taken at 20x and tile scans were taken of areas of interest: NTS (three levels: 
caudal, area postrema and 4th ventricle; Paper I), and lateral and medial PBN 
(Paper II). 
EPIFLUORESCENT MICROSCOPY 
A fluorescent microscope is a traditional optical microscope equipped with a 
high-intensity light source, which enables the excitation of light of a specific 
wavelength to illuminate a sample.  
The sample is illuminated with light of a specific wavelength, which excites the 
fluorophore. The illumination light is separated using an excitation filter, 
allowing for only the excited light to be transmitted and detected by the 
detector, providing a high signal- to- noise ratio. 
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Photomicrographs were acquired using a Nikon 80i (Nikon DS-QI1, 1280x1024 
resolution, 1.45 megapixel) under epifluorescent illumination, or as optical slices 
using a Zeiss LSM 700 UGRB Confocal System (controlled by Zeiss Zen 
software). For details on confocal microscopy, see section above. 
GENE EXPRESSION ANALYSIS 
Gene expression is the process in which a gene from the DNA is transcribed 
and translated into a protein. Gene expression analysis is used to gain insight in 
the level at which a specific gene is expressed within a tissue; analysis can take 
place at several different steps in the expression process, during transcriptional, 
post-transcriptional, translational, and post-translational protein modification. 
Transcription is the process in which a complementary RNA strand is made 
from the DNA sequence. This process is regulated by the binding of regulatory 
proteins, or through direct influence on the transcriptional machinery of the cell. 
The RNA strand is then spliced, in which noncoding intron sequences are 
removed, and the sequence is capped with a poly(A) tail, creating messenger 
RNA or mRNA. The mRNA is then transported from the cell nucleus to the 
cytosol where it can be translated to a protein, and undergo posttranslational 
modifications such as folding. 
Gene expression can, for example, be analyzed by measuring mRNA levels 
using quantitative reverse transcription PCR (RT-qPCR). In this method, 
mRNA is first extracted and transcribed to a complementary DNA (cDNA) 
strand by reverse transcriptase. The cDNA template that is created is then 
amplified in the quantitative step, the qPCR reaction, in which fluorescence is 
emitted from commercially labeled hybridization probes. Using the standard 
curve, one can then determine the absolute number of copies of original 
mRNA. 
RNA EXTRACTION AND RT-qPCR METHODOLOGY 
Individual brain samples were homogenized in Qiazol (Qiagen, Hilden, 
Germany) using a TissueLyzer (Qiagen). Total RNA was extracted using 
RNeasy Lipid Tissue Mini Kit (Qiagen) with additional DNAse treatment 
(Qiagen). RNA quality and quantity were assessed by spectrophotometric 
measurements (Nanodrop 1000, NanoDrop Technologies, USA). For cDNA 
synthesis, iScript cDNA Synthesis kit (BioRad) was used. TaqMan PCR was 
used to quantify gene expression. The TaqMan gene expression assay uses a pair 
of unlabeled PCR primers which contains a probe attached to a fluorescent dye 
label on the 5´ end, and a non-fluorescent quencher at the 3´ end. When the dye 
and quencher are in close proximity of each other, the dye is quenched and 
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cannot fluoresce. When the cDNA segment binds to the primer and the probe, 
the probe is cleaved by TaqMan polymerase and the fluorescent dye is released 
from the quencher, enabling florescence. The amount of fluorescence is relative 
to the level of the gene expressed, which can be calculated using the ΔΔCt 
method (Livak and Schmittgen, 2001). Peptidylprolyl isomerase A (PPIA) or β-
Actin were used as reference genes. The selection of the specific reference gene 
was based on the assessment of their stable expression between control and test 
samples.  
DETERMINATION OF ESTROUS CYCLE PHASE 
As mentioned above, the rodent estrous cycle is a 4-5 day cycle which consists 
of 4 phases: diestrus, proestrus, estrus and metaestrus. The diestrus phase is 
characterized by the presence of neutrophils, also known as leukocytes, which 
appear as small, round cells with multiobulated nuclei. Proestrus samples consist 
mainly of small nucleated epithelial cells. These cells are small, albeit larger than 
neutrophils, and possess a round or oval shape. They are non-keratinized, with a 
high nuclear to cytoplasmic ratio, and often stain darker than neutrophil cells. 
Estrus mainly consists of large cornified, nucleated epithelial cells; these cells 
have a lower nuclear to cytoplasmic ratio and are much larger than the other cell 
types. The estrus phase also includes large anucleated keratinized epitheal cells, 
which are large, aged cells that lack nuclei. Lastly, metestrus is characterized by 
the presence of all cell types, though neutrophils are in the majority. Each cycle 
phase varies in its average duration, with proestrus lasting approximately 14 
hours, estrus 24-48 hours, metestrus 6-8 hours and diestrus 48-72 hours in rats 
(B., 1939; Long J. A., 1922; M., 1951). 
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 Representative images of each phase of the estrous cycle: proestrus, estrus, metestrus Figure 8.
(diestrus I) and diestrus (diestrus II). 
METHODOLOGY 
Smears were collected by injecting 50 µL of saline into the opening of the vagina 
with a pipette, and flushing 2-3 times before sucking up the liquid and ejecting it 
on a glass slide. Estrous cycle phase was initially assessed by microscope 
examination of unstained smear preparations collected from the females each 
morning, or immediately after operant conditioning. Cycle phase was 
additionally, later confirmed after Papanicolaou staining as described previously 
(Chateau et al., 1996). Briefly, vaginal samples were stained with Hematoxylin 
and Eosin using the following protocol: Samples were incubated in Hematoxylin 
for 10 minutes, rinsed in distillated H2O and placed in eosin for 2 minutes. They 
were again rinsed with H2O prior to dehydration using 70% ethanol for 1 
minute, followed by 5 minutes in 95% ethanol. Finally, the slides were placed in 
xylene for 10 minutes and allowed to dry before slides were mounted with 
Pertex glue and covered with a coverslip. The samples were observed using a 
standard, white light microscope and cycle phase was determined. 
STATISTICAL ANALYSIS  
All the data are presented as mean ± Standard Error of the Mean (SEM). 
Statistical significance was analyzed using Student’s t-test, or one- or two-way 
analysis of variance (ANOVA) when appropriate (GraphPad Software, Inc., San 
Diego, CA).  
The student’s t-test was used for comparisons between treatment groups; the 
unpaired t-test was used when comparison took place between two separate 
groups while paired t-test was conducted when values were compared within the 
same individuals, e.g. in counterbalanced experiments. ANOVA was used for 
comparisons between two or more treatment groups, when comparing one or 
more independent variables. ANOVA can be carried out using one-way or two-
way analysis: one-way analysis is used when comparing one independent variable 
(e.g. treatment), while two-way analysis is used for two independent variables 
(e.g. treatment and sex). 
 p-values lower than 0.05 were considered statistically significant. 
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PAPER I 
GLP-1 reduces food intake by acting on GLP-1Rs located in key central energy 
balance regulating areas, such as the hypothalamus and the brainstem (Barrera et 
al., 2009; Goke et al., 1995; Hayes et al., 2009; Hayes et al., 2008; McMahon and 
Wellman, 1997, 1998; Pannacciulli et al., 2007; Turton et al., 1996). In addition, 
GLP-1 has been shown to reduce food reward behavior by acting on receptors 
within the mesolimbic system (Alhadeff et al., 2012; Dickson et al., 2012; Dossat 
et al., 2011). Previous data therefore suggest a neuroanatomical segregation 
between the homeostatic and hedonic effects of the peptide. In Paper I, we 
aimed to challenge this view and hypothesized that GLP-1 can regulate food 
reward behavior by acting directly on the brainstem, on GLP-1Rs in the NTS, 
the primary source of central GLP-1. 
NTS GLP-1R ACTIVATION PREFERENTIALLY 
AFFECTS THE INTAKE OF PALATABLE FOOD 
To determine if the actions of GLP-1 on food intake in the NTS are affected by 
the palatability of the food item, we conducted a palatable food-choice test. 
Direct NTS GLP-1R stimulation was shown to specifically reduce the intake of 
the palatable food item (peanut butter), without affecting the intake of chow, 
the non-palatable food choice (chow; Figure 9A). Thus, GLP-1’s actions on food 
intake seem to be selective to palatable foods.  
Chemical lesions of the area postrema and NTS were previously shown to 
exclusively reduce the intake of palatable food, but not chow, suggesting a 
selective role for the NTS in food intake regulation (Ritter and Edwards, 1984; 
South and Ritter, 1983). Since GLP-1R signaling in the current study seems to 
function in the same manner, it is interesting to postulate that NTS GLP-1 
neurons may represent at least one of the neuronal populations lesioned in these 
studies. 
When chow was offered as the sole food choice, Ex4 significantly reduced chow 
intake (Figure 9B & C). In addition body weight was reduced 22 hours after 
treatment (Figure 9D). These results are in line with previous studies by Hayes et 
al demonstrating the anorexic actions of GLP-1R stimulation within this area 
(Hayes et al., 2009; Hayes et al., 2008). 
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 Direct NTS GLP-1R stimulation with Ex4 (0.05 µg) suppressed the intake of palatable food (peanut Figure 9.
butter), but not chow, when both food types were offered simultaneously (A). However, when chow is offered alone, 
GLP-1R stimulation significantly reduces the intake of chow 1 (B) and 22 hours (C) after injection. A significant 
reduction in body weight was also observed at 22 hours (D). Data are expressed as mean ±SEM. n = 12 per 
treatment group (A) and n = 11 per each treatment group (B-D). * p<0.05, ** p<0.01, *** p<0.005. 
The anorexigenic actions of GLP-1R stimulation in the NTS were not 
associated with nausea (Figure 10). This is an important factor since nausea is 
one of the primary side-effects of synthetic GLP-1R agonist treatment in 
humans, which often leads to discontinuation of the treatment (DeFronzo et al., 
2005). While food intake and body weight were significantly reduced (Figure 
10A) after direct microinjection of Ex4 into the NTS, there was no effect on the 
intake of kaolin (Figure 10B), suggesting that the nausea-inducing effects of 
GLP-1R treatment are mediated through other central GLP-1R populations, 
and not through actions on GLP-1R in the NTS. 
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 GLP-1R stimulation in the NTS reduced chow intake (A), without altering the intake of the Figure 10.
nonnutritive food item kaolin (B). Data are expressed as mean ±SEM. n = 8 per treatment group. ***p< 0.005, 
**** p<0.0005. 
ACTIVATION OF GLP-1RS IN THE NTS REDUCES 
FOOD REWARD BEHAVIOR 
In addition to the anorexigenic effects on intra-NTS GLP-1Rs, GLP-1R 
stimulation in this area also reduced food-motivated behavior (Figure 11). Ex4 
injection, or injection of the endogenous peptide GLP-1, into the NTS, 
significantly reduced the amount of sucrose rewards earned (Figure 11A & D) 
and lever presses for sucrose (Figure 11B & E) in the operant conditioning test. 
Importantly, there was no effect on locomotor activity (Figure 11C & F), 
indicating that the effects of Ex4 and GLP-1 on motivated behavior in this area 
are not due to motor impairment or malaise.  
GLP-1R stimulation in the NTS also reduced food-reward behavior in the CPP 
test (Figure 12); Ex4 injected rats spent significantly less time in the food-paired 
chamber compared to the vehicle-treated group (Figure 12A). Ex4 treated rats 
also displayed a preference shift toward the non-food paired chamber (Figure 
12B). 
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 GLP-1R stimulation by synthetic agonist Ex4, or GLP-1, potently reduced the number of sucrose Figure 11.
rewards earned (A & D) and active lever presses (B & E) in the operant conditioning test. Importantly, this 
suppression in food-motivated behavior was not associated with a reduction in locomotor activity (C & F). n =11 per 
each treatment group. * p<0.05, ** p<0.01, ***p < 0.0005. 
 Intra-NTS Ex4 administration reduced the preference for the food-paired chamber (A) and shifted the Figure 12.
preference to the non-food paired chamber (B) in the conditioned place preference (CPP) test. The preference (%CPP) 
was calculated using the following formula: ((test-pretest)/(total time-pretest))x100. Data represent mean ±SEM. 
n=11 (vehicle group) and 8 (Ex4 group). **** p<0.0005.  
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GLP-1 FIBERS ARE IN CLOSE PROXIMITY TO NTS 
NORADRENERGIC NEURONS 
The demonstrated effects of GLP-1R stimulation in the NTS may be mediated 
by NTS GLP-1R activity transmitted to the mesolimbic system. NTS neurons 
were previously shown to project to both the NAc and the VTA; these neurons 
(A2) express TH, the precursor for adrenaline, noradrenaline and dopamine, and 
are a major source of noradrenaline to the NAc (Delfs et al., 1998; Rinaman, 
2011; Wang et al., 1992). Interestingly, NTS A2 neurons have already been 
implicated in the control of rewarding effects of substances of abuse (Delfs et 
al., 2000; Olson et al., 2006). Based on these previous results we decided to 
investigate if GLP-1 neurons possess the ability to interact with NTS A2 
neurons, providing a potential connection to the reward system. 
Taking advantage of the venus mice which express PPG-YFP we confirmed the 
distribution of YFP-labeled cell bodies compared to previous studies. The 
location of TH positive cells is also in line with the neuroanatomical position of 
NAc-projecting TH neurons previously reported (Figure 13) (Larsen et al., 1997; 
Llewellyn-Smith et al., 2013; Rinaman, 2011; Wang et al., 1992) 
In addition, TH immunoreactive neurons in the NTS were found to receive 
close appositions from PPG-YFP fibers, indicating that GLP-1 may exert its 
effects on reward by acting on mesolimbic-projecting A2 neurons. This 
interaction was observed at the level of the caudal NTS (Figure 13A & B) and at 
the level of the area postrema (Figure 13C & D).  At more rostral levels of the 
NTS, by the caudal 4th ventricle, very few PPG-YFP fibers were identified 
(Figure 13E & F). 
In addition to NTS noradrenergic A2 neurons, TH immunoreactivity may also 
mark adrenergic C2 neurons, which can also be found in the NTS (Minson et 
al., 1990; Rinaman, 2011). However, the presence of C2 neurons is relatively 
sparse in the areas of the NTS exhibiting GLP-1 fiber detection, therefore most 
of the TH positive cells visualized in this study are most likely noradrenergic. 
EX4 INJECTION IN THE NTS INCREASES TH AND 
DOPAMINE 2 RECEPTOR EXPRESSION IN THE 
VTA 
To further evaluate if GLP-1R stimulation in the NTS affects areas of the 
mesolimbic system, gene expression of dopamine-related genes, in addition to 
other genes previously associated with changes in reward behavior, was 
investigated in the NAc and VTA after Ex4 injection. Intra-NTS Ex4 
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administration led to a significant increase in TH and dopamine 2 receptor 
mRNA expression in the VTA (Figure 14A).  
TH expression was previously shown to increase in response to GLP-1R 
stimulation in the VTA (Mietlicki-Baase et al., 2013), suggesting that GLP-1R 
stimulation in the NTS and the VTA may lead to similar effects on dopamine 
production. In addition to the NAc, dopaminergic VTA neurons also project to 
the amygdala, and increased dopamine activity in this area has previously been 
associated with reduced sucrose-driven food-motivated behavior (Anderberg et 
al., 2014). Connections transferred from the NTS to the amygdala (NTS-VTA-
Amygdala) therefore provide a potential mechanism for the reward-reducing 
effects of GLP-1 acting in the NTS. 
In addition to TH, the expression of dopamine 2 receptors was also increased in 
the VTA in response to intra-NTS GLP-1R stimulation. Dopamine 2 receptors 
in the VTA are primarily thought to function as autoreceptors, mediating a 
negative feedback effect on the dopaminergic neurons on which they are 
expressed, resulting in a reduction in dopamine release. However, only select 
populations of dopaminergic neurons are inhibited by these receptors; 
dopaminergic neurons innervating the NAc are inhibited by dopamine 2 
receptors, while nearly none of the amygdala projecting dopaminergic neurons 
are affected (Margolis et al., 2008). Therefore, it is possible that the reduction in 
food reward behavior after intra-NTS GLP-1R stimulation in this study is due 
to the inhibitory action of GLP-1 on dopamine neurons projecting to the NAc. 
mRNA levels of TH and dopamine 2 receptors were not altered in the NAc 
after intra-NTS Ex4 injections (Figure 14C). 
The expression of other dopamine receptors was not altered in either the VTA 
or the NAc (Figure 14A & C). In addition, the expression of reward related 
genes: FBJ osteosarcoma viral oncogene B (FosB), transcription factor cAMP 
responsive element binding protein 1 (Creb1) and glutamate decarbolylase 1 
(Gad1) were also measured. No changes in mRNA expression of these genes 
were detected after intra-NTS Ex4 administration, neither in the VTA or the 
NAc (Figure 14B & D). 
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Figure 13. Yellow fluorescent protein (YFP)-immunoreactive axons (green) are in close apposition to tyrosine 
hydroxylase (TH) positive neurons (Egecioglu et al.) of the NTS. Micrographs show representative images of 
three levels of the NTS: the caudal NTS (A-B), the NTS at the level of the area postrema (C-D) and the 
NTS at the level of the 4th ventricle (E-F). White arrows indicate NTS tyrosine positive neuronal cell bodies 
closely apposed to GLP-1 fibers. NTS = nucleus of the solitary tract, AP = area postrema, cc = central canal, 
DMV = dorsal motor nucleus of the vagus, GR = gracile nucleus, 4thV = 4th ventricle. 
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Figure 14. Intra-NTS GLP-1R activation increased mRNA expression of the gene that encodes tyrosine 
hydroxylase (TH), and the dopamine 2 receptor (Drd2) without significantly altering mRNA expression of 
other dopamine receptors in the VTA (A). Expression of reward-related genes FosB, Creb1 and Gad1 
remained unchanged (B). Receptor expression in the nucleus accumbens was unaltered (C & D). Data are 
expressed as mean ±SEM. n = 6 (vehicle group) and n = 5 (Ex4 group). ** p<0.01, *** p<0.005. Drd1a 
= Dopamine receptor 1, Drd3 = dopamine receptor 3, Drd5 = dopamine receptor 5, Gad1= glutamate 
decarboxylase 1, Creb1 = cAMP responsive element binding protein 1, FosB = FBJ osteosarcoma viral 
oncogene B. 
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PAPER II 
The PBN is an important nucleus in food intake regulation; it integrates signals 
from the hypothalamus and periphery, as well as the immune system, to control 
energy balance (de Araujo, 2009). Inhibitory hypothalamic projections to the 
PBN are critical for normal food intake maintenance, and loss of these signals 
leads to starvation (Carter et al., 2013; Wu et al., 2009; Wu and Palmiter, 2011; 
Wu et al., 2013). In addition, viscerosensory stimuli result in neuronal activation 
of the PBN (Wu et al., 2009; Wu et al., 2012; Wu et al., 2013). However, the 
origin and character of this neuronal input was recently unknown. The PBN 
expresses GLP-1Rs and GLP-1 mRNA has been found in this area. In Paper II 
we therefore investigated if GLP-1 neurons, originating from the NTS, project 
to the PBN and if GLP-1 acts in this area to regulate feeding behavior. 
HINDBRAIN GLP-1 NEURONS INNERVATE THE 
PBN 
Fibers from fluorescent YFP-PPG neurons, most likely originating from the 
NTS (Figure 15A & B), were detected in the medial and lPBN. Over half 
(55±1.2%) of the cell bodies in the lPBN were in close proximity to these fibers, 
while approximately 31% (31±2.3%) of the cell bodies in the medial PBN 
appeared to be innervated (Figure 15C-F). 
These data are in line with previous studies showing that the PBN is densely 
innervated by NTS neurons; in addition, innervation from the NTS was shown 
to overlap with GLP-1 positive terminals, and NTS-PBN projecting neurons 
were indicated to co-localize with NTS GLP-1 producing neurons (Alhadeff et 
al., 2014; Rinaman, 2010). 
GLP-1R STIMULATION IN THE lPBN REDUCES 
FOOD INTAKE AND BODY WEIGHT 
Intra-PBN injection of Ex4 significantly reduced the intake of chocolate pellets 
(Figure 16A), liquid saccharine (Figure 16B) and chow (Figure 16C). In addition, 
24-hour body weight change was significantly reduced (Figure 16D). 
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 Fluorescent YFP-PPG neurons (green) and DAPI (nuclear stain, blue) in coronal sections Figure 15.
throughout the NTS and the PBN of YFP-PPG mice. Micrographs showing the cell bodies of green 
YFP-immunoreactive PPG neurons (yellow arrows) in the NTS (A and B), micrographs showing the 
lateral PBN (lPBN; C and D), and the region of the medial PBN (mPBN) just below the superior 
cerebellar peduncles (E and F). White arrows indicate PBN cell bodies in close apposition to GLP-1 
fibers, whereas red arrows indicate cell bodies in this region that were not apposed by GLP-1 fibers. 
Insets in D and F show the interaction at a single cell level. cc, central canal, scp = superior cerebellar 
peduncles. B, D, and F show higher magnification of areas in A, C, and D, respectively. 
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These results demonstrate that GLP-1R stimulation in the PBN reduces the 
intake of foods with a variety of different caloric and palatable characteristics. 
Saccharine is a non-caloric sweetener, therefore a reduction in its intake suggests 
that GLP-1 modulates intake in this area regardless of caloric content. 
Importantly, the reduction is not due to differences in food type (liquid vs 
solid), or potential effects on water homeostasis, since water intake was not 
altered by Ex4 injection (Figure 16B). 
 Lateral PBN (lPBN) injection of Ex4 (0.1 µg) reduced 2-hour chocolate pellet consumption (A), in Figure 16.
addition to reduced liquid saccharine consumption, but not water intake, during a 4 hour time period (B) Chow 
intake (C) and body weight (D) were also reduced 24 hours after injection. Data are expressed as mean ± 
SEM. n=11 (chocolate pellet group), n=12 (saccharine group) and n=11 (chow intake group). *p<0.05, 
**p<0 .01, ***p<0 .005. 
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ENDOGENOUS GLP-1 REGULATES FEEDING 
AND BODY WEIGHT VIA PBN GLP-1RS 
Blockade of GLP-1Rs in the lPBN, using the GLP-1R antagonist Ex9, 
significantly increased chow intake 2 and 3 hours after injection (Figure 17A). 
The effect of Ex9 on chow intake was no longer present after 16 hours (Figure 
17B), but the manipulation did lead to a significant increase in overnight body 
weight change (Figure 17C). These data indicate that not only pharmacological 
stimulation of GLP-1Rs in this area, but also endogenously released GLP-1, acts 
in the lPBN to regulate food intake and body weight. 
 Intra-PBN delivery of Ex9 increased chow intake 2 and 3 hours after injection (A). Overnight chow Figure 17.
intake, measured 16 hours after Ex9 injection, was not altered (B). However, Ex9 increased 16-hour body 
weight gain. (C). Data are expressed as mean ± SEM. n = 12. *p<0 .05. 
CENTRAL GLP-1R ACTIVATION INDUCES 
INTERLEUKIN-6 (IL-6) AND CALCITONIN GENE-
RELATED PEPTIDE (CGRP) EXPRESSION IN THE 
PBN 
In order to begin to understand the potential downstream circuitry activated by 
GLP-1R stimulation in the PBN, gene expression of molecules recently shown 
to be associated with suppression of appetite in the PBN was analyzed (Carter et 
al., 2013; Roman et al., 2016; Shah et al., 2014; Wu et al., 2009). 
Jennifer Richard 
61 
 
Ex4 injection into the lateral ventricle led to a significant increase in the 
expression of the inflammatory signal IL-6 in the PBN of ad libitum fed and 
overnight-fasted rats; while interleukin-1β (IL-1β) expression was unaffected 
under both conditions (Figure 18C & D). GLP-1 mediated increase of IL-6 
expression is in line with previous research; IL-1β and IL-6 were previously 
shown to mediate the appetite-suppressing effects of GLP-1 in the 
hypothalamus and brainstem (Shirazi et al., 2013a). In fact, in addition to their 
role in the inflammatory system, IL-1β and IL-6 have also been implicated to 
play a role in the regulation of metabolic function in healthy animals. In 
addition, IL-6 or IL-6 receptor knockout in mice leads to obesity and disturbed 
glucose metabolism (Erta et al., 2012; Garcia et al., 2006; McGillicuddy et al., 
2011; Wallenius et al., 2002). Therefore, in addition to the hypothalamus and 
brainstem, IL-6 seems to mediate the effects of GLP-1 on food intake in the 
PBN. 
 GLP-1R activation increased mRNA expression of the gene that encodes CGRP (Calca), without Figure 18.
significantly changing the mRNA expression of other genes previously shown to be associated with changes in food 
intake in the PBN in ad libitum fed rats (A). Gene expression in the PBN was unaltered after Ex4 injection 
in overnight-food restricted rats (B). Ex4 increased the expression of IL-6, but not IL-1β, in both ad libitum-fed 
(C) and fasted (D) rats. Data are expressed as mean ± SEM. n = 6-9. Mc4r = melanocortin 4 receptor, 
CGRP = calcitonin gene-related peptide, Gabrd = γ-Aminobutyric acid, Gad1 = Glutamate decarboxylase 1, 
Grin2b = glutamate ionotropic receptor NMDA type subunit 2B, IL1β = interleukin 1β, IL6 = interleukin 
6. **p<0 .01. 
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Central GLP-1R stimulation also led to a significant increase in the expression 
of CGRP in the PBN, in ad libitum fed rats (Figure 18A). However, this change 
was not seen in overnight-fasted rats (Figure 18B).  CGRP neurons are 
exclusively found in the lPBN and have been shown to play an important role in 
appetite suppression (Carter et al., 2013; Lutz et al., 1997; Paues et al., 
2001).While CGRP-neurons have been shown to reduce food intake regardless 
of feeding state, the ability of GLP-1 to reduce food intake has previously been 
shown to depend largely on nutritional status. GLP-1 reduces appetite in a fed, 
but not fasted state; this effect is thought to be based on the amount of GLP-
1Rs available on the plasma membrane, with increasing levels of GLP-1Rs 
trafficked to the membrane in response to a meal (Ronveaux et al., 2014). Taken 
together, although stimulation of CGRP-expressing neurons have been shown 
to reduce food intake regardless of feeding state, animals that underwent an 
overnight fast may have had a reduced number of GLP-1Rs available on the cell 
membrane, and the level of activation of these cells may therefore be 
insufficient to further stimulate CGRP neurons in this area. Thus, neuronal 
activation of CGRP-expressing neurons could therefore be a potential 
mechanism in which GLP-1 can mediate its anorexic effects in the PBN. 
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lPBN CGRP NEURONS ARE INNERVATED BY 
GLP-1 FIBERS 
In order to determine a potential connection between GLP-1 and CGRP-
expressing neurons in the lPBN we examined if CGRP neurons in this area are 
innervated by GLP-1 fibers.  
Fluorescent fibers from YFP-PPG neurons were found in close proximity to 
CGRP neurons (Figure 19A & B). In fact, most of the GLP-1 fibers found in 
the lPBN innervated CGRP-positive cells, and nearly half of the CGRP-
expressing cells in the lPBN receive GLP-1 innervation (Figure 19C & D). 
 YFP-immunoreactive axons (green) were found in close apposition to CGRP neurons (red) in the lateral Figure 19.
PBN (lPBN; A). Yellow arrows indicate CGRP-labeled lPBN cell bodies closely apposed by the GLP-1 fibers, 
whereas white arrows indicate CGRP-labeled cell bodies in this region that were not apposed to GLP-1 fibers. 
Higher magnification of the lPBN region (B).Cell nuclei are stained with DAPI (blue). Half of the CGRP-positive 
cells in the lPBN receive GLP-1 innervation (C), and the majority of GLP-1 innervated cells were CGRP-positive 
(D). 
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INTRA-PBN INJECTION OF CGRP REDUCES 
FOOD INTAKE 
Direct injection of CGRP into the lPBN resulted in a significant reduction in 
food intake; however, the effect of CGRP on food intake was short-lived and 
only lasted approximately 2 hours (Figure 20A). No significant differences in 
food intake were seen 3 or 16 hours after treatment (Figure 20A & B). These 
results indicate that part of the effects of GLP-1 on food intake in the lPBN 
may be due, in part, to its actions on CGRP neurons and receptors in this area. 
To further determine the necessity of CGRP- neurons for the effects of intra-
lPBN GLP-1R stimulation on food intake, further experiments blocking these 
neurons prior to intra-lPBN GLP-1R stimulation, together with food intake 
measurements, are required. However, in addition to CGRP-neuronal activation, 
other central mechanisms are most likely also involved, at least in the long term 
regulation of food intake of the peptide, as CGRP only produces a transient 
reduction on food intake, and isn’t sufficient to produce long term changes in 
body weight. 
 Lateral PBN injection of CGRP reduced chow consumption up to 2 hours after injection (A). This effect Figure 20.
was short lasting; chow intake (B) and body weight (C) measured 16 hours after injection were not altered. Data are 
expressed as mean ± SEM. n = 12.*p<0 .05. 
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PAPER III 
The effects of certain food-intake regulating hormones, for example leptin and 
ghrelin, have been shown to have differential effects in males and females 
(Clegg et al., 2006; Clegg et al., 2007; Clegg et al., 2003). In addition, sex 
differences have been implicated in drug addiction, modulating the rewarding 
effects of drugs of abuse by acting in reward-regulating areas (Becker, 1990; 
Becker et al., 1984; Justice and De Wit, 2000; Zhang et al., 2008). However, little 
is known about the actions of sex hormones on food reward. In this paper we 
aimed to investigate potential differences, between sexes, in the effects of GLP-
1 on food intake and reward. 
SEX MODIFIES THE EFFECT OF CENTRAL GLP-
1R STIMULATION ON FOOD REWARD 
To investigate potential differences in the central effects of GLP-1R stimulation 
on food-motivated behavior, a group of rats of each sex received 
intracerebroventricular injections of Ex4 prior to operant-conditioning testing. 
Central GLP-1R stimulation reduced food-motivated behavior in females, but 
not males, in ad libitum fed rats (Figure 21A & B). While the main effect of sex 
on these parameters was not significant, there was a significant interaction 
between the effect of Ex4 and sex. After overnight food restriction, central Ex4 
treatment successfully reduced food-motivated behavior in both sexes, although 
to a larger extent in females than males (Figure 21E & F). The interaction 
between drug treatment and sex was also significant, indicating a sex difference 
in the central effects of GLP-1R stimulation on food reward.  
The effects of Ex4 treatment on food intake did however not differ between 
sexes. While there was a significant reduction in both palatable (peanut butter) 
and standard food intake after Ex4 treatment, the effects of the treatment on 
males and females were not significantly different (Figure 21C, D, G & H). 
These results suggest that the sex differences in food-reward behavior may be 
specific to the “wanting” component of food reward, and not “liking”. 
However, one must take into account that peanut butter consumption is not an 
ideal test for palatability, or “liking”, especially in comparisons between sexes, 
since one cannot rule out differences in ingestion, satiety levels or an interaction 
with satiety signals. “Liking” is commonly investigated by studying facial 
expressions in response to a taste, where positive, or “liking”, responses include 
licking of the lips and rhythmic tongue protrusions (Berridge et al., 2009). These 
tests were not included in the current study; examination of these behaviors is 
Central targets for the effects of glucagon-like peptide-1 on food intake and reward 
66 
 
necessary to draw more accurate conclusions regarding the effects of Ex4 on 
palatability.  
Despite previous studies demonstrating a reduction in food-reward behavior in 
males after Ex4 treatment (Dickson et al., 2012; Shirazi et al., 2013b), males in 
this study did not exhibit any effects of treatment on food reward in the non-
food deprived state. The absence of this effect may be due to differences in 
feeding state during training and testing, as rats in the specified studies were 
food restricted for these tasks, while rats in the current experiment were not; 
this may indicate a sensitivity to feeding state in the effects of Ex4 on food-
motivated behavior. 
 Central Ex4 treatment led to a significant reduction in sucrose rewards earned (% of vehicle value; Figure 21.
A) and active lever presses for sucrose (% of vehicle value; B) in ad libitum fed females, but not males. In the 
food restricted feeding state, Ex4 treatment led to a significant reduction in both parameters in both sexes (E & 
F). Intake of peanut butter and chow were significantly reduced in both ad libitum fed and food restricted males 
and females; however, the effect of treatment did not differ between sexes (C, D, G, H). Data are expressed as 
mean ± SEM. n = 20 (females) and 18 (males) per treatment group in the ad libitum condition and n = 10 
(females) and 9 (males) per treatment group under the food restricted condition. *p < 0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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CENTRAL ESTROGEN BLOCKADE ATTENUATES 
THE EFFECTS OF EX4 ON FOOD-MOTIVATED 
BEHAVIOR 
To investigate if the sex differences in the effects of GLP-1R stimulation on 
food-motivated behavior are mediated by estrogens, central estrogen receptors 
(ERα and ERβ) were blocked prior to central Ex4 injections and operant 
conditioning testing in food-restricted males and females. Central estrogen 
receptor blockade, using the selective estrogen receptor antagonist ICI, led to 
the attenuation of Ex4’s effects of on food-motivated behavior in females 
(Figure 22C & D). Interestingly, similar effects of estrogen receptor blockade on 
this behavior were also present in males, since the effects of Ex4 on sucrose 
rewards earned were attenuated by pretreatment with ICI (Figure 22A). Ex4 
treatment in males did not result in a significant reduction in active lever presses 
for sucrose (Figure 22B). Male and female data combined revealed a significant 
difference between the Ex4 vs ICI/Ex4 groups in sucrose rewards earned 
(Figure 22E). Importantly, ICI treatment alone did not have any effects on 
reward-related behavior.  
In contrast to food-motivated behavior, estrogen receptor blockade did not 
attenuate the effects of Ex4 on the intake of palatable food (peanut butter) 
in males or females (Figure 23A & C), nor did it attenuate the effects of Ex4 
on 24-hour chow intake in males (Figure 23B). Surprisingly, Ex4 did not 
significantly reduce peanut butter in males in the current experiment, though 
it has been shown to do so in previous studies (Dickson et al., 2012). This 
difference may be due to an insufficient amount of test subjects. In contrast 
to peanut butter, ICI treatment attenuated the Ex4-mediated reduction in 
chow intake in females (Figure 23D).  
Since estrogen is mainly considered a “female hormone”, it may be 
surprising that the hormone is able to increase the potency of Ex4 in both 
sexes. However, estrogen is produced in the periphery and brain in both 
sexes (Marrocco and McEwen, 2016). In addition, estrogen has previously 
been shown to potentiate the effects of Ex4 in both sexes in one recent 
studies where co-administration of GLP-1 and estrogen in a conjugated 
form was shown to reduce food intake and body weight, at doses of the 
hormones that were ineffective alone, in both males and females (Finan et 
al., 2012; Vogel et al., 2016). Taken together with the current data, this 
suggests that estrogen signaling is sufficient to enhance the effects of 
centrally acting GLP-1 on food-motivated behavior in both sexes, but not 
necessary for its effects on food intake in males. 
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Figure 22. Combined treatment with the selective estrogen antagonist ICI and Ex4 attenuated the reduction in 
sucrose rewards earned in females (C) and males (A) compared to Ex4 treatment alone; this effect was however 
not significant. Reduction of active lever presses for sucrose was also attenuated in females after ICI treatment 
(D). Active lever presses was not significantly reduced by Ex4 treatment in males (B). The number of sucrose 
rewards earned for males and females combined was reduced after central Ex4 injection (E); this effect was 
attenuated after co-administration with ICI. Combined results for males and females also demonstrate a 
significant reduction in lever presses for sucrose after central GLP-1R stimulation (F); attenuation by the ICI 
treatment did not reach statistical significance. Data are expressed as mean ± SEM. n = 10 (females) and 18 
(males) per treatment group. *p<0.05, **p<0.01, ****p<0.0001. 
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Figure 23. Central GLP-1R stimulation did not reduce peanut butter intake in males (A); it did however 
reduce the intake of peanut butter in females (C), and chow in both sexes (B & D). ICI only attenuated the 
actions of Ex4 on chow intake in females (D). Data are expressed as mean ± SEM. n = 10 (females) and 9 
(males) per treatment group for peanut butter measurement and n = 10 (females) and 18 (males) per treatment 
group for chow intake. *p<0.05, ***p<0.001. 
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THE ESTROGEN-MEDIATED POTENTIATION OF 
EX4’S EFFECTS ON FOOD-MOTIVATED 
BEHAVIOR MAY BE DUE TO ACTIONS ON ERα 
ERα has previously been shown to play an important role in homeostatic food 
intake and body weight regulation, while studies have failed to find a connection 
in these behaviors with ERβ (Asarian and Geary, 2013). In addition, ERβ, but 
not ERα, activation was previously shown to increase cocaine-seeking behavior 
(Larson and Carroll, 2007), in contrast to potentiating a reduction in food-
reward in the current study; we therefore aimed to investigate if the enhanced 
effects of estrogen on GLP-1R activation induced effects on food intake and 
reward were mediated by ERα. 
ERα blockade using the specific ERα antagonist MPPd led to an attenuation of 
the Ex4-mediated reduction in sucrose rewards earned in both males and 
females (Figure 24A and C), and active lever presses for sucrose in females (Figure 
24D). In males, Ex4 treatment did not lead to a significant reduction in active 
lever presses for sucrose (Figure 24B). When analyzing males and females 
combined, there was a significant difference between the Ex4 and MPPd/Ex4 
injected groups (Figure 24E). While the effects of Ex4 on active lever presses for 
sucrose of males and females was attenuated by MPPd treatment, differences 
between the Ex4 and MPPd/Ex4 groups did not reach significance (Figure 24F). 
In contrast, MPPd treatment did not attenuate the effects of Ex4 on peanut 
butter or chow intake in either sex (Figure 25A-D).  
While the neural systems controlling ingestive and motivated behaviors are 
connected, food also has the ability to tap into, and affect, one of these systems 
without altering the other. For instance, peripheral signals transmitting signals 
about food intake and energy balance can increase intake in times of metabolic 
need, while appetitive foods, such as those high in sugar and fat, can increase 
the drive to eat when no such need is present as previously discussed. 
Therefore, it is plausible that ERα only affects the “liking” and “wanting” 
aspects of Ex4s effects on food intake, without altering general consummatory 
behaviors.  
ERα antagonist MPPd was previously shown to be insufficient to attenuate the 
effects of estradiol on food intake (Santollo and Eckel, 2009). MPPd did 
however reduce the estrogen-related decrease in food intake present in the 
estrus phase of intact, cycling females; it may therefore be of interest to analyze 
the effects of ERα blockade on Ex4 treatment in females, divided based on 
cycle phase, in future studies, as cycle phase was not determined in the present 
study. 
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 Central administration of Ex4 in food-restricted rats led to a reduction in sucrose rewards Figure 24.
earned in females (C) and males (A). Ex4 no longer significantly reduced sucrose rewards earned after 
administration of the specific ERα-antagonist MPPd. Ex4 treatment also reduced lever presses for 
sucrose earned in females (D) and produced a trend for a reduction in males (B). Compilation of female 
and male data revealed a significant reduction in sucrose rewards earned (E) and active lever presses (F) 
after Ex4 treatment that was attenuated after combined MPP/Ex4 treatment. Data are expressed as 
mean ± SEM. n = 7–9 for males and females. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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 Central injection with the GLP-1R agonist Ex4 significantly reduced peanut butter intake Figure 25.
and chow intake in males (A & B) and females (C & D). The reduction was still present after 
treatment with the ERα-antagonist MPPd. Data are expressed as mean ± SEM. n = 7–9 for males 
and females. **p<0.01, ***p<0.001. 
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PAPER IV 
The LH is known as “the feeding center” and has been shown to play an 
important role in the drive to feed. In addition, the nucleus also regulates 
motivated behavior and is one of the most potent self-stimulation centers of the 
brain (Hoebel and Teitelbaum, 1962; Margules and Olds, 1962; Olds, 1962); the 
LH is therefore suggested to act as an interface between the homeostatic and 
hedonic control of feeding behavior, integrating metabolic and reward signals. 
GLP-1 neurons innervate the LH and GLP-1Rs are expressed  throughout this 
area (Larsen et al., 1997; Merchenthaler et al., 1999); however, despite studies 
demonatrating the role of GLP-1 in the regulation of food reward in other 
areas, whether this peptide alters food-reward behavior by acting in the LH was 
previously unknown. 
GLP-1RS ARE PRESENT ON LH-VTA PROJECTING 
NEURONS 
To investigate a potential connection between GLP-1 in the LH and the reward 
system, we began by examining if LH-VTA projecting neurons express GLP-
1Rs.  
Approximately 55% of LH-VTA projecting cells contain GLP-1R mRNA, 
suggesting that the VTA may be one of the underlying targets behind potential 
effects of intra-LH GLP-1R stimulation on food reward behavior (Figure 26). 
 Representative images of GLP-1Rs on LH neurons that project to the VTA. Site of injection in the Figure 26.
VTA of cholera toxin subunit B (CTB) conjugated to AlexaFluor 488 (A). Back-labeled cells were present in the 
rostral LH region, dorsal to the fornix (B). Representative images of GLP-1R in situ hybridization (red; C), back-
labeled CTB-positive neurons from the VTA (green; D) and DAPI nuclear stain (blue; F). Merged image showing 
colocalization of GLP-1R and CTB in the LH (white arrows; G), and a confocal image of a double-labeled GLP-
1R and CTB-positive neuron with DAPI counterstain (H). 
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ACUTE LH-TARGETTED GLP-1R ACTIVATION 
REDUCES FOOD INTAKE AND FOOD-
MOTIVATED BEHAVIOR 
After finding a potential connection with the reward system, we next 
investigated if LH GLP-1R stimulation indeed alters food-motivated behavior. 
In male rats, intra-LH injection of Ex4 led to a significant reduction in sucrose-
rewards earned (Figure 27A) and active lever presses for reward (Figure 27B). In 
addition, chow intake was reduced 1 and 24 hours after treatment (Figure 27C & 
D). 
 Intra-LH GLP-1 analogue Ex4 microinjection reduced the amount of sucrose rewards earned (A,) Figure 27.
and the number of lever presses for the rewards (B), in a progressive ratio schedule in male rats. Food ingestion 
is also affected, as illustrated by a potent reduction in 1 (C) and 24 hour (D) chow intake. Data are expressed 
as mean±SEM. n=14–15 (male rats). *p<0.05, **p<0.01,***p<0.001, ****p<0.0001. 
In addition, the same treatment produced a slightly less potent suppression in 
food-motivated behavior in females, where only the higher dose of Ex4 was 
sufficient to reduce sucrose rewards earned (Figure 28A); active lever pressing 
did not reach significance at any of the doses administered (Figure 28B). Food 
ingestion was also affected by intra-LH Ex4 treatment in females; however, 1 
hour intake in females was only reduced after administration of the higher dose 
of Ex4, while both doses significantly reduced 24- hour chow intake (Figure 28C 
& D). 
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EFFECTS OF INTRA-LH GLP-1R STIMULATION 
ON FOOD INTAKE AND FOOD-MOTIVATED 
BEHAVIOR IS DEPENDENT ON ESTROUS CYCLE 
PHASE 
Estrogen levels vary with the reproductive cycle and these variations have been 
shown to affect appetite, both through actions on ERs and by interacting with 
various peptides, such as leptin, ghrelin and CCK. In addition, sex and estrogens 
have been shown to play a role in reward behavior, with direct effects of cycle 
phase on the reward system. Due to the sex differences observed in Ex4’s effect 
on food-reward behavior in the previous experiment, we decided to investigate 
if these differences are due to an influence of the hormonal variations of the 
estrous cycle. 
Females in the estrus, but not mestaestrus/diestrus, responded to intra-LH Ex4 
treatment with reduced food-motivated behavior (Figure 29A & B). Food intake 
was significantly reduced in all examined estrous phases (Figure 29C & D). 
 
Figure 28. In females, only the higher dose of Ex4 reduced the amount of sucrose rewards earned (A) and 
resulted in a trend to reduce the number of lever presses for rewards (B) in the operant conditioning test. Food 
ingestion was also affected in female rats as illustrated by a reduction in 1 (C) and 24 hour (D) chow intake. 
Data are expressed as mean ±SEM. n=9-37. *p<0.05, ***p<0.001, ****p<0.0001. 
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 Intra-LH Ex4 reduced the effort to obtain a reward (A & B) in a sucrose-motivated progressive Figure 29.
ratio task in females in the estrus phase (E), but not metestrus or diestrus (MD) phases, of their cycle. Ex4 
potently reduced ingestive behavior in all females irrespective of the cycle phase (C & D). Data are expressed as 
mean ±SEM. n=19 (vehicle in E), n=20 (Ex4 in E), n=8 (vehicle in MD) and n=8 (Ex4 in MD). 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
LH GLP-1R ACTIVATION ALTERS LH 
NEUROPEPTIDE EXPRESSION IN A SEX 
DIVERGENT MANNER 
To investigate potential downstream mechanisms of the effects of intra-LH 
GLP-1R stimulation, gene expression of molecules previously shown to alter 
food intake and reward in this area was examined (Reichelt et al., 2015; 
Schroeder and Leinninger, 2018; Shirazi et al., 2013a). 
Intra-LH Ex4 treatment led to a significant increase in the anorexic interleukins 
IL-1 and IL-6 in males; in addition, MCH expression was reduced in this area 
(Figure 30A). In females, the estrous-dependent differences in the effect of Ex4 
on intake and reward were mirrored by the gene expression results. Expression 
of IL-1, IL-6, neurotensin and orexin was reduced in females, only in the estrus 
phase (Figure 30B). A reduction in MCH was detected in all cycle phases. 
Changes in LH gene expression are similar between males and females in estrus, 
though males display a stronger IL-6 induction than females, while females in 
metaestrus/diestrus show no changes in IL-1 and IL-6 expression (statistical 
comparisons not shown). 
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Interleukins IL-1 and IL-6 have previously been suggested to mediate the 
anorexic effects of GLP-1 in the CNS (Shirazi et al., 2013a). In addition, the 
expression of MCH, the orexigenic LH neuropeptide, was reduced in response 
to LH GLP-1R stimulation in both sexes. The increase in anorexic interleukins, 
and reduction in orexigenic MCH expression, most likely contribute to the food 
intake and food-reward reducing effects of GLP-1R stimulation in the LH. 
 Ex4 administration selectively within the LH increased the expression of interleukins IL-1 and IL-6 in Figure 30.
males (A) and females in the estrus (E) phase, but not meteaestrus/diestrus (M) phases (B). In addition, melanin-
concentrating hormone (MCH) expression was reduced in males (A), and in all females, regardless of cycle phase (B). 
The expression on neurotensin (NT) and orexin (ORX) was reduced in response to intra-LH Ex4 treatment in 
females. Data were normalized to the housekeeping gene β-actin and are expressed as mean ±SEM. n=19 
(vehicle in E, n=20 (Ex4 in E), n=8 (vehicle in M) and n=8 (Ex4 in M). *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
In females, there was also a significant reduction in orexin expression. A 
potential link between GLP-1 and orexin neurons in the LH was previously 
suggested by Acuna et al, where GLP-1 was shown to depolarize orexin neurons 
(Acuna-Goycolea and van den Pol, 2004); a reduction in neuronal activity of 
these neurons could therefore also contribute to the reductions in food intake 
and reward, specifically in females. 
Interestingly, estrous cycle phase played an important role in the effects of 
GLP-1R stimulation in the LH of females. Both behavioral (reward and food 
intake), and gene expression, changes in this area were dependent on cycle 
phase, with most potent effects displayed in a high estrogen signaling phase 
(estrus), and nearly no effect in low estrogen signaling phases 
(metaestus/diestrus). Hormonal fluctuations within the estrous cycle may 
therefore drive the differences in the studied behaviors between males and 
females. 
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ACUTE PHARMACOLOGICAL BLOCKADE OF 
GLP-1RS IN THE LH INCREASES FOOD-
MOTIVATED BEHAVIOR IN MALES 
Intra-LH GLP-1R blockade led to a significant increase in sucrose rewards 
earned (Figure 31A) and active lever presses (Figure 31B), only in males. 
Surprisingly, food intake was unaltered by Ex9 treatment in both sexes (Figure 
31C & D). 
Since GLP-1R stimulation in the LH of females was only effective in the estrus 
phase, Ex9 treatment was also administered to a separate group of females, only 
in this specific cycle phase; however, no significant differences of the treatment 
were found in this experimental group (data not shown). These data suggest that 
while LH GLP-1R activation seems to be sufficient to reduce food intake and 
motivated behavior in both sexes, it is only necessary for motivated behavior in 
males. 
That Ex4 exerts a more potent effect on food intake and reward in this area in 
males is somewhat surprising, since previous results in our lab demonstrated 
larger effects on these behaviors in females after central Ex4 treatment (Richard 
et al., 2016). However, more recent data indicate that the LH is not affected by 
the potentiating effects of estrogen on these behaviors (Vogel et al., 2016); 
therefore the cycle dependent effects and male/females differences may be due 
to another cycle-phase dependent hormone. 
Figure 31. LH microinjection of GLP-1R antagonist, Ex9 increased the amount of sucrose rewards earned 
(A), and the number of lever presses for the rewards (B), in a progressive ratio schedule in male rats. None of 
these parameters were altered in female rats (A & B). Food ingestion, measured at 1 (C) and 24 hours (D), 
was unaffected in both sexes. Data are expressed as mean ±s.e.m. n=8–10 (male rats) and n=14 (female rats). 
*p<0.05, **p<0.01, #p=0.07. 
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CHRONIC INTRA-LH GLP-1R BLOCKADE 
INCREASES FOOD INTAKE, BODY WEIGHT AND 
REWARD PARAMETERS IN MALES, BUT NOT 
FEMALES 
To determine whether chronic GLP-1R blockade alters food intake or food-
motivated behavior, GLP-1Rs were knocked down virally in a bilateral manner; 
this manipulation led to an approximate 50% and 80% reduction in GLP-1R 
expression in males and females respectively (Figure 32A & B). 
 GLP-1R expression in LH of males (A) and females (B) after site-specific GLP-1R knockdown. Data Figure 32.
are expressed as mean ±SEM. n=14–15 (males), n=10 (females). *p<0.05. 
In males, intra-LH GLP-1R knockdown led to a significant increase in food 
intake (Figure 33A) and body weight (Figure 33B). In addition, decreased GLP-
1R expression in this area increased the fat mass of gonadal and inguinal adipose 
tissues (Figure 33C). Interestingly these results are in contrast to whole body, or 
CNS specific, GLP-1R knockout studies in mice, where no changes in body 
weight, food intake or fat mass were reported (Finan et al., 2012; Scrocchi et al., 
2000; Sisley et al., 2014). The lack of effects of GLP-1R knockout in these 
previous studies may be due to species differences or developmental 
compensation of the knockout in the mice. In addition, since acute 
pharmacological blockade of intra-LH GLP-1Rs failed to increase these 
parameters, the effects of acute blockade of these receptors may be 
compensated for by, for instance, other GLP-1R-expressing sites. Effects of 
intra-LH knockdown on food intake and body weight were not present in 
females (Figure 33D-F). 
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Knockdown of GLP-1Rs in the LH also led to a significant increase in sucrose 
rewards earned (Figure 33G), and a trend in active lever presses for reward (Figure 
32H) in males. Again, no significant effects of intra-LH GLP-1R knockdown on 
food-motivated behavior were seen in females (Figure 33I & J) 
.  
 Chronic blockade of GLP-1 receptors in the LH led to a significant increase in food intake (A), Figure 33.
body weight (B) and gonadal (GWAT) and inguinal (IWAT) adipose tissue (C) in males. No significant 
differences in food intake (D), body weight (E) or fat mass (F) were present after GLP-R knockdown in 
females. A significant reduction in sucrose rewards earned was present in males (G) after chronic GLP-1R 
knockdown, while active lever presses for sucrose rewards did not reach significance (H). These parameters were 
not altered in females (I & J). Data are expressed as mean ±SEM. n=14–15 (males), n=10 (females). 
*p<0.05, **p<0.01, #p<0.1. 
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Obesity and related conditions pose one of the biggest physical threats on our 
society today. With sparse treatment options, and the majority of current 
treatments resulting in suboptimal therapeutic outcomes, the development of 
more effective pharmaceutical options is required. 
The current primary treatment for obesity is the prescription of lifestyle 
changes, i.e. dietary changes, physical activity and behavioral therapy. It has, 
however, become evident that enforcing these changes poses many difficulties, 
leading to low adherence and resulting in no more than 5-10% body weight loss 
(Wadden et al., 2012). 
The most effective weight-loss treatment is currently bariatric surgery, for 
instance gastric bypass (Roux-en-Y) surgery, a procedure in which the majority 
of the stomach is bypassed, and food is directed directly to the small intestine. 
This leads to a reduction in the quantity of food that can be consumed by the 
individual and the absorption of nutrients and energy, resulting in reduced body 
weight. Gastric bypass was shown to reduce body weight by approximately 30% 
in the first year, with patients still maintaining a 20% weight loss 10 years after 
surgery (Maciejewski et al., 2016). However, gastric bypass surgery also poses a 
number of short- and long-term risks for the individual, even resulting in death 
in rare cases. Furthermore, the procedure cannot be applied as a general 
solution for the ever-growing obese population, as it comes with substantial 
costs for both the individual and society, making it a suboptimal treatment 
choice for obese individuals in general. 
Apart from weight-loss surgery, there are a number of available pharmaceutical 
treatments on the market; orlistat (Xenical), lorcaserin (Belviq), phentermine-
topiramate (Qsymia) and naltrexone-bupropion (Contrave) are some of the 
most commonly prescribed. The treatments work through a variety of 
mechanisms, both central and peripheral. However, these medications only 
result in an approximate weight-loss of 3-9% (Yanovski and Yanovski, 2014), 
and increase the risk of a number of side-effects including gastrointestinal 
issues, nausea, headaches, increased heart rate and/or blood pressure. 
In addition to the pharmaceutical treatments mentioned above, the synthetic 
GLP-1R agonist Liraglutide (Saxenda) was also recently approved for weight-
loss treatment. Liraglutide treatment does not exclude the risk of side-effects; it 
has an increased risk of nausea, diarrhea, constipation, abdominal pain, 
headaches and increased pulse. While the weight loss effects of this drug are 
slightly larger than orlistat or lorcaserin, liraglutide treatment only results in a 5-
10% reduction in body weight (Mehta et al., 2017). Since GLP-1R agonist 
treatment is already on the market, and widely used in the obese population, 
both as a treatment for obesity and type II diabetes, it is of great importance to 
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investigate the full nature of the peptide on the CNS. In addition, determining 
the sites responsible for the positive effects of the drug on food intake, body 
weight and food reward, may enable enhanced outcomes of the drug on these 
parameters, in addition to circumventing unwanted side-effects. 
The included studies identify several new nuclei in the actions of GLP-1R 
stimulation on food intake and reward, such as the NTS, the PBN and the LH, 
increasing the understanding of the central mechanisms of the hormone on 
these behaviors. In addition, site-specific treatment in these areas did not seem 
to result in nausea, as rodents did not display signs of pica and/or locomotor 
impairment after GLP-1R agonist administration. The current data therefore 
identifies several nuclei for future site-specific GLP-1R treatment to reduce the 
risk of certain side-effects. 
Several molecules mediating the anorexigenic and food reward reducing effects 
of GLP-1 were also identified, for example CGRP, IL-6 and estrogen. Targeted 
combination of GLP-1R agonist with one or more of these molecules may 
therefore also facilitate the development of more effective weight-loss 
treatments. However, more research is necessary to evaluate the safety and 
effects of combined treatments, in addition to examining the presence of these 
effects in the human population. 
GLP-1-based treatment is prescribed for obesity and type II diabetes in both 
men and women. However, few preclinical studies have explored the 
neurobiology and physiology of food-intake and reward regulation in females. 
Furthermore, drug safety and efficacy have, until recently, not been studied in a 
sex specific manner, neither in animals or humans (Liu and Mager, 2016). Lack 
of this knowledge increases the risk of differences in clinical outcome between 
men and women, i.e. effectiveness and potency of the drug, and differences in 
incidence and/or severity of side-effects.  
Prior to Paper III, little was known about the actions of GLP-1 on reward in 
females. Together with Paper IV, our data suggest that GLP-1R agonist 
treatment may have a differential ability to regulate motivated and ingestive 
behaviors in males and females; in addition, administered synthetic GLP-1 may 
act in a sex-specific manner on select brain nuclei in the CNS to alter these 
behaviors. These data therefore highlight the dichotomy between ingestive and 
food reward studies, where sex differences may be present in one behavior, but 
absent in the other. In general, our data indicate a higher sensitivity to GLP-1-
based substances, centrally in females. However, distinct GLP-1R populations, 
for instance in the LH, may be less sensitive to actions of the hormone.  
While most preclinical studies on GLP-1’s effects were previously conducted 
exclusively in males, clinical studies often include both sexes; regardless these 
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studies often fail to examine the presence of potential sex differences. In 
addition, human fMRI studies often fail to test for sex differences as studies are 
either conducted exclusively in one sex, or the numbers are not powered for 
detecting differences when both sexes are included. Interestingly, in a recent 
study examining Ex4’s effects in diabetic patients, men and women displayed 
different sensitivity to the effects of exanatide, where men showed higher 
sensitivity to the glucose-regulating effects of GLP-1 agonist treatment, while 
women displayed a higher sensitivity to its weight-loss effects (Anichini et al., 
2013). Increased weight loss in females, compared to males, is also in line with 
our data in Paper III, indicating that sex differences in the effects of GLP-1 
agonist treatment may be present across several species, including humans, and 
not specific to rodents. While further studies in a healthy, obese population are 
required to determine whether these differences persist in a non-diabetic state, 
these data suggest that there is a need for sex-specific therapies for treatment 
with GLP-1 agonists, where differential prescription guidelines, based on 
indication, may be necessary. In addition, studies investigating potential sex 
differences in the effects of GLP-1 agonists on food reward in humans are 
needed, as to my knowledge, this has not yet been investigated. 
Though the risk for obesity and/or type II diabetes increases significantly after 
menopause, to my knowledge, there are no studies investigating potential 
differences in GLP-1 agonist therapy in pre- versus post-menopausal women. 
Estrogen, a hormone which is drastically reduced after menopause, was recently 
shown to increase endogenous GLP-1 production, contributing to estrogen’s 
protective role against type II diabetes (Handgraaf et al., 2018). These data are in 
line with previous reports demonstrating that pre-menopausal women have 
higher systemic GLP-1 levels than post-menopausal women, and men (Santos-
Marcos et al., 2018). Furthermore, ER expression has been shown to vary based 
on estrogen level and reproductive state, and central estrogen levels are affected 
by ovarian estrogen production (Fukuda et al., 2000; Kato et al., 2013; Konkle 
and McCarthy, 2011; Shughrue et al., 1992). Together with the current data, 
demonstrating the ability of estrogen to alter the effects of GLP-1 treatment on 
food reward, GLP-1-based obesity treatment regimens may also have to take 
menopausal state, and/ or cycle phase, into account. 
Beyond diabetes and obesity, GLP-1 agonists are also under evaluation as 
potential treatments for several other diseases and disorders, including substance 
abuse. There are prominent gender differences in the prevalence of addiction 
and substance abuse where  men have higher rates of use and dependence of 
both alcohol and illegal substances (Substance Abuse and Mental Health 
Services Administration, 2016). However, women have been suggested to be 
more susceptible to craving, and at higher risk for relapse (Fox et al., 2014; 
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Hitschfeld et al., 2015; Kennedy et al., 2013; Kippin et al., 2005; Robbins et al., 
1999; Rubonis et al., 1994).  
Ex4 has previously been shown to reduce alcohol-mediated behaviors and is a 
promising candidate for alcohol dependence treatment (Egecioglu et al., 2013; 
Shirazi et al., 2013b; Vallof et al., 2016). In addition, initial experiments from the 
Jerlhag lab indicate that there may be differences in the effectiveness of GLP-1 
analogue treatment between males and females, particularly regarding long-term 
treatment and relapse after cessation of treatment (manuscript in progress). 
These data suggest that the sex differences in the effects of GLP-1 based 
treatment on food reward, demonstrated above, may also be relevant when used 
to treat other forms of addiction.  
Moreover, a series of recently published papers demonstrate that Ex4 attenuates 
cocaine seeking in rodents; however, none of these studies took sex into 
account (Hernandez et al., 2018; Hernandez et al., 2019; Schmidt et al., 2016). 
Women have previously been shown to progress faster to cocaine dependence, 
and display a greater incidence of relapse (Fox et al., 2014; Robbins et al., 1999). 
In addition, female rats display a greater preference for cocaine rewards; an 
effect which has been shown to be estrogen-dependent (Kerstetter et al., 2012; 
Kerstetter and Kippin, 2011). Thus, future therapies for cocaine addiction may 
need to take menstrual cycle phase into account.  
In addition to addiction, GLP-1 agonists are currently being investigated as a 
potential treatment for neurodegenerative diseases, such as Alzheimer’s and 
Parkinson’s disease. GLP-1 agonist treatment has been shown to exert 
neuroprotective effects and improve cognitive symptoms, and Ex4 was recently 
shown to improve motor symptoms in Parkinson’s disease (Athauda et al., 2017; 
Salcedo et al., 2012). Despite that it is well known that sex largely impacts the 
prevalence, risk factors and outcomes for these diseases (Podcasy and 
Epperson, 2016), there are currently no studies evaluating potential sex 
differences in the sensitivity, or outcome of GLP-1-based treatments. 
Interestingly, sex was previously suggested to affect the treatment response of 
intranasal insulin in men and women, where the beneficial effect of the drug on 
cognitive improvement was superior in men (Claxton et al., 2013). Since part of 
the neuroprotective effect of GLP-1 agonists on neurodegenerative disease is 
thought to be mediated by improving central insulin signaling (Holscher, 2012), 
sex differences in the efficacy of GLP-1-based therapies on neurodegeneration 
may also exist. 
Taken together, these data suggest that specific guidelines for GLP-1 agonist 
treatment may be necessary based on sex and reproductive state. In addition, 
such guidelines may also be required for future GLP-1 based treatments 
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targeting other conditions, such as drug addiction or Alzheimer’s and 
Parkinson’s disease.  
In summary, this thesis identifies three novel sites of action through which 
GLP-1 mediates its actions on food intake and/or food reward: 1. The NTS, 
where GLP-1 alters dopaminergic transmission in the VTA by acting on intra-
NTS noradrenergic neurons. 2. The PBN, where effects on food intake and 
body weight are mediated through an increase in CGRP and the cytokine IL-6, 
and 3. The LH, where GLP-1R stimulation results in a reduction in food intake, 
body weight and food reward; effects attributed to an increase in the cytokines 
IL-1 and IL-6. Actions of the hormone in this area are sex specific; necessary 
and sufficient in males, while solely sufficient in females. In addition, the sex 
steroid estrogen alters the effects of GLP-1 on reward by acting on ERα-
receptors, and females have a higher sensitivity to the food-reward reducing 
effects of GLP-1 than males. A working model for the combined results is 
demonstrated in Figure 34. 
 
 Working model of the effects of GLP-1R stimulation on specific brain nuclei, and sex specific actions, Figure 34.
as demonstrated in this thesis. GLP-1 = glucagon-like peptide-1, GLP-1R = GLP-1 receptor, NTS = 
nucleus of the solitary tract, VTA = ventral tegmental area, NAc = nucleus accumbens, LH = lateral 
hypothalamus, PBN = parabrachial nucleus, ERα = estrogen receptor alpha, NA = noradrenaline, DA = 
dopamine, TH = tyrosine hydroxylase, IL-6 = interleukin 6, IL-1 = interleukin 1, MCH = melanocortin-
stimulating hormone, NT = neurotensin, CGRP =calcitonin gene-related peptide. 
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Abstract
The gut/brain peptide, glucagon like peptide 1 (GLP-1), suppresses food intake by acting on
receptors located in key energy balance regulating CNS areas, the hypothalamus or the
hindbrain. Moreover, GLP-1 can reduce reward derived from food and motivation to obtain
food by acting on its mesolimbic receptors. Together these data suggest a neuroanatomical
segregation between homeostatic and reward effects of GLP-1. Here we aim to challenge
this view and hypothesize that GLP-1 can regulate food reward behavior by acting directly
on the hindbrain, the nucleus of the solitary tract (NTS), GLP-1 receptors (GLP-1R). Using
two models of food reward, sucrose progressive ratio operant conditioning and conditioned
place preference for food in rats, we show that intra-NTS microinjections of GLP-1 or Exen-
din-4, a stable analogue of GLP-1, inhibit food reward behavior. When the rats were given a
choice between palatable food and chow, intra-NTS Exendin-4 treatment preferentially re-
duced intake of palatable food but not chow. However, chow intake and body weight were
reduced by the NTS GLP-1R activation if chow was offered alone. The NTS GLP-1 activa-
tion did not alter general locomotor activity and did not induce nausea, measured by PICA.
We further show that GLP-1 fibers are in close apposition to the NTS noradrenergic neu-
rons, which were previously shown to provide a monosynaptic connection between the
NTS and the mesolimbic system. Central GLP-1R activation also increased NTS expres-
sion of dopamine-β-hydroxylase, a key enzyme in noradrenaline synthesis, indicating a bio-
logical link between these two systems. Moreover, NTS GLP-1R activation altered the
expression of dopamine-related genes in the ventral tegmental area. These data reveal a
food reward-suppressing role of the NTS GLP-1R and indicate that the neurobiological tar-
gets underlying food reward control are not limited to the mesolimbic system, instead they
are distributed throughout the CNS.
PLOSONE | DOI:10.1371/journal.pone.0119034 March 20, 2015 1 / 21
OPEN ACCESS
Citation: Richard JE, Anderberg RH, Göteson A,
Gribble FM, Reimann F, Skibicka KP (2015)
Activation of the GLP-1 Receptors in the Nucleus of
the Solitary Tract Reduces Food Reward Behavior
and Targets the Mesolimbic System. PLoS ONE 10
(3): e0119034. doi:10.1371/journal.pone.0119034
Academic Editor: Julie A. Chowen, Hosptial Infantil
Universitario Niño Jesús, CIBEROBN, SPAIN
Received: October 21, 2014
Accepted: January 9, 2015
Published: March 20, 2015
Copyright: © 2015 Richard et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This research was funded by the Novo
Nordisk Foundation Excellence project grant (to
KPS), Swedish Research Council (2011-3054 to
KPS). FMG and FR were funded by the Wellcome
Trust (WT088357/Z/09/Z, WT084210/Z/07/Z). The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Introduction
Feeding behavior is thought to be regulated by two intermingled central nervous system (CNS)
pathways: homeostatic and hedonic [1–3]. Hedonic eating is suggested to be one of the main
culprits behind the increasing rates of obesity [4]; it is therefore incredibly important to investi-
gate the mechanisms underlying the drive to excessively consume palatable food. Dopamine
within the mesolimbic system is considered crucial for the hedonic aspects of feeding behavior
[5]. The intake of palatable food increases the activity of dopamine neurons in the ventral teg-
mental area (VTA) and the release of dopamine in the nucleus accumbens [6,7]. These two
mesolimbic nuclei are therefore considered crucial for food reward control and remain the
main neuroanatomical sites investigated in studies with a food reward focus. Here, however,
we suggest that this may be a limiting perspective and propose that the focus of the food reward
regulation studies should be expanded; we suggest that the nucleus of the solitary tract (NTS)
in the hindbrain may be an important neural substrate for regulation of food reward.
Glucagon-like peptide-1 (GLP-1) is one of the key signals involved in the CNS regulation of
feeding behavior [8–11]. GLP-1 is produced in intestinal L-cells and in the hindbrain, primarily
in the NTS [12]. GLP-1-producing neurons innervate the classic homeostatic energy balance-
controlling brain regions that include the hypothalamus and the NTS [12–14] and GLP-1 re-
ceptors (GLP-1R) have been found in these areas [15]. Hypothalamic and hindbrain GLP-1R
have been shown to play an important role in the homeostatic regulation of food intake
[16,17]. Stimulation and blockade of these receptors reduces and increases the amount of food
eaten respectively [16,17]. However, we have recently demonstrated that in addition to reduc-
ing the amount of food eaten central GLP-1R activation also reduces food reward behavior
which may represent the hedonic aspect of feeding behavior [18]. This impact of GLP-1R on
food reward behavior is thought to be mediated through its actions on the mesolimbic GLP-
1R, in areas commonly associated with reward, such as the nucleus accumbens and the VTA
[18]. Collectively these findings fit with the view that homeostatic aspects of feeding are regu-
lated by the action of GLP-1 in classically homeostatic areas and reward-driven aspects are
controlled by the mesolimbic actions of GLP-1. Here we want to challenge this view by hypoth-
esizing that GLP-1 can impact food reward by acting on its receptors in the hindbrain’s NTS.
Our hypothesis is strengthened by two recent reports that show that the fat produced hormone
leptin and the hypothalamic neuropeptide orexin impact on food reward behavior by acting on
their NTS receptors [19,20].
To test the role of NTS GLP-1R stimulation in food-motivated behavior and food reward
we utilized two behavioral models typically used to determine the addictive properties of sub-
stances, the progressive ratio operant conditioning test and conditioned place preference
(CPP) paradigm. The first task is a well-established test of motivated behavior [21], where the
higher the motivation to obtain the rewarding substance the harder the rat is willing to work
(press a lever) for it. In the conditioned place preference test the more rewarding the animal
finds the food, the more time it will spend in the food-associated compartment based on a
learned association between the food and the visuospatial cues from the reinforced location.
This procedure allows for testing in the absence of food, reducing any potential confounding
effects of postingestive feedback during testing. NTS noradrenergic neurons and neurons con-
taining cholecystokinin (CCK) send ascending projections from the NTS to the nucleus accum-
bens and the VTA providing a possible pathway in which GLP-1 acting within the brainstem
can affect the reward system [22]. Therefore in order to determine a potential link between
GLP-1 activation with activation of these two neuronal phenotypes, we first evaluated whether
central GLP-1R activation changes the gene expression of NTS CCK, and also two enzymes
key for noradrenaline production tyrosine hydroxylase (TH) and dopamine-β-hydroxylase
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(dBH). We next utilized a transgenic mouse [14] that expresses yellow fluorescent protein
(YFP) selectively in the GLP-1-producing neurons to determine whether these neurons inner-
vate TH-positive neurons in the NTS allowing a monosynaptic connection between GLP-1R
activation and the mesolimbic system. To further assess the impact of NTS GLP-1R activation
on the mesolimbic function we also determined the gene expression of key reward behavior as-
sociated genes in the VTA and nucleus accumbens induced by NTS GLP-1R stimulation. Col-
lectively our findings support the notion that the caudal brainstem participates in the control
of food reward and food-motivated behavior and identify potential mechanisms via which the
NTS GLP-1R-evoked signal may be transmitted to the mesolimbic pathways to reduce food-
reward behavior.
Materials and Methods
Animals
Male Sprague-Dawley rats (180–250 g at arrival and 400 g during the drug administration
tests, Charles River, Germany) were housed in a 12 h light/dark cycle, in individual cages with
free access to chow and water, except during the period of operant testing or peanut butter con-
sumption. Adult female and male mGLU-124 Venus yellow fluorescent protein transgenic
mice (YFP-PPG mice; University of Cambridge, United Kingdom [23]) were housed in plastic
cages with water and standard chow available ad libitum. All studies were carried out with ethi-
cal permissions from the Animal Welfare Committee of the Göteborg University, in accor-
dance with legal requirements of the European Community (Decree 86/609/EEC). All efforts
were made to minimize suffering.
Surgery
Rats were implanted with a guide cannula targeting the NTS or the lateral ventricle (26 gauge;
Plastics One, Roanoke, VA) under ketamine anesthesia as described previously [24,25]. The
following coordinates were chosen for the NTS: ±0.75mm from the midline/on occipital su-
ture/-4.9mm, with injector aimed 6.9 mm ventral to skull; the following coordinates were used
for the lateral: ±1.6 from the midline, 0.9 mm posterior to bregma, and 2.0 mm ventral to skull,
with injector aimed 4.0 mm ventral to the skull. NTS cannula placement was first verified one
week after the surgery by the measurement of the sympathoadrenal-mediated glycemic re-
sponse by microinjection of 5-thio-D-glucose (24μg/0.3μl) [26]. An elevation of plasma glucose
levels by 100% or more was required for subject inclusion in the study. Placement was also as-
sessed histologically post mortem by injection of India ink (0.3 μl volume matched drug deliv-
ery in the experiments). Only rats whose dye injection site was found within the NTS were
included in the data analysis (Fig. 1). The lateral ventricle placement was verified with the an-
giotensin II drinking test. Angiotensin II was injected at a dose of 20ng in 2μL of aCSF and
water intake was measured immediately. Rats that drank at least 5ml of water in 30 min, were
considered to have a correct cannula placement.
Drugs
Exendin-4 (Ex4), GLP-1 (7–36) and angiotensin II, were purchased from Tocris (Bristol, UK)
dissolved in aCSF (vehicle for all central injections) and stored as aliquots in -20°C.
Palatable food-choice test
Preference for palatable food (peanut butter) or chow was determined by offering the two
foods simultaneously on the test day. In order to determine the effect of NTS GLP-1R
Activation of GLP-1R in the NTS Reduces Food Reward Behavior
PLOS ONE | DOI:10.1371/journal.pone.0119034 March 20, 2015 3 / 21
activation on the palatable food choice, food presentation was preceded by intra-NTS microin-
jection of Ex4 (0.05 μg) or aCSF and the amount of chow and peanut butter eaten was mea-
sured at 1,3, and 6h. Injections were done in a counterbalanced, Latin square design with at
least 48h separating each injection condition. Variations in consumption due to neophobia
were reduced by familiarizing all the rats with the peanut butter on at least one occasion prior
to the test day. The amount of calories consumed was computed using the following values:
4.1 kcal/g for chow and 6.6 kcal/g for peanut butter.
PICA test
To determine whether Ex4 injections into the NTS are associated with nausea, the PICA re-
sponse was measured (consumption of non-nutritive substances that mimics emesis in species
not capable of the emetic response). Rats were allowed to sample kaolin for at least 3 days be-
fore the Ex4 injection to avoid association of kaolin with Ex4 injections. Kaolin intake and
chow intake were measured at 1,3,6, and 24h after injection in rats mildly food-restricted over-
night (10g of chow available overnight). The dose of Ex4 (0.05 μg) was chosen to reduce chow
intake by at least 50%.
Operant conditioning
Food-induced operant conditioning training and testing were conducted in rat conditioning
chambers (Med-Associates, Georgia, VT, USA) as described previously [18,27]. Rats were
trained to press a lever for a 45mg sucrose reward. Training was conducted in four stages: rats
were first trained on the fixed ratio 1 (FR1) schedule (single press on the active lever resulted in
the delivery of one sucrose pellet), followed by FR3 and FR5 (3 and 5 presses per pellet respec-
tively), where a minimum of 50 responses per session on the active lever was required for the
advancement to the next schedule, culminating with progressive ratio conditioning until stable
responding was achieved. Each progressive ratio session lasted for 90 min. Responding was
considered stable when the number of pellets earned per session did not differ more than 15%
for three consecutive sessions. All operant response testing was performed after the responses
stabilized. Rats received drug injections early in the light cycle after partial (10g of chow avail-
able) overnight food restriction. This paradigm was chosen to provide a higher motivation to
work for sucrose, which was hypothesized to be subsequently attenuated by Ex4 or GLP-1. In-
jections were done in a counterbalanced, Latin square design with at least 48h separating each
Fig 1. Representative photomicrograph of a coronal section of the rat brain at the level of the NTS illustrating the microinjection site (encircled
area) for the behavioral experiments (right panel) and a schematic representation of the NTS from the rat atlas (Paxinos andWatson, 1998) (left
panel). Area postrema (AP), central canal (cc), gracile nucleus (Gr).
doi:10.1371/journal.pone.0119034.g001
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injection condition. Testing was performed during the light cycle. Immediately after the oper-
ant boxes test rats were returned to their home cages and offered chow, the amount of chow
eaten was measured after 1h and 22h. Body weight was measured at 22h. Locomotor activity
was measured during the operant testing with infrared beams installed inside the operant
chambers.
Conditioned place preference (CPP)
The CPP test was performed in rats using an apparatus that comprised of two connected cham-
bers with distinct visual and tactile qualities (Med-Associates). Initial preference for one chamber
was assessed on the first and second day with 20 min pretests on each day, and the least preferred
compartment was determined by taking the average amount of time spent in each compartment
across the two pretest days. Subsequently the least preferred compartment was paired with 4g of
palatable food (chocolate or peanut butter). The pretest was followed by 16 days of conditioning
sessions (2 sessions per day). One day following the last conditioning session rats were injected
(intra-NTS) with vehicle (aCSF) or Ex4 (0.05μg) 30min before being placed in the CPP apparatus
for 10 min. The behavior of the animals was detected by infrared beams in each chamber and
time spent in each compartment was determined. To assure that all palatable food was always
consumed during the training sessions the rats had restricted access to chow in their home-cages
(to 70% of normal daily chow intake) throughout the CPP experiment.
GLP-1 fiber detection
Mice were anaesthetized with ketamine/xylazine solution and perfused transcardially with hep-
arinized saline followed by fresh fixative solution (paraformaldehyde (PFA, 4%) in 0.1 M phos-
phate buffer). The brains were collected, and cut into coronal 25 μm sections using a cryostat,
sections were then collected into tubes containing tissue storage solution consisting of 50 ml
glycerin, 50ml ethylene glycol and 100 ml 0.1 M phosphate buffer (pH 7.5) and stored until use
in 4°C. The sections were washed (3 x 15 min) in TNT with Triton-X (0,1%) (Sigma-Aldrich
St.Louis, MO, USA). For tyrosine hydroxylase (TH) visualization, the sections were incubated
for two days in TNB blocking solution (Perkin Elmer, Akron, Ohio, USA) with 1:2000 Goat
polyclonal antibody to TH (ab6211, Abcam, Cambridge, UK). The sections were then washed
in TNT with Triton-X (0,1%) and incubated in TNB blocking solution with 1:1000 Donkey
anti-goat Alexa Fluor 568 (ab36001, Abcam). The cell nuclei were stained with DAPI (1:5000;
Life Technologies, Carlsbad, CA, USA). The sections were then washed in TNT (2 x 15 min),
submerged in 0.1M PB and mounted on microscope slides (Superfrost Plus, Menzel) together
with ProLong Gold Antifade (Life Technologies). The GLP-1 fibers were visualized with a con-
focal microscope (LSM 700; Carl Zeiss, Oberkochen, Germany).
RNA isolation and mRNA expression
VTA and nucleus accumbens gene expression levels were measured after intra-NTS injection
of Ex4 (0.05μg) or vehicle (aCSF). The following genes were examined: TH, Drd1a, Drd2, Drd3,
Drd5, Slc6a3, Gad1, Creb1, FosB. They were selected because of their previously reported role
in reward behavior regulation or their connection to GLP-1. Ninety minutes after Ex4 or aCSF
injection the brains were rapidly removed and the VTA and nucleus accumbens were dissected
using a brain matrix, frozen in liquid nitrogen and stored at -80°C. Individual brain samples
were homogenized in Qiazol (Qiagen, Hilden, Germany) using a TissueLyzer (Qiagen). Total
RNA was extracted using RNeasy Lipid Tissue Mini Kit (Qiagen) with additional DNAse treat-
ment (Qiagen). RNA quality and quantity were assessed by spectrophotometric measurements
(Nanodrop 1000, NanoDrop Technologies, USA). For cDNA synthesis iScript cDNA Synthesis
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kit (BioRad) was used. Real-time RT PCR was performed using TaqMan probe and primer sets
for target genes chosen from an on-line catalogue (Applied Biosystems; reference numbers
were as follows: Actb-Rn00667869_m1, TH-Rn00562500_m1, Drd1a-rCG24308, Drd2-
rCG57985, Drd3-rCG52650, Drd5-rCG35929, Slc6a3-rCG41956, Gad1-rCG26162, Creb1-
rCG22512, Fos-rCG20898). Gene expression values were calculated based on the ΔΔCt method
[28], where the vehicle-injected group was designated as the calibrator. Beta-actin was used as
a reference gene. To determine the NTS gene expression of CCK (Rn00563215_m1) and two
enzymes key to noradrenaline synthesis, dBH (Rn00565819_m1) and TH, rats were injected
into the lateral ventricle with 0.2 μg of Ex4 or vehicle (aCSF) and ninety minutes later an NTS-
enriched dorsal brainstem tissue block was dissected. The tissue was rapidly frozen, stored at
-80°C, and mRNA extraction, cDNA synthesis and TaqMan PCR were performed as described
above. Peptidylprolyl isomerase A (ppia, Rn00690933_m1) was determined to be a more stable
gene for the NTS than β-actin, and used as a control gene.
Statistical analysis
All the data are presented as mean ± Standard Error of the Mean (SEM). Statistical significance
was analyzed using Student’s t test, one- or two-way ANOVA when appropriate (GraphPad Soft-
ware, Inc., San Diego, CA). P- values lower than 0.05 were considered statistically significant.
Results
NTS GLP-1R activation preferentially affects intake of palatable food but
not chow
Direct NTS GLP-1R stimulation with Ex4 suppressed the intake of palatable food (peanut but-
ter) but not chow when both were offered simultaneously (one-way ANOVAs, 1h: F(3,33) = 8.52,
p<0.005; 3h: F(3,33) = 7.40, p<0.01; 6h: F(3,33) = 4.42, p<0.05; Fig. 2). The effect of Ex4 was
noted at the first, 1h, measurement time point and lasted throughout 6h of measurements.
Two-way ANOVAs revealed a significant interaction between the drug treatment and food
type at each time point tested (1h: F (1, 11) = 6.469, p<0.05, 3h: F (1, 11) = 8.163, p<0.05, 6h:
F (1, 11) = 7.729, p<0.05). Chow intake of vehicle-treated rats comprised 30% of their total in-
take while 50% of the Ex4 treated animals intake consisted of chow (with respect to amount of
grams consumed during the experiment), thus while the intake of chow in vehicle-treated rats
was lower than that of peanut butter, it was not negligible. Total amount of calories eaten
(chow and peanut butter combined) was as follows: 1h intake vehicle: 37.0±5.9 Ex4:17.7±
4.9 p<0.0005; 3h intake vehicle: 45.7±7.3, Ex4:23.2±6.7 p<0.005; 6h intake vehicle: 53.0±9.1,
Ex4:29.8±9.3 p<0.05. Three rats that were determined to have cannula placements not reach-
ing the NTS (injections were localized mostly to the ventral edge of the cerebellum) did not sig-
nificantly reduce the palatable food or chow intake after Ex4 treatment (vehicle: 9.9±4.2, Ex4:
6.9±2.2 and vehicle: 5.4±2.0, Ex4: 5.3±1.6 for chow and peanut butter respectively; one-way
ANOVAs, 6h: F(3,9) = 1.1, p = 0.4).
Intake of chow when offered alone
However, when chow was offered as the sole source of food, intake of chow was significantly re-
duced after intra-NTS Ex4 application (Fig. 3). In this experimental setup the chow intake at 1h
(one-way ANOVA: F(2,20) = 24.12, p<0.0001; Fig. 3A) and 22h (one-way ANOVA: F(2,20) =
9.56, p<0.005; Fig. 3B) was significantly reduced by both doses of Ex4. The body weight mea-
sured at 22h was also significantly reduced after the NTS Ex4 microinjection (one-way
ANOVA: F(2,20) = 4.11, p<0.05; Fig. 3C).
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PICA
Intra-NTS administered Ex4 did not induce a PICA response at a dose of Ex4 that potently re-
duced 1,3,6, and 24h chow intake (nearly a 50% reduction; Fig. 3D). The lack of PICA response,
as measured by lack of significant increase in kaolin intake at any time point measured
Fig 2. NTSGLP-1R activation preferentially affects intake of palatable food but not chow.Direct NTS
GLP-1R stimulation with Ex4 suppressed the intake of palatable food (peanut butter) but not chow when both
were offered simultaneously. The effect of Ex4 had a short latency (noted 1h after injection), and lasted
throughout the 6h of measurements. The food intake data are represented as grams eaten (A), as calories
consumed, since the two foods differ in their caloric density (B), and as the fraction of total intake (by calories)
that was represented by the palatable peanut butter intake(C). Data are expressed as mean ±SEM. n = 12
per each treatment group. * p<0.05, ** p<0.01, *** p<0.005.
doi:10.1371/journal.pone.0119034.g002
Fig 3. GLP-1R stimulation by Ex4 in the NTS reduces chow intake and body weight. Intra-NTS delivery of Ex4 reduced the consumption of chow over
the 22h period of data collection (A-B). Body weight (g) was also reduced 22h after injections (C). In a second group of rats intake of kaolin (PICA response)
was measured simultaneously with chow intake. While the chow intake was significantly reduced after intra NTS Ex4 administration (D), intake of kaolin
was not altered by Ex4 (E). Data are expressed as mean ±SEM. n = 11 per each treatment group (A-C), n = 8 per each treatment group (D-E). * p<0.05,
** p<0.01, ***P< 0.005, **** p<0.0005.
doi:10.1371/journal.pone.0119034.g003
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(Fig. 3E), may indicate that intra-NTS GLP-1R activation, at least at an Ex4 dose of 0.05 μg, is
not associated with nausea.
NTS GLP-1R activation decreased food-motivated behavior
Rats responding for a sucrose reward (45mg pellet) under a progressive ratio reinforcement
schedule (i.e. a schedule in which the number of presses required to obtain a single sucrose pel-
let increases progressively) were treated with a selective, long-lasting GLP-1R agonist, Ex4
(0.05 or 0.1 μg/0.3 μl) 10 min prior to placement in the operant boxes. The doses were chosen
based on [18]. Intra-NTS administered Ex4 significantly and potently decreased the number of
sucrose rewards earned (one-way ANOVA: F(2,20) = 12.48, p<0.0005; Fig. 4A) and the number
of lever presses emitted for sucrose (one-way ANOVA: F(2,20) = 9.82, p<0.005; Fig. 4B). Post-
hoc Tukey tests indicated that both doses of Ex4 were effective at reducing the number of re-
wards earned and lever presses. These reductions in food-motivated behavior were not accom-
panied by a general reduction in locomotor activity (Fig. 4C).
Similar results were obtained after intra-NTS application of the endogenous peptide: GLP-1
(2.0 μg/0.3 μl), though the effect of GLP-1 was much less potent compared to that of Ex4. The
number of sucrose rewards earned (p<0.05; Fig. 5A) and the number of lever presses emitted
for sucrose (p<0.05; Fig. 5B) were both significantly reduced after GLP-1 treatment. These re-
ductions in food-motivated behavior were not accompanied by a general reduction in locomo-
tor activity (Fig. 5C).
NTS GLP-1R activation decreased food-reward behavior
The food-induced CPP is a complementary test of food reward behavior, in which a rat shows
preference for a chamber previously paired with palatable food over a chamber previously
paired with no food exposure. The CPP test informs how rewarding the rat finds the palatable
food. Importantly, during the CPP test rats do not have access to food enabling dissociation
of the intake of palatable food from the reward evaluation process. Rats microinjected with
Ex4 (0.05 μg) into the NTS 10 min prior to the CPP test spent significantly less time in the
Fig 4. GLP-1R stimulation in the NTS decreased food-motivated behavior. The effect of intra-NTS injection of Ex4 on progressive ratio operant
responding for sucrose was tested. Ex4 potently decreased the number of sucrose rewards earned (A) and the number of active lever presses (B) in an
operant lever-pressing paradigm. Importantly this suppression in food-motivated behavior was not associated with a reduction in locomotor activity (C). n =
11 per each treatment group. ** p<0.01, ***P< 0.0005.
doi:10.1371/journal.pone.0119034.g004
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food-paired chamber compared to the vehicle-treated group, and unlike the vehicle treated
rats, showed a preference for the non-food paired chamber (Fig. 6).
NTS expression of CCK and two enzymes key in noradrenaline
synthesis after central GLP-1R stimulation
Central activation of the GLP-1R with Ex4 increased the expression of dBH (Fig. 7), an enzyme
that catalyzes the hydroxylation of dopamine to noradrenaline. The expression of TH, an en-
zyme that catalyzes an earlier step in the noradrenaline synthesis (the reaction in which L-tyro-
sine is hydroxylated to obtain L-DOPA) was not altered by Ex4 treatment. The expression of
CCK was also unaltered.
GLP-1 fibers closely appose NTS noradrenergic neurons
Guided by previous data showing that neurons expressing the enzyme TH (a marker for cate-
cholamine neurons) in the NTS project to both key mesolimbic nuclei [22,29], the VTA and
the nucleus accumbens, we set out to determine whether GLP-1 fibers can be found in close ap-
position to the NTS TH-positive neurons. TH-immunoreactive neurons that received close ap-
positions from green YFP-positive fibers were found at several levels of the NTS. The TH-
positive neurons were most prevalent at the level of the area postrema and just caudally from
area postrema (Fig. 8 A-D); at the level of the caudal 4th ventricle the TH-positive neurons
were more sparse (Fig. 8 E-F). The distribution of the YFP-labeled cell bodies (Fig. 8 A-D), de-
tected within the caudal lateral NTS and lateral NTS at the level of the area postrema, was con-
sistent with previous literature [11,12]. Few GLP-1-producing cell bodies were also found near
the hypoglossal nucleus (Fig. 8C) [14]. Consistent with previous reports [12,29,30], we did not
see any colocalization between TH-positive and YFP-labeled cell bodies, which indicated that
GLP-1-producing neurons are likely not producing noradrenaline. It should be noted that TH-
immunoreactivity within the NTS, particularly in the rostral sections of this nucleus, may also
be found in C2 adrenergic neurons in addition to A2 adrenergic neurons. However, since C2
neurons are relatively sparse in the NTS at the level of the area postrema and just caudal to this
Fig 5. GLP-1 injected into the NTS decreased food-motivated behavior.GLP-1 decreased the number of sucrose rewards earned (A) and the number of
active lever presses (B) in an operant lever-pressing paradigm, and this suppression in food-motivated behavior was not associated with a reduction in
locomotor activity (C). n = 11 per each treatment group. * p<0.05.
doi:10.1371/journal.pone.0119034.g005
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area, most TH-immunoreactive neurons in this area are noradrenergic, thus allowing the con-
clusion that GLP-1 fibers closely appose noradrenergic neurons in the NTS.
Mesolimbic gene expression
GLP-1R stimulation in the NTS resulted in a nearly fourfold increase in expression of mRNA
encoding TH (Fig. 9A), an enzyme required for the synthesis of dopamine in the VTA and a
marker for dopamine neurons in this area. Furthermore, the expression of dopamine 2 receptor
(D2R) in the VTA was twofold increased after intra-NTS Ex4 microinjection (Fig. 9A). The ex-
pression of other dopamine receptors was not altered (Fig. 9A). Similarly the expression of sev-
eral other genes previously associated with changes in reward behavior: FosB, transcription
factor (Creb1), as well as the gene encoding glutamate decarboxylase (Gad1) remained un-
changed after intra-NTS Ex4 treatment in this experimental paradigm (Fig. 9B). Intra-NTS
Ex4 treatment did not alter the expression of dopamine receptors, dopamine transporter
(DAT), FosB, Gad1 or Creb1 in the nucleus accumbens (Fig. 9C-D).
Discussion
GLP-1, through its activity on the central receptors, is a key regulator of food intake [8–10,31].
Recently it was also suggested that GLP-1 is essential for control of food reward behavior [18].
Much of the earlier literature reports are focused on neuroanatomical substrates associated
Fig 6. GLP-1R stimulation in the NTS decreased food reward behavior. The effect of intra-NTS injection of Ex4 on the ability of palatable food to
condition a place preference was tested. Preference for the chamber paired to palatable food was abolished by Ex4 treatment. The preference [%
conditioned place preference (CPP)] was calculated using the following formula: ((test − pre-test)/(total time − pre-test)) × 100. n = 11 (vehicle group) and n =
8 (Ex4 group). ****p< 0.0005. Data represent mean ±SEM.
doi:10.1371/journal.pone.0119034.g006
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with either homeostatic or hedonic feeding. For GLP-1, the hypothalamus and the hindbrain
are considered key sites from which GLP-1 reduces ingestive behavior, while reward effects of
GLP-1 are ascribed to the mesolimbic GLP-1R [18,32,33]. Here we report six findings that pro-
vide key information about the impact of activation of GLP-1R in the hindbrain, specifically
the NTS, on reward behavior: 1) NTS-directed GLP-1R activation resulted in a selective reduc-
tion in intake of palatable food. 2) Both GLP-1 and Ex4 microinjected into the NTS suppressed
food-motivated behavior for sucrose in a progressive ratio test. 3) NTS GLP-1R activation sup-
pressed food reward behavior in a CPP test. 4) NTS GLP-1-producing neurons are found in
close apposition to the NTS noradrenergic neurons, previously shown to send direct projec-
tions to the mesolimbic system, specifically the nucleus accumbens and the VTA, providing a
potential direct neuroanatomical link between GLP-1 action in the NTS and the mesolimbic
system. 5) Central GLP-1R stimulation also increases the NTS expression of dBH, key enzyme
in noradrenaline synthesis providing a biological link between GLP-1R activation and NTS
noradrenergic neurons. 6) NTS GLP-1R activation altered the expression of dopamine-related
genes in the VTA.
Rats given a choice of consuming highly palatable peanut butter or less palatable chow
chose to consume nearly four times more calories from the palatable food compared to chow.
However, the NTS-directed activation of the GLP-1R attenuated this preference by selectively
reducing the amount of palatable food consumed. Thus, it seems that this GLP-1R manipula-
tion selectively affected intake of palatable food. The role for the caudal brainstem, specifically
the area postrema and the NTS, in the palatable food-selective ingestive behavior control, was
suggested by previous studies utilizing chemical lesions of these regions. Rats with capsaicin-
induced neuronal damage to the area postrema and NTS regions overconsumed palatable
Fig 7. NTS expression of two enzymes key in noradrenaline synthesis after central GLP-1R
stimulation. Central activation of GLP-1R with Ex4 increases the expression of dBH but not TH or CCK. Data
are expressed as mean ±SEM. n = 9 (pair-fed control group), n = 11 (ad libitum fed control group) and n = 10
(Ex4 group). *p<0.05. Tyrosine hydroxylase (TH) and dopamine-beta-hydroxylase (dBH).
doi:10.1371/journal.pone.0119034.g007
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Fig 8. Many YFP-immunoreactive axons (green) closely apposed the TH-positive neurons (red) of the NTS. Fluorescent YFP– preproglucagon
neurons (green) and DAPI (nuclear stain, blue) in coronal sections through the NTS of YFP–PPGmice. Micrographs showing the caudal NTS (A-B), the NTS
at the level of the area postrema (C-D) and the NTS at the level of the 4th ventricle (E-F). Cell bodies of YFP-immunoreactive preproglucagon neurons (green)
were detected at the level of the area postrema and just caudally to the area postrema (A-D). Many green YFP-immunoreactive axons closely appose blue
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food, but not chow [34,35]. These rats did not exhibit any other behavioral or physiological
changes, underscoring the specificity of this effect. These studies concluded that the capsaicin
lesions selectively impair a discrete population of neurons that normally inhibits the exaggerat-
ed consumption of preferred food. In light of the current data, an interesting possibility could
be that the inputs to the NTS GLP-1-producing neurons, or their downstream neuronal targets
within the NTS, may represent one of these discrete populations, inputs to which are disrupted
by the hindbrain-injected capsaicin resulting in an exaggerated intake of palatable preferred
foods.
DAPI-labeled cell bodies in the NTS. White arrows indicate NTS TH-positive neuronal cell bodies closely apposed by the GLP-1 fibers. Insets in panels B,D
and F show the interaction at a single neuron level. Area postrema (AP), central canal (cc), dorsal motor nucleus of the vagus (DMV), gracile nucleus (Gr), 4th
ventricle (4thV). B,D and F show higher magnification of areas in A,C and D, respectively.
doi:10.1371/journal.pone.0119034.g008
Fig 9. Activation of GLP-1R in the NTS alters gene expression in the mesolimbic reward system.GLP-1R activation by Ex4 in the NTS increased the
mRNA expression of the gene that encodes tyrosine hydroxylase (TH), and dopamine 2 receptor (Drd2) without significantly changing the mRNA expression
of other dopamine receptors in the VTA (A). The expression of several other genes previously associated with changes in reward behavior: FosB, Creb1 and
Gad1 remained unchanged after intra-NTS Ex4 treatment (B). Intra-NTS Ex4 treatment did not alter the expression of dopamine receptors, dopamine
transporter (DAT), FosB,Gad1 or Creb1 in the nucleus accumbens (Fig C-D). Data are expressed as mean ±SEM. n = 6 (vehicle group) and n = 5 (Ex4
group). ** p<0.01, *** p<0.005. Dopamine receptor 1 (Drd1a), dopamine receptor 3 (Drd3), dopamine receptor 5 (Drd5), glutamate decarboxylase 1
(Gad1), cAMP responsive element binding protein 1 (Creb1), FBJ osteosarcoma viral oncogene B (FosB).
doi:10.1371/journal.pone.0119034.g009
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The palatable food selective ingestive changes seen here after intra-NTS GLP-1R activation
are also akin to those already demonstrated for central blockade of opioid receptors [for review
see: [36,37]]. Similarly to the current results, in a no-choice paradigm (animals are offered only
one type of food at a time), opioids change the intake of any kind of food, however when the
animals are given a choice opioids selectively alter the intakes of preferred foods [38–40].
There is a neuroanatomical overlap between the opioid and the GLP-1 control of feeding;
NTS-selective mu-opioid receptor stimulation and blockade were shown to increase and de-
crease food intake respectively [41]. The potential functional interaction of the two systems in
the hindbrain to control intake of preferred foods is an interesting emerging hypothesis for fu-
ture investigation. The differential effect of Ex4 on chow intake in a choice vs non-choice food
test was already demonstrated in the mesolimbic system, via microinjection of Ex4 into the
VTA and the nucleus accumbens shell, where concurrent offering of high-fat and chow re-
sulted in a selective reduction of the high-fat intake [42]. However, when chow was offered
alone a potent reduction of chow intake was observed [18]. Since the rats choose to consume
more of the palatable food than chow, an alternative explanation to the reduced reward hy-
pothesis could be that Ex4 simply reduces the intake of the principle source of calories. Thus,
the food choice experiment alone would not be sufficient to conclude that NTS GLP-1R activa-
tion reduces food reward. However, considering that both progressive ratio operant condition-
ing and CPP for food were reduced by Ex4, both more direct tests of food reward, we conclude
that Ex4 does reduce food reward behavior when injected into the NTS. Additionally, in the
current study rats consuming chow alone were food restricted to 50% of their regular overnight
food intake. Food restriction increases the palatability of any available source of calories, mak-
ing the consumption of any available food rewarding. Thus, while we cannot eliminate the pos-
sibility that mechanisms other than reward suppression are involved in the chow intake
suppression after NTS GLP-1R activation, due to the background of food restriction, food re-
ward suppression represents one potential mechanism of reduced chow consumption in the
current study.
Two complementary tests of food reward behavior used here, progressive ratio operant con-
ditioning and CPP, clearly demonstrate a role for NTS GLP-1R in food reward suppression.
The intra-NTS Ex4 microinjection potently reduced the rats’ motivation to work for sucrose
pellets. These rats earned 30% less sucrose reward and were willing to put in only a third of the
effort (active lever presses) compared to the vehicle-injected control rats. Also in the CPP test,
a test that allows complete separation of food consumption and food reward seeking (since no
food is offered on the testing day), the intra-NTS Ex4 injected rats showed a suppressed food
reward behavior. Unlike control rats, which showed a small but significant increase in the
amount of time spent in the environment paired with palatable food during training, the Ex4-
treated rats chose to spend significantly more time in the non-food paired environment indi-
cating reduced food-reward seeking behavior. Notably, the changes in reward behavior demon-
strated here were not associated with general locomotor inhibition. These results are in line
with a recent report that demonstrates that NTS Ex4 can reduce food-reward behavior even 3h
after injection [43]. We also report here, for the first time, that the endogenous peptide GLP-1
reduces food reward behavior in the progressive ratio operant task. This is an important find-
ing that strengthens the overall idea of the reward-suppressing role of the central GLP-1 system
and attends to the potential criticism posing that the reward-suppressing action of Ex4 is drug-
specific. The idea of a differential action of Ex4 and GLP-1 in the brain was suggested by previ-
ous studies [44].
We have previously showed that VTA and nucleus accumbens GLP-1R activation with Ex4
reduces food reward behavior [18]. These two mesolimbic sites represent classic neuroanatom-
ical sites accepted for their role in regulation of reward derived from food and drugs of
Activation of GLP-1R in the NTS Reduces Food Reward Behavior
PLOS ONE | DOI:10.1371/journal.pone.0119034 March 20, 2015 15 / 21
addiction. Interestingly our current results, combined with the previously reported intra-meso-
limbic Ex4 injections, indicate that the NTS GLP-1R were just as sensitive to the reward sup-
pressing action of Ex4 as their VTA and nucleus accumbens counterparts. Thus, even though
the caudal brainstem in general, and NTS in particular, is rarely thought of as a reward modu-
lating CNS region, current results clearly call for its addition to the reward-control brain sites.
The mesolimbic circuitry plays a key role in the control of reward behavior. Thus, it is likely
that in order for the hindbrain GLP-1R activation to affect reward behavior the NTS GLP-1R-
induced activity should be ultimately transmitted to the mesolimbic system. NTS neurons ex-
pressing the enzyme TH (a potential label for noradrenergic and adrenergic neurons in the
NTS) were previously shown to send direct projections to the nucleus accumbens and the VTA
[22,29,45]. In fact NTS A2 neurons are a major source of noradrenaline to the nucleus accum-
bens and these A2 neurons were already implicated to be crucial in opioid reward and with-
drawal behavior [46,47]. Current data indicate that the NTS TH-positive neurons are closely
apposed by GLP-1 fibers. Importantly the location of the GLP-1-fiber apposed TH-cell bodies
is in line with that previously indicated for nucleus accumbens-projecting TH-positive neurons
[22]. These results are in line with one previous study [30]. This neuroanatomical evidence sug-
gests that GLP-1 and activation of GLP-1R in the NTS may reach the key mesolimbic nuclei by
changing the activity of the TH-positive neurons. This idea is further supported by our data
showing that central GLP-1R activation with Ex4 increases the expression of a key enzyme re-
quired for noradrenaline synthesis, dBH. Other possible routes via which GLP-1R activation in
the NTS could affect mesolimbic activity may include changing the activity of GLP-1, CCK or
neurotensin-positive neurons since all three have been retrogradely labeled from the nucleus
accumbens to the NTS [22,42]. The activation of NTS CCK neurons by GLP-1 treatment is not
supported by our gene expression data. Also, the activation of GLP-1 neurons by GLP-1R stim-
ulation in the NTS seems unlikely since, at least in a mouse, GLP-1 neurons do not express
GLP-1R [48].
Further evidence for the NTS GLP-1R stimulation impacting on activity in the mesolimbic
system is provided by current data showing that dopamine-related gene expression in the VTA
is altered by NTS GLP-1R stimulation. We show that dopamine 2 receptor (D2R) expression
was selectively twofold increased by GLP-1R activation in the NTS, leaving the expression of
dopamine 1, 3 and 5 receptor genes unchanged. In the VTA D2R are primarily thought to
function as autoreceptors that decrease the activity of the dopaminergic neurons they are ex-
pressed by. Interestingly only select populations of dopaminergic neurons may be under this
inhibitory control of D2R [49]. Specifically, the majority of the dopaminergic neurons that in-
nervate the nucleus accumbens are inhibited by D2R activation, however nearly none of the do-
pamine neurons projecting to the amygdala are sensitive to this inhibition [49]. Thus the
upregulation of D2R reported here may be consistent with a reduction of the ability of accum-
bens-projecting dopamine neurons to be activated by reward signals like the palatable food
used here. This idea is consistent with the suppression of food-reward behavior. The expression
of TH, an enzyme in the VTA associated with an increased production of dopamine, was nearly
fourfold increased by the NTS-directed Ex4 treatment. One previous study reported a similar
increase in TH protein levels in the VTA after intra-VTA GLP-1R activation [50], thus both
GLP-1R populations, in the VTA and in the NTS, despite their neuroanatomical distance, may
exert a similar effect on the VTA dopamine production. The projection target/s of the dopami-
nergic neurons that increase their TH production in response to NTS GLP-1R activation re-
mains to be determined. However, based on previous data it is likely that it is the amygdala.
Central GLP-1R activation via lateral ventricle injection of GLP-1R agonist, likely reaching
many GLP-1R populations in the brain including those in the VTA and NTS, increases dopa-
mine release in the amygdala [51]. Increased dopamine activity in the amygdala was associated
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with reduced food-motivated behavior for sucrose [51]. The case for the amygdala as a likely
target may also be strengthened by the fact that amygdala-projecting dopamine neurons would
not be inhibited by the simultaneous increase in D2R-mediated inhibition. Alternatively (or in
addition to the amygdala release) the increased TH levels in the VTA may contribute to in-
creased somatodendritic release of dopamine in the VTA [52], associated with inhibition of nu-
cleus accumbens and cortex-projecting dopamine neurons.
The reward suppressing GLP-1-driven circuitry outlined here may be engaged by both cen-
tral and peripheral energy balance controlling signals. Leptin, released from the adipose tissue,
has been shown to activate GLP-1 neurons. The anorexic effect of leptin may be partly mediat-
ed by GLP-1 [53]. However, just as hindbrain GLP-1R activation may be participating in food
reward control, the hindbrain action of leptin may also extend to reward behavior control. Sup-
portively, recent data indicate that activation of leptin receptors in the medial NTS results in a
selective reduction in reward derived from food, but not drugs of abuse like morphine [19].
Considering that both hindbrain GLP-1 and leptin receptor activation leads to reward suppres-
sion, and the previous studies already show a functional interaction between the two systems.
It is possible that the food reward-suppressing effects of leptin are mediated by the central
GLP-1 system.
In addition to peripheral signals, NTS neurons may also be engaged by central signals de-
scending from the forebrain in order to regulate food reward behavior. For example orexin, an
orexigenic neuropeptide produced in the lateral hypothalamus previously shown to increase
food reward behavior [54,55], may be released in the NTS [56,57] to increase the rewarding
value of food and food-motivated behavior [20]. Furthermore orexin neurons may innervate
the NTS GLP-1 neurons as well as the NTS TH neurons [56]. Thus the two systems, GLP-1
and orexin, may interact within the NTS both by acting on the same downstream neurons
(possibly the noradrenergic neurons already shown to link the NTS to the mesolimbic reward
system), or alternatively orexin may directly inhibit the GLP-1-producing neurons.
The central GLP-1 system is engaged by signals associated with viscerosensory malaise and
formation of consequent conditioned taste aversions, conditions that are associated with re-
duced food intake. Hindbrain administration of GLP-1 agonists is not associated with condi-
tioned taste aversions [58]. However, medial NTS administration of Ex4 has previously been
shown to induce PICA, consumption of non-nutritive substances that may be indicative of vis-
cerosensory malaise [58]. However, the feeding suppression induced by NTS GLP-1R activa-
tion does not seem to rely on nausea induction, since at low doses of NTS Ex4, that still
potently reduce food intake and reward, our current data and others[43] show that Ex4 does
not induce the PICA response. Lack of a sickness response is also supported by the fact that
there are no changes in locomotor activity, as sickness responses are typically associated with a
reduction in motor activity. Collectively, while it is clear that feeding suppression resulting
from NTS GLP-1 stimulation is not always accompanied by nausea, it is entirely possible that
with a stronger activation of GLP-1 neurons the NTS GLP-1R activation contributes to reward
behavior reduction accompanying visceral malaise. Moreover, NTS GLP-1 neurons are also a
key element of the anorexia-inducing neurocircuitry that follows bacterial infection [59]. In
fact, NTS noradrenergic neurons are also activated by the bacterial infection mimicking agent-
lipopolysaccharide [60]. Thus the NTS GLP-1 to TH circuit suggested by current data may par-
ticipate in infection-induced anorexia and food-motivated behavior suppression.
Considering the proximity of the NTS to the area postrema with its leaky blood brain barrier
it is likely that peripherally injected long-acting GLP-1 analogues utilized clinically (for exam-
ple Ex4 used here, or liraglutide) may also gain access to the relevant GLP-1R populations to
reduce food reward behavior. Thus, the neuronal circuitry identified here may be clinically rel-
evant. Collectively our findings support the idea that the caudal brainstem participates in the
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control of food reward and food motivated behavior and identify potential mechanisms via
which the NTS GLP-1R-evoked signal may be transmitted to the mesolimbic pathways to re-
duce food reward behavior.
Acknowledgments
We thank Fredrik Anesten for his expert immunohistochemistry advice. We also thank the
Centre for Cellular Imaging at the University of Gothenburg for the use of imaging equipment,
as well as the technical support received from Julia Fernandez-Rodriguez, Maria Smedh and
Carolina Tängemo.
Author Contributions
Conceived and designed the experiments: JR RHA KPS. Performed the experiments: JR RHA
AG. Analyzed the data: JR RHA KPS. Contributed reagents/materials/analysis tools: FMG FR.
Wrote the paper: JR RHA KPS AG FMG FR.
References
1. Saper CB, Chou TC, Elmquist JK (2002) The need to feed: homeostatic and hedonic control of eating.
Neuron 36: 199–211. PMID: 12383777
2. Grill HJ, Skibicka KP, Hayes MR (2007) Imaging obesity: fMRI, food reward, and feeding. Cell Metab 6:
423–425. PMID: 18054310
3. Berthoud HR (2011) Metabolic and hedonic drives in the neural control of appetite: who is the boss?
Curr Opin Neurobiol 21: 888–896. doi: 10.1016/j.conb.2011.09.004 PMID: 21981809
4. Zheng H, Lenard NR, Shin AC, Berthoud HR (2009) Appetite control and energy balance regulation in
the modern world: reward-driven brain overrides repletion signals. Int J Obes (Lond) 33 Suppl 2: S8–
13.
5. Vucetic Z, Reyes TM (2010) Central dopaminergic circuitry controlling food intake and reward: implica-
tions for the regulation of obesity. Wiley Interdiscip Rev Syst Biol Med 2: 577–593. doi: 10.1002/wsbm.
77 PMID: 20836049
6. Hernandez L, Hoebel BG (1988) Food reward and cocaine increase extracellular dopamine in the nu-
cleus accumbens as measured by microdialysis. Life Sci 42: 1705–1712. PMID: 3362036
7. Hernandez L, Hoebel BG (1988) Feeding and hypothalamic stimulation increase dopamine turnover in
the accumbens. Physiol Behav 44: 599–606. PMID: 3237847
8. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, et al. (1996) Central administra-
tion of GLP-1-(7–36) amide inhibits food and water intake in rats. Am J Physiol 271: R848–856. PMID:
8897973
9. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, et al. (1996) A role for glucagon-like peptide-1 in
the central regulation of feeding. Nature 379: 69–72. PMID: 8538742
10. Skibicka KP (2013) The central GLP-1: implications for food and drug reward. Front Neurosci 7: 181.
doi: 10.3389/fnins.2013.00181 PMID: 24133407
11. Hayes MR (2012) Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and
glycemic effects. Physiol Behav 106: 413–416. doi: 10.1016/j.physbeh.2012.02.017 PMID: 22366059
12. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C (1997) Distribution of glucagon-like peptide-1 and
other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77: 257–
270. PMID: 9044391
13. Han VK, Hynes MA, Jin C, Towle AC, Lauder JM, et al. (1986) Cellular localization of proglucagon/glu-
cagon-like peptide I messenger RNAs in rat brain. J Neurosci Res 16: 97–107. PMID: 2427741
14. Llewellyn-Smith IJ, Reimann F, Gribble FM, Trapp S (2011) Preproglucagon neurons project widely to
autonomic control areas in the mouse brain. Neuroscience 180: 111–121. doi: 10.1016/j.neuroscience.
2011.02.023 PMID: 21329743
15. Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like pep-
tide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403: 261–280.
PMID: 9886047
Activation of GLP-1R in the NTS Reduces Food Reward Behavior
PLOS ONE | DOI:10.1371/journal.pone.0119034 March 20, 2015 18 / 21
16. Schick RR, Zimmermann JP, vormWalde T, Schusdziarra V (2003) Peptides that regulate food intake:
glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding
in rats. Am J Physiol Regul Integr Comp Physiol 284: R1427–1435. PMID: 12776726
17. Hayes MR, Bradley L, Grill HJ (2009) Endogenous hindbrain glucagon-like peptide-1 receptor activa-
tion contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology
150: 2654–2659. doi: 10.1210/en.2008-1479 PMID: 19264875
18. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. (2012) The glucagon-like
peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolim-
bic GLP-1 receptors. J Neurosci 32: 4812–4820. doi: 10.1523/JNEUROSCI.6326-11.2012 PMID:
22492036
19. Kanoski SE, Alhadeff AL, Fortin SM, Gilbert JR, Grill HJ (2014) Leptin signaling in the medial nucleus
tractus solitarius reduces food seeking and willingness to work for food. Neuropsychopharmacology
39: 605–613. doi: 10.1038/npp.2013.235 PMID: 24002186
20. Kay K, Parise EM, Lilly N, Williams DL (2014) Hindbrain orexin 1 receptors influence palatable food in-
take, operant responding for food, and food-conditioned place preference in rats. Psychopharmacology
(Berl) 231: 419–427. doi: 10.1007/s00213-013-3248-9 PMID: 23978908
21. HodosW (1961) Progressive ratio as a measure of reward strength. Science 134: 943–944. PMID:
13714876
22. Wang ZJ, Rao ZR, Shi JW (1992) Tyrosine hydroxylase-, neurotensin-, or cholecystokinin-containing
neurons in the nucleus tractus solitarii send projection fibers to the nucleus accumbens in the rat. Brain
Res 578: 347–350. PMID: 1380865
23. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, et al. (2008) Glucose sensing in L cells: a pri-
mary cell study. Cell Metab 8: 532–539. doi: 10.1016/j.cmet.2008.11.002 PMID: 19041768
24. Skibicka KP, Grill HJ (2009) Hypothalamic and hindbrain melanocortin receptors contribute to the feed-
ing, thermogenic, and cardiovascular action of melanocortins. Endocrinology 150: 5351–5361. doi: 10.
1210/en.2009-0804 PMID: 19854868
25. Skibicka KP, Alhadeff AL, Leichner TM, Grill HJ (2011) Neural controls of prostaglandin 2 pyrogenic,
tachycardic, and anorexic actions are anatomically distributed. Endocrinology 152: 2400–2408. doi:
10.1210/en.2010-1309 PMID: 21447632
26. Ritter RC, Slusser PG, Stone S (1981) Glucoreceptors controlling feeding and blood glucose: location
in the hindbrain. Science 213: 451–452. PMID: 6264602
27. la Fleur SE, Vanderschuren LJ, Luijendijk MC, Kloeze BM, Tiesjema B, et al. (2007) A reciprocal inter-
action between food-motivated behavior and diet-induced obesity. Int J Obes (Lond) 31: 1286–1294.
PMID: 17325683
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative
PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408. PMID: 11846609
29. Rinaman L (2011) Hindbrain noradrenergic A2 neurons: diverse roles in autonomic, endocrine, cogni-
tive, and behavioral functions. Am J Physiol Regul Integr Comp Physiol 300: R222–235. doi: 10.1152/
ajpregu.00556.2010 PMID: 20962208
30. Llewellyn-Smith IJ, Gnanamanickam GJ, Reimann F, Gribble FM, Trapp S (2013) Preproglucagon
(PPG) neurons innervate neurochemically identified autonomic neurons in the mouse brainstem. Neu-
roscience 229: 130–143. doi: 10.1016/j.neuroscience.2012.09.071 PMID: 23069752
31. Hayes MR, De Jonghe BC, Kanoski SE (2010) Role of the glucagon-like-peptide-1 receptor in the con-
trol of energy balance. Physiol Behav 100: 503–510. doi: 10.1016/j.physbeh.2010.02.029 PMID:
20226203
32. Dossat AM, Lilly N, Kay K, Williams DL (2011) Glucagon-like peptide 1 receptors in nucleus accumbens
affect food intake. J Neurosci 31: 14453–14457. doi: 10.1523/JNEUROSCI.3262-11.2011 PMID:
21994361
33. Alhadeff AL, Rupprecht LE, Hayes MR (2012) GLP-1 neurons in the nucleus of the solitary tract project
directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology
153: 647–658. doi: 10.1210/en.2011-1443 PMID: 22128031
34. Ritter RC, Edwards GL (1984) Area postrema lesions cause overconsumption of palatable foods but
not calories. Physiol Behav 32: 923–927. PMID: 6494309
35. South EH, Ritter RC (1983) Overconsumption of preferred foods following capsaicin pretreatment of
the area postrema and adjacent nucleus of the solitary tract. Brain Res 288: 243–251. PMID: 6661619
36. Olszewski PK, Levine AS (2007) Central opioids and consumption of sweet tastants: when reward out-
weighs homeostasis. Physiol Behav 91: 506–512. PMID: 17316713
37. Olszewski PK, Alsio J, Schioth HB, Levine AS (2011) Opioids as facilitators of feeding: can any food be
rewarding? Physiol Behav 104: 105–110. doi: 10.1016/j.physbeh.2011.04.033 PMID: 21536057
Activation of GLP-1R in the NTS Reduces Food Reward Behavior
PLOS ONE | DOI:10.1371/journal.pone.0119034 March 20, 2015 19 / 21
38. Naleid AM, Grace MK, Chimukangara M, Billington CJ, Levine AS (2007) Paraventricular opioids alter
intake of high-fat but not high-sucrose diet depending on diet preference in a binge model of feeding.
Am J Physiol Regul Integr Comp Physiol 293: R99–105. PMID: 17428895
39. Gosnell BA, Krahn DD, Majchrzak MJ (1990) The effects of morphine on diet selection are dependent
upon baseline diet preferences. Pharmacol Biochem Behav 37: 207–212. PMID: 2080183
40. Levine AS, Weldon DT, Grace M, Cleary JP, Billington CJ (1995) Naloxone blocks that portion of feed-
ing driven by sweet taste in food-restricted rats. Am J Physiol 268: R248–252. PMID: 7840328
41. Kotz CM, Billington CJ, Levine AS (1997) Opioids in the nucleus of the solitary tract are involved in feed-
ing in the rat. Am J Physiol 272: R1028–1032. PMID: 9139997
42. Alhadeff AL, Rupprecht LE, Hayes MR (2011) GLP-1 Neurons in the Nucleus of the Solitary Tract Proj-
ect Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake.
Endocrinology.
43. Alhadeff AL, Grill HJ (2014) Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor sig-
naling reduces appetitive and motivational aspects of feeding. Am J Physiol Regul Integr Comp
Physiol.
44. Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ (2009) Differences in the central anorec-
tic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 58: 2820–2827. doi: 10.2337/
db09-0281 PMID: 19741167
45. Delfs JM, Zhu Y, Druhan JP, Aston-Jones GS (1998) Origin of noradrenergic afferents to the shell sub-
region of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res
806: 127–140. PMID: 9739125
46. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G (2000) Noradrenaline in the ventral forebrain is critical for
opiate withdrawal-induced aversion. Nature 403: 430–434. PMID: 10667795
47. Olson VG, Heusner CL, Bland RJ, During MJ, Weinshenker D, et al. (2006) Role of noradrenergic sig-
naling by the nucleus tractus solitarius in mediating opiate reward. Science 311: 1017–1020. PMID:
16484499
48. Hisadome K, Reimann F, Gribble FM, Trapp S (2010) Leptin directly depolarizes preproglucagon neu-
rons in the nucleus tractus solitarius: electrical properties of glucagon-like Peptide 1 neurons. Diabetes
59: 1890–1898. doi: 10.2337/db10-0128 PMID: 20522593
49. Margolis EB, Mitchell JM, Ishikawa J, Hjelmstad GO, Fields HL (2008) Midbrain dopamine neurons:
projection target determines action potential duration and dopamine D(2) receptor inhibition. J Neurosci
28: 8908–8913. doi: 10.1523/JNEUROSCI.1526-08.2008 PMID: 18768684
50. Mietlicki-Baase EG, Ortinski PI, Rupprecht LE, Olivos DR, Alhadeff AL, et al. (2013) The food intake-
suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are me-
diated by AMPA/kainate receptors. Am J Physiol Endocrinol Metab.
51. Anderberg RH, Anefors C, Bergquist F, Nissbrandt H, Skibicka KP (2014) Dopamine signaling in the
amygdala, increased by food ingestion and GLP-1, regulates feeding behavior. Physiol Behav.
52. Adell A, Artigas F (2004) The somatodendritic release of dopamine in the ventral tegmental area and its
regulation by afferent transmitter systems. Neurosci Biobehav Rev 28: 415–431. PMID: 15289006
53. Nowak A, Bojanowska E (2008) Effects of peripheral or central GLP-1 receptor blockade on leptin-in-
duced suppression of appetite. J Physiol Pharmacol 59: 501–510. PMID: 18953093
54. Harris GC, Wimmer M, Aston-Jones G (2005) A role for lateral hypothalamic orexin neurons in reward
seeking. Nature 437: 556–559. PMID: 16100511
55. Cason AM, Smith RJ, Tahsili-Fahadan P, Moorman DE, Sartor GC, et al. (2010) Role of orexin/hypo-
cretin in reward-seeking and addiction: implications for obesity. Physiol Behav 100: 419–428. doi: 10.
1016/j.physbeh.2010.03.009 PMID: 20338186
56. Zheng H, Patterson LM, Berthoud HR (2005) Orexin-A projections to the caudal medulla and orexin-in-
duced c-Fos expression, food intake, and autonomic function. J Comp Neurol 485: 127–142. PMID:
15776447
57. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, et al. (1998) Neurons containing hypocre-
tin (orexin) project to multiple neuronal systems. J Neurosci 18: 9996–10015. PMID: 9822755
58. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR (2012) The role of nausea in food in-
take and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
Neuropharmacology 62: 1916–1927. doi: 10.1016/j.neuropharm.2011.12.022 PMID: 22227019
59. Grill HJ, Carmody JS, Amanda Sadacca L, Williams DL, Kaplan JM (2004) Attenuation of lipopolysac-
charide anorexia by antagonism of caudal brain stem but not forebrain GLP-1-R. Am J Physiol Regul
Integr Comp Physiol 287: R1190–1193. PMID: 15231492
Activation of GLP-1R in the NTS Reduces Food Reward Behavior
PLOS ONE | DOI:10.1371/journal.pone.0119034 March 20, 2015 20 / 21
60. Gaykema RP, Daniels TE, Shapiro NJ, Thacker GC, Park SM, et al. (2009) Immune challenge and sati-
ety-related activation of both distinct and overlapping neuronal populations in the brainstem indicate
parallel pathways for viscerosensory signaling. Brain Res 1294: 61–79. doi: 10.1016/j.brainres.2009.
07.076 PMID: 19646973
Activation of GLP-1R in the NTS Reduces Food Reward Behavior
PLOS ONE | DOI:10.1371/journal.pone.0119034 March 20, 2015 21 / 21

II
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Parabrachial Nucleus Reduces Food Intake:
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Metabolic Science (F.M.G., F.R.), University of Cambridge, Cambridge CB2 2XY, United Kingdom
The parabrachial nucleus (PBN) is a key nucleus for the regulation of feeding behavior. Inhibitory
inputs from the hypothalamus to the PBN play a crucial role in the normalmaintenance of feeding
behavior, because their loss leads to starvation. Viscerosensory stimuli result in neuronal activation
of the PBN.However, theorigin andneurochemical identity of the excitatory neuronal input to the
PBN remain largely unexplored. Here, we hypothesize that hindbrain glucagon-like peptide 1
(GLP-1) neurons provide excitatory inputs to the PBN, activation of which may lead to a reduction
in feeding behavior. Our data, obtained from mice expressing the yellow fluorescent protein in
GLP-1-producing neurons, revealed that hindbrain GLP-1-producing neurons project to the lateral
PBN (lPBN). Stimulation of lPBN GLP-1 receptors (GLP-1Rs) reduced the intake of chow and palat-
able foodanddecreasedbodyweight in rats. It alsoactivated lPBNneurons, reflectedbyan increase
in the number of c-Fos-positive cells in this region. Further support for an excitatory role of GLP-1
in the PBN is provided by electrophysiological studies showing a remarkable increase in firing of
lPBN neurons after Exendin-4 application. We show that within the PBN, GLP-1R activation in-
creased gene expression of 2 energy balance regulating peptides, calcitonin gene-related peptide
(CGRP) and IL-6. Moreover, nearly 70% of the lPBN GLP-1 fibers innervated lPBN CGRP neurons.
Direct intra-lPBN CGRP application resulted in anorexia. Collectively, our molecular, anatomical,
electrophysiological, pharmacological, and behavioral data provide evidence for a functional role
of the GLP-1R for feeding control in the PBN. (Endocrinology 155: 4356–4367, 2014)
Glucagon-like peptide 1 (GLP-1), produced in intesti-nal L-cells and the nucleus of the solitary tract (NTS)
in thehindbrain, regulates bloodglucose and reduces feed-
ing behavior (1). Much is known about the mechanisms
underlying the glucoregulatory function of GLP-1, and
this ability of GLP-1 has already been used in the clinic.
Genetic and pharmacological data have established that
GLP-1 receptor (GLP-1R) activation reduces food intake
and, conversely, that a reduction of activity at theGLP-1R
increases food intake. Although GLP-1 is a key player in
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energy balance control, the mechanisms and neural sub-
strates engaged by GLP-1 to regulate food intake are only
beginning to be identified.GLP-1 neurons innervatemany
brain areas relevant for energy balance control (2, 3). Ini-
tially, the literature has emphasized the hypothalamus as
the primary target for the feeding inhibition by GLP-1 (4,
5). However, the energy balance control system extends
beyond the hypothalamus. Subsequent studies indicate
that both local GLP-1 neuronal projections within the
NTS and far reaching projections to the mesolimbic ven-
tral tegmental area and the nucleus accumbens are impor-
tant for the normal regulation of feeding (6–9). In addi-
tion, GLP-1R and its mRNA have been identified in the
pontine parabrachial nucleus (PBN) (10). Here, we inves-
tigate the functional role of GLP-1 in this nucleus for feed-
ing control and the mechanisms involved.
The PBN integrates neural and possibly hormonal sig-
nals associatedwith gustatory properties of food aswell as
visceral satiety and illness signals. Many neuropeptides
central to feeding regulation act on PBN neurons to mod-
ulate feeding behavior. Melanocortin and prostaglandin
receptor ligands applied directly to the PBNdecrease feed-
ing behavior (11, 21), whereas cannabinoid and -opioid
receptor ligands increase feeding (12, 13). The PBN is a
critical nucleus for the creation of taste associations but
only in rodents; in primates, andpresumably also humans,
the PBN mainly functions as a relay and integrator for
viscerosensory inputs (14). Recently, interest in the PBN
has been rejuvenated by data showing that -aminobu-
tyric acid (GABA)ergic and glutamatergic inputs to the
PBN are pivotal in the regulation of feeding behavior.
When the PBN glutamate/GABA input balance is dis-
turbed, mice stop eating and die of starvation (15–18), a
finding that underscores the critical role of the PBN in the
regulation of feeding behavior.
The PBN receives direct projections fromNTS neurons
relaying taste and viscerosensory information in rodents
(19), but the neuropeptides that these fibers carry have yet
to be elucidated. It is well known that GLP-1 is produced
by cell bodies of the NTS and that projections from these
cells reach many parts of the brain. Here, using a unique
mouse model that expresses a fluorescent protein in GLP-
1-producing neurons,we investigatewhether theseGLP-1
neurons also project to the PBN, thereby providing a
source of the endogenous ligand to the PBN GLP-1R. We
further evaluatedwhether the PBNGLP-1Rplays a role in
feeding behavior control. Because treatments that induce
hypophagia drastically increase activity in the lateral PBN
(lPBN) neurons, we evaluated whether central GLP-1R
stimulation can induce c-Fos protein expression in the
PBN and whether GLP-1R activation in the PBN changes
the electrical activity of the PBN neurons. Lastly, we iden-
tify potential downstream mediators of GLP-1R activa-
tion in thePBN,whichmay include calcitoningene-related
peptide (CGRP) and IL-6. Collectively, our molecular,
electrophysiological, pharmacological, and behavioral
data provide evidence for a functional role of GLP-1R in
the PBN in the control of feeding behavior and identify the
neurochemical mechanisms involved.
Materials and Methods
Animals
Adult female and male mGLU-124 Venus yellow fluorescent
protein (YFP) transgenicmice (YFP-preproglucagon [PPG]mice;
University of Cambridge) (20) were housed in plastic cages with
water and standard chow available ad libitum. Male Sprague-
Dawley rats (180–250 g at arrival and 450 g during the drug
administration tests; Charles River) were housed in a 12-hour
light, 12-hour dark cycle, in individual cages with free access to
chow and water, except during the period of chocolate and sac-
charine consumption. All studies were carried out with ethical
permissions from theAnimalWelfare Committee of the Institute
of Experimental Medicine and University of Gothenburg, in ac-
cordance with legal requirements of the European Community
(decree 86/609/EEC).
Surgery
Rats were implanted with a guide cannula targeting the lPBN
or the lateral ventricle (26 gauge; PlasticsOne) under isofluorane
anesthesia as describedpreviously (11, 21). Thenext coordinates
were chosen: lateral ventricle, 1.6/0.9/2.5 mm (midline/
bregma/skull, respectively), with injector aimed 4.5 mm ventral
to skull; and lPBN2.0/9.5/4.5mm,with injector aimed6.5mm
ventral to skull. PBN cannula placement was verified histolog-
ically postmortem by injection of India ink (0.2-L volume
matched drug delivery in the experiments). Only rats whose dye
injection site was found within the lPBN were included in the
data analysis.
GLP-1 fiber detection
Mice were anesthetized with ketamine/xylazine solution and
perfused transcardiallywith heparinized saline followedby fresh
fixative solution (paraformaldehyde 4%) in 0.1M phosphate
buffer. The brains were collected, coronal 25-m sections were
cut using a cryostat, then collected in tubes containing tissue
storage solution consisting of 50-mL glycerin, 50-mL ethylene
glycol, and 100-mL 0.1Mphosphate buffer (pH 7.5), and stored
until use in 4°C. The sections were washed (3 15min) in TRIS
NaCl Tween 20-buffer (TNT-buffer) with Triton X-100 (0.1%)
(Sigma-Aldrich). For CGRP visualization, the sections were in-
cubated for 2days inTRISNaClBoehringerMilk Powder-buffer
(TNB-buffer) blocking solution (PerkinElmer) with 1:2000 goat
polyclonal antibody to CGRP (ab36001; Abcam). The sections
were then washed in TNT with Triton X-100 (0.1%) and incu-
bated in TNB blocking solution with 1:1000 Donkey antigoat
Alexa Fluor 568 (ab36001; Abcam). The cell nuclei were stained
with diamidino-2-phenylindole (DAPI) (1:5000; Life Technolo-
gies). The sections were then washed in TNT (2  15 min),
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submerged in 0.1M phosphate buffer (PB), and mounted on mi-
croscope slides (Superfrost Plus;Menzel) together with ProLong
Gold Antifade (Life Technologies). The GLP-1 fibers were visu-
alized with a confocal microscope (LSM 700; Carl Zeiss). LPBN
and medial PBN (mPBN) DAPI-labeled cells and lPBN CGRP-
positive cells receiving GLP-1 innervation were quantified from
at least 4 25-m sections per brain. Triple channel confocal im-
ages (to cover the entire PBN) were generated with a Plan Fluor
20/0.75 lens and a solid-state laser.A tile scanof 33 tileswas
obtained from the center of the lPBN and mPBN, respectively.
Neuronswere consideredCGRP-labeledwhen their stainingwas
clearly above background and their cell nucleus was in the plane
of image. Innervation of cells in the PBN by GLP-1 fibers was
determined by switching between green- and blue-channel im-
ages (for quantification of GLP-1 innervated cells in mPBN and
lPBN) and red-, green-, and blue-channel images (for colocal-
ization of GLP-1 fibers with CGRP-labeled neurons).
Food intake and saccharine-drinking
measurements after lPBN GLP-1R activation
Consumption of 1) chocolate pellets (n  11), 2) 0.1% sac-
charine (n12), and 3) chow (n11)wasmeasured in 3 groups
of rats unilaterally infused (0.2-L) with a selective and potent
GLP-1R agonist Exendin-4 (Ex-4) (0.1- and 1-g; Tocris) or
vehicle (artificial cerebrospinal fluid, aCSF; Tocris) into the
lPBN. All injections were performed early in the light cycle. Rats
were exposed to both saccharine solution and chocolate pellets
on at least 6 occasions before the test to achieve a stable intake
and reduce the novelty of the food. Additionally, 24-hour body
weight change was measured (n 11) in the third group of rats.
Rats had free access to water at all times and to chow at all times
except during the period of chocolate and saccharine intake
measurement.
Food intake and body weight measurements after
lPBN GLP-1R blockade
Consumption of chow was measured in rats (n 12) unilat-
erally infused (0.3 L) with a selective GLP-1R antagonist Ex-9
(20 g; Tocris) or vehicle (aCSF; Tocris) into the lPBN. Body
weight change was measured overnight, 16 hours after drug in-
jections. Injections were performed 60 minutes before dark on-
set. Rats had free access to water at all times and to chow at all
times except5hoursbefore injections (during the light cycle); this
was done to ensure equal levels of satiety at the start of the
experiment.A similar experimental designwasusedwhen testing
the effects of intra-lPBN-injected CGRP (3.8 g; Tocris) or ve-
hicle (aCSF).
Loose-patch clamp electrophysiology
Ratswere anesthetized using Isoflurane inhalation. The brain
was removed rapidly and immersed in ice-cold sodium-free so-
lution (22). Acute 300-m-thick coronal slices containing the
lPBNwere prepared with a VT-1000S vibratome (Leica GmBH)
in the sodium-free solutionand then equilibrated innormal aCSF
(naCSF) (135mMNaCl, 3.5mMKCl, 26mMNaHCO3, 1.2mM
MgSO4, 1.25mM NaH2PO4, 2.5mM CaCl2, and 10mM glu-
cose, bubbled with O2/CO2). Loose-patch clamp measurements
to record action currents were carried out as described earlier
(23)with slightmodifications. Briefly, pipette potential was held
at0mV,pipette resistance1–2M, and resistanceof loose-patch
seal 7–40 M. The pipette solution contained: 123mM NaCl,
3.5mMKCl, 2.5mMCaCl2, 1.3mMMgCl2, 10mMHEPES, and
10mMglucose (pH7.3;withNaOH). lPBNwas identified under
microscopic control, and large ovoid cells of this area (24) were
chosen for recordings. Measurements were carried out with an
initial control recording (4 min); then in the first experimental
group of neurons, Ex-4 (1M) (25) was added to the naCSF by
a single bolus into the recording chamber, and the recording
continued for a subsequent 11minutes. In a second experimental
group of neurons, the GLP-1R antagonist Ex-9 (1M; Tocris)
(25) was applied after the initial recording of basal firing. Ex-9
was then present in the naCSF continuously. Ten minutes after
starting Ex-9 application, firing was recorded, then Ex-4 was
added and the recording continued. Each neuron served as its
own control when drug effects were evaluated.
c-Fos expression
Treatment
On the day of experiment, rats were injected with Ex-4 (0.3
g in 1L) or aCSF (1L) into the lateral ventricle (n 3–4 per
treatment group). Rats were treated and killed during the light
cycle. Rats had ad libitum access to food throughout the study.
Ninety minutes after the injections, all of the rats were anesthe-
tized with ketamine-xylazine solution and transcardially per-
fused with heparinized saline solution, followed by 4% parafor-
maldehyde in 0.1M PB.
Immunocytochemistry for detection of c-Fos-protein
in brain sections
Immunohistochemical detection of c-Fos protein was per-
formedas describedpreviously (26). Briefly, coronal sections (40
m) were cut on a cryostat through the lPBN, and every third
section was collected into PB. Endogenous peroxidases were de-
activated, and sections were incubated with a rabbit polyclonal
anti-Fos antibody (Ab-5, PC-38 Calbiochem; CN Biosciences
UK). Bound antibodywas detectedwith peroxidase-labeled goat
antirabbit IgG (Vector Laboratories Ltd) and visualized using a
nickel-intensified diaminobenzidine reaction giving a purple-
black precipitate within cell nuclei. PBN-containing brainstem
sections were viewed under a microscope, and all c-Fos-positive
cells were counted in the lPBNby an experimenter blinded to the
conditions. Data were expressed as average of total c-Fos counts
of all rats; total number per rat was calculated by adding total
number of c-Fos-positive cells from the left and right lPBN.
RNA isolation and mRNA expression
PBN gene expression levels were measured after lateral ven-
tricle injection of Ex-4 or vehicle (aCSF) in 2 separate groups of
rats. One group was restricted to 10 g (50% of average over-
night intake) of chow overnight, and the second was allowed to
eat ad libitum (n  6–9 per treatment group). The following
geneswere examined:Calca,Gabr,Gad1,Grin2b, Il1b, Il6, and
Mc4r. They were selected because of their reported role in feed-
ing regulation in PBNor their connection toGLP-1.Ninetymin-
utes after Ex-4 or aCSF injection, the brains were rapidly re-
moved, and the PBNwas dissected using a brain matrix, frozen in
liquidnitrogen,andstoredat80°C.Individualbrainsampleswere
homogenized in Qiazol (QIAGEN) using a TissueLyzer (QIA-
GEN). Total RNAwas extracted using RNeasy Lipid TissueMini
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kit (QIAGEN) with additional deoxyribonuclease treatment
(QIAGEN). RNA quality and quantity were assessed by spectropho-
tometric measurements (Nanodrop 1000; NanoDrop Technologies).
For cDNA synthesis, iScript cDNA Synthesis kit (Bio-Rad) was used.
Real-timeRT-PCRwas performed usingTaqManprobe, and primer
sets fortargetgeneswerechosenfromanon-linecatalogue (reference
numbers were as follows: Actb-Rn00667869_m1, Mc4r-
Rn01491866_s1, Calca-Rn01511353_g1, Grin2b-Rn00680474_
m1, Gabrd-Rn01517017_g1, Gad1-Rn00690300_m1, IL1b-
Rn00580432_m1, and IL6-Rn01410330_m1) (Applied Biosystems).
Gene expression values were calculated based on the Ct
method (27), where the vehicle-injected groupwas designated as
the calibrator (results shown in figure 5
below). -Actin was used as reference
gene.
Statistical analysis
All the data are presented as mean 
SEM. For electrophysiology group, data
were expressed asmean SEM, andper-
centage change in the frequency of the
firing rate due to the application of the
Ex-4 or the Ex-9 was calculated. Each
electrophysiological experimental group
contained10 recorded cells from6–7an-
imals. Patch clamp recordings were
stored and analyzed off-line. Event de-
tection in the recordings was performed
using the Clampfit module of PClamp
9.2 software (Molecular Devices Co).
For electrophysiology, c-Fos results and
feeding data statistical significance was
analyzed using Student’s t test or one- or
two-way ANOVA when appropriate
(GraphPad Software, Inc). P 	 .05 was
considered statistically significant.
Results
GLP-1 fibers in the PBN
Fluorescent YFP-PPG neurons
were detected at the caudal region of
the NTS of YFP-PPGmice (Figure 1,
A and B). Green YFP-immunoreac-
tive axons were found to closely ap-
pose blueDAPI-labeled cell bodies in
the lPBN (Figure 1, C and D). Over
half (55  1.2%) of the lPBN cell
bodies were found to receive fibers
from the hindbrain GLP-1 neurons.
The medial region of the PBN was
also found to receive YFP-immuno-
reactive fibers, however to a lesser
extent than the lPBN region (31 
2.3% of the DAPI-positive mPBN
cells were innervated by GLP-1 fi-
bers) (Figure 1, E and F).
Food intake, saccharine drinking, and body weight
after intra-lPBN GLP-1R stimulation
The goal of the in vivo experiments was to determine
whether GLP-1R activation in the PBN can contribute to
food intake reduction across a variety of caloric, palatable
and less palatable, aswell as noncaloric sweet liquid foods.
PBNGLP-1R stimulation via microinjection of a selective
GLP-1R agonist Ex-4 significantly reduced chocolate pel-
let consumption over the 2-hour period of measurement
Figure 1. GLP-1 innervation of the PBN. Fluorescent YFP-PPG neurons (green) and DAPI (nuclear
stain, blue) in coronal sections through the PBN and the NTS of YFP-PPG mice. Micrographs
showing the cell bodies of green YFP-immunoreactive PPG neurons (yellow arrows) in the NTS (A
and B). Micrographs showing the lPBN (C and D), and the region of the mPBN just below the
superior cerebellar peduncles (scp) (E and F). Many green YFP-immunoreactive axons closely appose
blue DAPI-labeled cell bodies in the lPBN. White arrows indicate PBN cell bodies closely apposed by
the GLP-1 fibers, whereas red arrows indicate cell bodies in this region that were not apposed by the
GLP-1 fibers. Insets in B, D, and F show the interaction at a single cell level. cc, central canal. B, D, and
F show higher magnification of areas in A, C, and D, respectively.
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(Figure 2A). Intra-PBN Ex-4 microinjection also reduced
the amountof saccharinedrunkbya separate groupof rats
(one-way ANOVA, F(2,35)  5.96; P 	 .008) (Figure 2B)
without affectingwater drinking (of-
fered in parallel with saccharine).
Moreover, the intake of normal
chow (one-way ANOVA, F(2,38) 
9.19;P	 .001) (Figure2C)andbody
weight (one-way ANOVA, F(2,35) 
10.5; P 	 .001) (Figure 2D) were
also reduced when measured over a
24-hour period.
Food intake and body weight
after intra-lPBN GLP-1R blockade
Blockade of lPBN GLP-1Rs re-
sulted in a significant increase in
chow intake at 2 and 3 hours after
Ex-9 injections and a significant in-
crease in body weight measured
overnight 16 hours after Ex-9 injec-
tion (Figure 3, A–C).
PBN GLP-1R stimulation results
in increased firing rate of lPBN
neurons
To test the hypothesis that Ex-4 in-
fluences function of large ovoid neu-
rons in the lPBN, we examined the
electrophysiological response of these
neurons to Ex-4. In the first experi-
mental group, Ex-4 (1M) was ap-
plied and increased the firing rate sig-
nificantly (330 60% of the control)
(Figure 4, A and B). The basal firing
rate (without any drugs) was 1.02 
0.44 Hz (Figure 4A). In a second ex-
perimental group, Ex-4 was adminis-
tered in the presence of the GLP-1 antagonist, Ex-9 (1M),
and the firing rate remained unaltered (13552%from the
firing rate obtained with Ex-9) (Figure 4, C and D). This
value was, however, significantly dif-
ferent from that achieved with Ex-4
alone (Figure 4E).ApplicationofEx-9
alone did not affect the firing rate of
the recorded neuron (115  34% of
the basal firing rate).
c-Fos protein expression
To confirm the electrophysiology
results from rat PBN slices in vivo, we
determinedwhetheracentral injection
of Ex-4 can activate PBN neurons.
Central GLP-1R stimulation via lateral
ventricle injection of Ex-4 increased the
Figure 2. GLP-1R stimulation by Ex-4 in the lPBN reduces food intake and body weight. Intra-
lPBN delivery of Ex-4 reduced the consumption of chocolate pellets over the 2-hour period of
data collection (A), the amount of saccharine drank (but not water consumption) over 4 hours of
data collection (B), the 24-hour chow intake (C), and 24-hour body weight change (D). Data are
expressed as mean  SEM. *, P 	 .05; **, P 	 .01; ***, P 	 .005. E, Representative
photomicrograph of a coronal section of rat brain at the level of the lPBN illustrating the
microinjection site (encircled area) for the behavioral experiments (left panel) and a schematic
representation of the PBN (right panel). scp, superior cerebellar peduncles; 4th V, 4th ventricle.
Figure 3. GLP-1R blockade in the lPBN increases food intake and body weight. Intra-lPBN
delivery of Ex-9 increased chow intake at 2 and 3 hours after injection (A). Overnight chow
intake measured at 16 hours after Ex-9 injection was not altered (B). Ex-9 increased 16-hour
body weight gain. C, Data are expressed as mean  SEM. *, P 	 .05.
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number of detected c-Fos-positive cells in the lPBN (Figure 4, F
and G).
Gene expression
Central activationofGLP-1Rs resulted in a 62% increase
in expression of mRNA encoding CGRP (Calca) (Figure
5A), an anorexic peptide that is expressed in the intra
PBN- and amygdala-projecting PBN neurons, in ad libi-
tum-fed rats. The expression of the gene encoding mela-
nocortin receptor 4, the stimulation of which in lPBNwas
previously shown to result in an-
orexia, was not altered. Similarly,
the expression of genes encoding re-
ceptors forN-methylD-aspartate re-
ceptor subtype 2B (Grin2b) and
GABA-A receptor  (Gabrd), as well
as the gene encoding glutamate de-
carboxylase (Gad1), remained un-
changed after Ex-4 treatment in this
experimental paradigm.We next de-
terminedwhether Ex-4 treatment in-
creased the expression of IL1 and
IL6, 2 molecules that mediate a part
of the anorexic effects of Ex-4 in the
hypothalamus and the hindbrain
(28), and showed that Ex-4 in-
creased IL6, but not IL1, gene ex-
pression in the PBN in both ad libi-
tum-fed and food-deprived rats
(Figure 5, C and D). The next aver-
age Ct values (SEM) relative to
-actin were detected for ad libitum-
fed rats:Calca (3.0 0.3, 2.3 0.1,
P 	 .01), Gabrd (5.6  0.2, 5.6 
0.2), Gad1 (5.2  0.2, 5.3  0.1),
Grin2b (6.6 0.2, 6.4 0.1),Mc4r
(9.0 0.3, 8.7 0.2), IL1  (9.2
0.2, 8.9 0.7), and IL6 (11.9 0.2,
9.4  0.7) (P 	 .005); values are
given for vehicle and Ex-4, respec-
tively. The next average Ct values
relative to -actin were detected for
overnight food-restricted rats:Calca
(2.6 0.2, 2.7 0.1),Gabrd (5.9
0.3, 5.2  0.3), Gad1 (5.6  0.3,
5.3 0.2),Grin2b (6.3 0.2, 6.4
0.1), Mc4r (8.9  0.2, 8.9  0.1),
IL1 (8.5 0.1, 8.1 0.4), and IL6
(11.3  0.2, 9.1  0.5) (P 	 .005);
values are given for vehicle andEx-4,
respectively.
Innervation of lPBN CGRP-positive cells and effect
of intra-lPBN CGRP injections on food intake and
body weight
Guided by results indicating an elevation in CGRP in
the PBN, we set out to determine whether the GLP-1
fibers provide direct innervation to the lPBN CGRP
neurons.Our results indicate thatmost lPBN-projecting
GLP-1 fibers innervate CGRP-positive cells, and nearly
half of the CGRP-expressing cells in the lPBN receive
GLP-1 innervation (Figure 6, A–D). Furthermore, we
Figure 4. Loose-patch clamp recordings of action currents in the neurons of the external
lPBN. Application of GLP-1R agonist Ex-4 (1M) in the extracellular solution increased the
firing rate (A and B). Extracellular administration of the GLP-1R antagonist Exendin-9(9-39)
(Ex-9) (1M), blocked this effect of Ex-4 (C and D). Histogram shows the relative percentages
of firing rate after application of Ex-4 with and without Ex-9 (E). Central GLP-1R stimulation
by lateral ventricle injection of Ex-4 increased c-Fos activation in the PBN. Quantified
immunoreactivity of Fos-positive neurons in the PBN after Ex-4 treatment in ad libitum-fed
rats (F) and representative images of the c-Fos study (G). Data are expressed as mean  SEM.
c-Fos data were expressed as average of total c-Fos count of all rats; total number per rat
was calculated by adding total number of c-Fos-positive cells from the left and right lPBN.
Each electrophysiological experimental group contained 10 recorded cells from 6–7 animals.
*, P 	 .05. scp, superior cerebellar peduncles; VEH, vehicle.
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determined whether elevated CGRP is sufficient to alter
food intake when applied directly and selectively to the
lPBN. Intra-lPBN CGRP injections resulted in a signif-
icant short-term (1–2 h) food intake reduction (Figure
7A). Food intake and body weight at 16 hours after
CGRP injections were not altered (Figure 7, B and C).
Discussion
Viscerosensory stimuli result in neuronal activation of the
PBN, but the origin and neurochemical identity of the
excitatory neuronal input to the PBN remain largely un-
explored. Here, we provide data implicating NTS-origi-
nating GLP-1-producing neurons as one source of excit-
atory projections to the PBN. Moreover, we demonstrate
a functional role for parabrachial GLP-1R activation in
food intake control. Several lines of evidence support this
conclusion. Direct activation of lPBN GLP-1R inhibited
food intake and body weight gain, and conversely lPBN
GLP-1R blockade increased food intake and body weight
gain in rats. These data indicate that lPBN GLP-1R are
necessary and sufficient for food intake control. Stimula-
tion of PBNGLP-1R potently activated PBN neurons, the
activation of which has previously been linked to an-
orexia. The activation of lPBN neurons via GLP-1R is
underscored both by an activational effect shown via elec-
trophysiology in rat brain slices, and as increased activity
of PBN neurons, reflected by a significant increase in the
number of c-Fos-positive cells in the lPBN after central
Ex-4 injection. Moreover, our neuroanatomical data im-
plicate solitary tract GLP-1 neurons as the source of en-
dogenous agonist for the GLP-1R in the lPBN. Using a
unique and well-validated Venus PPG reporter mouse (3,
20, 29, 30), we showGLP-1-containing fibers in the lPBN
that are very likely to originate from the NTS, the only
major source of GLP-1-producing neurons in the brain.
We also identify the downstream neurochemical mecha-
nismof the anorexic effect ofGLP-1 in the lPBN.We show
that in lPBN, GLP-1R activation increased the expression
of CGRP, and most NTS-originating GLP-1 fibers inner-
vated lPBN CGRP-producing neurons. Moreover, in-
creasedCGRP signaling in the lPBN induced anorexia and
body weight reduction.
Stimulation of GLP-1R in the PBN increased the activ-
ity of neurons in this area, as implied by our electrophys-
iology and c-Fos data. These data fit remarkablywell with
previous studies showing that activation of neurons in the
PBN, by removal of the hypothalamic inhibitory GABAe-
rgic projections to the PBNor by optogenetic activation of
lPBN CGRP-expressing neurons, resulted in hypophagia
inmice (17, 18). Here, we propose that activation of lPBN
neurons by GLP-1 may be one of the excitatory mecha-
nisms that are uncoveredwhen the hypothalamic brake on
the PBN neurons is removed. It is likely, however, that
GLP-1 transmission is not the only excitatory input to the
PBN. Glutamatergic input may also be involved, because
knockdownofN-methyl-D-aspartate glutamate receptors
in the PBN can prevent the hypophagia resulting from
GABAergic signal removal (16). Moreover, GLP-1-pro-
ducing neuronsmay also produce a fast neurotransmitter,
which couldbe glutamate. Even thoughEx-4, a potent and
selective agonist forGLP-1R,wasused in the current study
our results are likely relevant for the GLP-1 peptide. In
fact, one previous report already indicated that central
injections of the native peptide, GLP-1, at the start of the
dark cycle in rats also induces c-Fos in the PBN (31).
Until recently, detection of the distribution of axonal
fibers of the GLP-1 neurons was hindered by the need to
use antibodies with neuronal tracers. This process was
facilitated by the creation of a transgenic mouse that ex-
presses a fluorescent signal, YFP, in PPG-expressing cells;
this mouse model has been used to identify GLP-1-pro-
ducing neurons in the brain (3, 20, 29, 30). The transgenic
YFP-PPGmice offer an advantage over previous methods
in the form of the strong YFP expression that allows for
clear visualization of the GLP-1-producing neuron axon
Figure 5. Gene expression after central GLP-1R stimulation. In ad
libitum-fed rats, GLP-1R activation by Ex-4 increased the mRNA
expression of the gene that encodes CGRP (Calca), without
significantly changing the mRNA expression of other genes previously
shown to be associated with changes in food intake in the PBN (A). In
overnight-fasted rats, Ex-4 did not significantly change the mRNA
expression of any of the genes measured (B). Ex-4 increased the
expression of IL6 (but not IL1), central mediators of GLP-1R-induced
anorexia in both ad libitum-fed (C) and fasted (D) rats. Data are
expressed as mean  SEM. **, P 	 .01.
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fibers and terminals. We detected dense YFP-positive ax-
ons at several levels of the PBN. GLP-1 innervation was
detected throughout the rostro-caudal extent of the PBN,
with denser innervation detected in the rostral region.
YFP-positive fibers were also found in the dorso-lateral
PBN, the external-lateral PBN, and the mPBN. Thus, we
show neuroanatomical grounds for NTS GLP-1 neuron
communication to all levels of the PBN. This potentially
allows GLP-1 to influence a wide range of physiological
responses controlled by different nu-
clei of the PBN.One potential down-
side of using the YFPmice in the cur-
rent study is that there may be a
species difference in the projection
targets of the GLP-1-producing neu-
rons. For example, leptin control of
GLP-1 neurons has been shown to
differ between mice and rats (32). In
mice, leptin receptors are located di-
rectly on the GLP-1-producing neu-
rons in theNTS,whereas in rats, lep-
tin may only be influencing GLP-1
neuron activity indirectly (32).
Nonetheless, some literature already
exists to support a direct, monosyn-
aptic, connectionbetween the caudal
NTS and the PBN in a rat. Indeed, it
seems that PBN, especially the lateral
subdivisions, receives very dense in-
nervation from the NTS also in the
rat (2). Innervation from the NTS
was shown to overlap with GLP-1-
positive terminals, and a retrograde
tracer injected into the lPBN was in-
dicated to colocalize withNTSGLP-
1-producing neurons in a rat (2, 33).
Combined with other data showing
expression of GLP-1R in the rat PBN (10) and the strong
behavioral effect of GLP-1R activation in this species, di-
rect projection to the PBN from the NTS seems rather
likely in the rat.
GLP-1 activation in the lPBN suppressed chow intake,
intake of palatable chocolate pellets, and also intake of
noncaloric saccharine solution. This indicates that
GLP-1R signaling in the lPBN can reduce food intake
across the palatability and caloric density spectrum. Im-
portantly PBN Ex-4 injections did
not reduce water intake. Collec-
tively, these data indicate that PBN
GLP-1 signaling may interact with
the caloric density, taste, and hedo-
nic properties of food. The PBN is a
crucial relay for the hedonic value of
food; lesion of the PBN blunts nu-
cleus accumbens dopamine eleva-
tion in response to palatable food
(34). Moreover, one recent study in-
dicates that lPBN-directed Ex-4 in-
jections reduce high-fat food intake
and suppress themotivation towork
for a high-fat reward in rats (33).
Figure 6. GLP-1 innervation of CGRP neurons in the lPBN. Many YFP-immunoreactive axons
(green) closely apposed the CGRP neurons (red) of the lPBN. Yellow arrows indicate CGRP-
labeled lPBN cell bodies closely apposed by the GLP-1 fibers, whereas white arrows indicate
CGRP-labeled cell bodies in this region that were not apposed by the GLP-1 fibers. B, Higher
magnification of the lPBN region presented in A. Inset in B shows the interaction at a single cell
level. Blue color represents DAPI the nuclear stain. Nearly half of the CGRP-positive cells in the
lPBN receive GLP-1 innervation (C), and most cells in the lPBN that were innervated by GLP-1
fibers were CGRP-positive (D).
Figure 7. CGRP reduces food intake via a direct action in lPBN. Intra-lPBN delivery of CGRP
reduced chow consumption up to 2 hours after injections (A). This effect was short lasting,
because chow intake (B) and body weight (C) measured 16 hours after injections were not
altered. Data are expressed as mean  SEM. *, P 	 .05.
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Both taste and caloric value, processed in the PBN, may
contribute to the PBN-relayed dopamine response. Acti-
vation of PBN neurons, akin to that observed here with
Ex-4, can reduce the hedonic properties of food and in-
hibition of PBN neurons by microinjections of GABA-A
receptor agonists into the PBN increases hedonic re-
sponses to oral sucrose (35).
The PBN is a heterogeneous nucleus with at least 12
distinct subnuclei and subdivisions of the PBN can be
clearly differentiated based on their neuronal inputs and
outputs (36). The gustatory afferents are represented in
the medial subdivision, and the viscerosensory, the car-
diovascular, and the respiratory functions in the lateral
subdivision. In the current study, the decision to target the
lPBN was based on the idea that caudally located GLP-1
neurons are likely to project to the viscerosensory lPBN
rather than the mPBN, because inputs from the caudal
viscerosensory NTS are segregated from the gustatory in-
puts from the rostral NTS to the mPBN. However, the
segregation of inputs does not prevent some cross-com-
munication, because even the gustatory PBNdisplays sen-
sitivity to themetabolic status, and the lPBN,especially the
dorsal part, is activated by noncaloric gustatory stimuli
like saccharine (37). This may be the reason why both
caloric food (chocolate and chow) and noncaloric saccha-
rine consumption were reduced in the current study. Our
study shows that activation of the GLP-1R can suppress
intake of a sweet noncaloric solution.
The PBN plays a critical role in
relaying visceral signals to the fore-
brain (38). The parabrachial-associ-
ated effect of a gut/brain peptide to
reduce food intake, demonstrated
here, fits well with previous studies
showing that lPBN lesion impairs
cholecystikinin (CCK)- and amylin-
induced food intake suppression and
attenuates the c-Fos activation nor-
mally expected from CCK and amy-
lin action in the central nucleus of the
amygdala (39, 40). Here, we show a
direct effect of GLP-1R in the PBN.
This is different from the previous
studies, performed with peripheral
injections ofCCKandamylin,which
could not determine whether these
peptides exert direct or indirect feed-
ing effects at the lPBN.
Signaling at the central GLP-1R is
necessary forhypophagia inducedby
satiety and metabolic signals, like
CCK and leptin, that are recruited in
health, but it is also a keymediator of hypophagia induced
by aversive stimuli, like lithium chloride and lipopolysac-
charide (41–43). Interestingly, the same sickness-associ-
ated hypophagic stimuli can activate PBN neurons, and
this activation may be a necessary component of the feed-
ing suppression they cause (44–46). These 2 components
are tied together by data indicating that hindbrain selec-
tive blockade of GLP-1R prevents lipopolysaccharide-in-
duced hypophagia (47). Thus, it is possible that the GLP-1
neuron projections to the PBN and the hypophagia result-
ing from lPBN GLP-1R activation are relevant relays for
sickness-induced hypophagia and not only for homeo-
static appetite during health, as discussed above.
PBN neurons project to the hypothalamus, limbic sys-
tem, and other forebrain regions. In order to begin to un-
derstand the potential downstream circuitry activated by
GLP-1R stimulation in the PBN, we determined gene ex-
pression levels for candidate genes recently shown to be
key for appetite suppression in the PBN. We found that
Calca, the gene that encodes CGRP, an anorexic peptide,
was elevated by Ex-4 treatment. CGRP neurons, found
exclusively in the lPBN, play a key role in appetite sup-
pression (18, 48, 49). Optogenetic stimulation of these
neurons suppresses food intake in fed and food-deprived
rats. c-Fos studies indicate that these neurons are activated
by satiety signals, like amylin andCCK, and also by illness
inducing signals like lithium chloride and lipopolysaccha-
ride.Here,we show thatGLP-1R activation can also stim-
Figure 8. Graphical summary of results. Collectively, our data reveal the lPBN as a neural
substrate for the feeding and body weight suppression effect of GLP-1 and identify the
mechanisms involved. Elements of this novel energy balance relevant circuit identified in the
current study are indicated in red. In contrast to the excitatory GLP-1 projections to the PBN, the
projections from the hypothalamus (green) to the PBN provide inhibitory inputs, and their
activation results in an orexigenic response.
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ulate CGRP gene expression. Our neuroanatomical and
immunohistochemical data suggest that this effect could
be exerted by direct inputs from GLP-1 releasing fibers
onto the CGRP-producing cells, because we found that
mostNTS-originatingGLP-1-producing fibers innervated
CGRP neurons in the lPBN. The elevation of CGRP levels
could contribute to the anorexic and weight-suppressing
effect of GLP-1, because direct intra-lPBN injections of
CGRP reduced both food intake and body weight gain. It
is noteworthy that GLP-1R stimulation increased CGRP
only in ad libitum-fed rats, a more physiological situation
for endogenous GLP-1 release. The lack of effect of
GLP-1R activation on CGRP in fasted rats may indicate
that orexigenic signals abundant during fasting may in-
hibit GLP-1’s ability to induceCGRP, thereby reducing its
ability to suppress food intake. This result is in line with a
previous report showing a nearly complete suppression of
GLP-1 neuron activation by food deprivation (50). Taken
together, the present and previous studies suggest that
fasting can suppress both production/release of GLP-1
and GLP-1-stimulated downstream anorexic pathways.
IL-1 and IL-6 are key regulators of the inflammatory
response (51,52), but theymayalsoplayan important role
in healthy animals to regulate metabolic function. Mice
lacking IL-1R or IL-6 develop late-onset obesity as well as
disturbed glucosemetabolism (53–56). Recently, we iden-
tified IL-1 and IL-6 as key mediators of the appetite-
suppressive effects of GLP-1 (28). The results of the cur-
rent study complement the previous data by showing that
GLP-1R activation can increase IL6 gene expression not
only in the hypothalamus and caudal brainstembut also in
the PBN. The elevation of IL-6 in the PBN was detected
irrespective of the feeding state of the animal, indicating
that the relationship between Ex-4 and IL-6 is robust. Pre-
vious data link CGRP and IL-6 in the pituitary (57). Al-
though our data do not directly examine this connection,
CGRPmaynotbenecessary for theEx-4 inductionof IL-6,
because IL-6 levels were elevated in fasted rats, whereas
CGRPremainedunchanged. IL-1mRNAwasnotaltered
in the PBN, in linewith previous data showing that GLP-1
can induce IL-1 in the hypothalamus but not the caudal
brainstem (28).
Collectively, this study reveals lPBN as a neural sub-
strate for the feeding suppression effect ofGLP-1and iden-
tifies themechanisms involved (Figure 8). Thismechanism
of action may be relevant to patients receiving Ex-4, or
other GLP-1 analogues, given that these pharmaceuticals
can cross the blood-brain barrier after peripheral appli-
cation, and c-Fos results indicate that peripheral Ex-4 in-
jections in rodents can activate the PBN (58).
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Sex and estrogens alter the action of
glucagon-like peptide-1 on reward
Jennifer E. Richard, Rozita H. Anderberg, Lorena López-Ferreras, Kajsa Olandersson and Karolina P. Skibicka*
Abstract
Background: Feeding behavior is regulated through an intricate array of anorexic and orexigenic hormones acting
on the central nervous system (CNS). Some of these hormones may have differential effects in males and females,
effects potentially attributed to actions of gonadal steroids, especially estrogens. Central stimulation of the
glucagon-like peptide-1 (GLP-1) receptors reduces feeding and food-reward behavior by acting on CNS regions
important for the anorexic actions of estrogens. Thus, we propose that the action of GLP-1 on food intake and
reward may differ between sexes.
Methods: Male and female rats were centrally injected with the GLP-1 analog exendin-4 (Ex4) in a non-deprived or
food-restricted state; reward behavior was measured in a progressive ratio operant conditioning task. Intake of
chow and palatable food were also measured. To determine if sex differences in the actions of Ex4 are due to
interactions with estrogens, Ex4 treatment was preceded by treatment with a nonselective estrogen receptor-α
(ERα) and ERβ or ERα-selective antagonist.
Results: Central injection of Ex4 revealed increased reward behavior suppression in females, compared to males, in
the operant conditioning task. This increase was present in both non-deprived and food-restricted animals with
larger differences in the fed state. Intake of chow and palatable food, after Ex4, were similar in males and females.
Food reward, but not food intake, effect of Ex4 was attenuated by pretreatment with ER antagonist in both sexes,
suggesting that estrogens may modulate effects of Ex4 in both sexes. Furthermore, central pretreatment with
ERα-selective antagonist was sufficient to attenuate effects of Ex4 on reward.
Conclusions: Collectively, these data reveal that females display much higher sensitivity to the food reward impact
of central GLP-1 receptor activation. Surprisingly, they also demonstrate that central ERα signaling is necessary for
the actions of GLP-1 on food-reward behavior in both sexes.
Keywords: Glucagon-like peptide-1, GLP-1, Exendin-4, Reward, Estrogens, Sex, Obesity
Background
Sex is a basic biological variable that influences physi-
ology and disease. Despite the overrepresentation of
women in diseases resulting from disordered eating [1, 2],
few preclinical studies have a clear focus to explore the
neurobiology and physiology of food intake regulation in
females. This sex gap is symptomatic of what is seen in
preclinical medical research overall. According to a recent
review of preclinical publications [3], nearly two out
of three papers did not even report the sex of the an-
imals used in the study. Nevertheless, physiology and
pathophysiology of feeding behavior differ in male
and female animals or humans. Recent data suggest
that the female brain responds differently to different
food intake regulating signals [4–6].
Glucagon-like peptide-1 (GLP-1) and its receptors
have emerged as a successful therapeutic target for treat-
ment of type-2 diabetes [7, 8]. The usage of GLP-1-
based therapy is increasing at a fast pace; however, some
aspects of GLP-1 function, especially pertaining to its
role in the central nervous system (CNS), remain unex-
plored. Considering the increasing amount of patients
receiving this treatment [9, 10], there is a certain
urgency to develop a better understanding of the action
of GLP-1 and its analogs on the CNS. Increasingly, more
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evidence is pointing to the CNS as a major target for
GLP-1 [11]. In fact, derived from preproglucagon, GLP-1
is produced not only in the periphery (intestine, pancreas)
but also in the CNS, primarily by neurons located in the
nucleus of the solitary tract (NTS). Central injections of
GLP-1 receptor (GLP-1R) agonists potently decrease food
intake; this anorexic action has been ascribed to the
hypothalamic and brainstem GLP-1R expressing targets
[11–15]; the same CNS regions are implicated for the
anorexic action of estrogens [16–19], providing neu-
roanatomical grounds for a potential interaction between
GLP-1R activation, sex, and estrogens proposed here.
Food intake is regulated not only from brain regions
traditionally recognized for their role in homeostatically
driven feeding, like the hypothalamus and the hindbrain,
but also from extra-homeostatic areas that control re-
warding aspects of eating [20, 21]. Food reward is an im-
portant component in the development of overeating
and obesity [22] and can be divided in two components,
“liking” and “wanting,” as previously described by
Berridge et al. [23, 24]. Wanting is associated with in-
centive salience and motivation for a certain type of food
and is often coupled to stimuli, which can trigger a de-
sire to acquire or work for the rewarding component.
Liking on the other hand is more commonly associated
with palatability. Though these two systems are closely
linked, they also have the ability to act independently of
each other, and via separate neural pathways, to modu-
late reward [23]. The wanting component of food reward
is closely linked to the mesolimbic neurocircuitry, espe-
cially the ventral tegmental area (VTA) and its dopamin-
ergic projections to the nucleus accumbens (NAc) [25].
GLP-1Rs and GLP-1-carrying fibers can also be found in
these areas of the brain, involved in motivated behavior
and addiction [26]. GLP-1 can change reward behavior
in males [27–31]. However, little is known about GLP-1-
driven food-reward control in females. Here, we deter-
mined whether there are sex differences in the sensitivity
of food reward, more specifically food motivation and
consumption of palatable food, and chow intake behav-
ior to central GLP-1R activation.
Methods
Animals
Female and male Sprague-Dawley rats (160–200 g at
arrival, and mean body weights of 260 and 480 g for
females and males, respectively, during testing, Charles
River, Germany) were housed in a 12-h light/dark cycle,
in individual cages with ad libitum access to chow and
water, unless otherwise specified. Female rats presented
with normal 4- to 5-day estrous cycles throughout the
experimental testing. However, this study was not de-
signed to analyze any potential impact of cycling. All
testing was conducted during the light cycle. All studies
were carried out with ethical permissions from the Animal
Welfare Committee of the University of Gothenburg, in
accordance with legal requirements of the European
Community (Decree 86/609/EEC). All efforts were made
to minimize suffering.
Drugs
Exendin-4, angiotensin II, ICI 182, 780 [32], and MPP
dihydrochloride (MPPd) were purchased from Tocris
(Bristol, UK). Ex4 and angiotensin II were dissolved in
artificial cerebral spinal fluid (aCSF, vehicle for central
injection), and ICI and MPPd were dissolved in aCSF
with 10 and 20 % DMSO, respectively. All drugs were
stored as aliquots at −20 °C.
Operant conditioning
The progressive ratio operant conditioning schedule is a
procedure used to analyze motivated behavior (reward
wanting, often compared to the human experience of
craving) and measures the amount of work or effort that
a subject is willing to put in to obtain a reward, in this
case rewarding food in the form of sucrose, and it there-
fore mainly measures the wanting component of food
reward. Operant conditioning training was conducted in
rat conditioning chambers (Med-Associates, Georgia,
VT, USA) as described previously [27, 33] in ad libitum
fed rats. Rats were trained to press a lever for a 45-mg
sucrose pellet. Training was conducted in four stages:
rats were first trained on the fixed ratio 1 (FR1) schedule
in 30-min sessions (single press on the active lever re-
sulted in the delivery of one sucrose pellet), followed by
FR3 and FR5 (3 and 5 presses per pellet, respectively),
where a minimum of 30 responses per session on the
active lever was required for advancement to the next
schedule, concluding with progressive ratio conditioning
until stable responding was achieved. Each progressive
ratio session lasted for 1 h. Responding was considered
stable when the number of pellets earned per session did
not differ more than 15 % between three consecutive
sessions. All operant response testing was performed
after the responses stabilized. All drug injections and
testing were performed during the light cycle, starting
2 h after lights-on as specified below, and testing com-
menced 20 min after drug injection. Injections were
done in a counterbalanced, Latin square design, with at
least 48 h separating each injection condition.
Brain cannulation
Due to variations in body weight between male and fe-
male subjects, in addition to differential fat pad location
and size [34], along with the fact that Ex4 can cross the
blood-brain barrier [35], direct brain administration was
chosen for all substances tested in order to avoid the po-
tential confounding effects from these variations. As a
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result, our experiments are not relevant to effects solely
mediated by peripheral GLP-1R. Rats were implanted
with a guide cannula targeting the lateral ventricle [36]
(26 gauge; Plastics One, Roanoke, VA): ±1.6 from the
midline, 0.9 mm posterior to bregma, and 2.0 mm ven-
tral to skull, with an injector aimed 4.0 mm ventral to
the skull under ketamine anesthesia. The cannulas were
attached to the skull with dental acrylic and jeweler’s
screws and closed with an obturator as described previ-
ously [37]. Placement was verified with the angiotensin
II drinking test. Angiotensin II was injected at a dose of
20 ng in 2 μL of aCSF, and water intake was measured
throughout the following 30 min. Rats who consumed a
minimum of 5 mL of water within the measured time
period were considered to have correctly positioned
cannulas.
Effects of central Ex4 in non-deprived males and females
on food-motivated behavior and food intake
Male and female rats were injected with Ex4 (0.1 or
0.3 μg/μL) or vehicle into the left ventricle (LV). Doses
were previously shown to reduce food motivation in
food-restricted male rats [27]. Twenty minutes after in-
jection, the rats were placed in the operant conditioning
chambers for a 1-h testing period. Testing was per-
formed in a non-deprived state 2 h following the dark
cycle period where rats had ad libitum access to chow.
After testing, the rats were returned to their home cages
and given access to palatable food—peanut butter. After
1 h, the amount of consumed peanut butter was mea-
sured and the rats received normal chow for the remain-
der of the 24-h period.
Effect of central Ex4 in overnight food-restricted males
and females on food-motivated behavior and food intake
Rats were food-restricted overnight to approximately
50 % of their normal intake. On the following day, rats
of each sex were injected with Ex4 (0.3 μg/μL) or vehicle
and the operant conditioning test was performed 20 min
after injection for 60 min. Peanut butter intake and
chow intake were measured as described above.
Effects of central estrogen blockade on male and female
food-motivated behavior after Ex4 treatment
Food-restricted male and female rats received injections
of the estrogen receptor (ER) antagonist ICI (10 μg/μL)
[38] or vehicle into the left ventricle (LV) prior to injec-
tion of Ex4 (0.3 μg/μL) or vehicle in this area. Food re-
striction and the higher Ex4 dose were chosen in order
to induce reliable reward behavior reduction in both
sexes. Operant conditioning, intake of peanut butter, and
chow consumption were measured as described above.
Effects of central administration of the ERα-antagonist on
male and female food-motivated behavior after Ex4
treatment
Overnight food-restricted rats were injected with 1.4 μg/μL
[39] of the estrogen receptor-α (ERα) (Esr1)—antagonist
MPPd or vehicle, accompanied by injection of 0.3 μg/μL
Ex4 or vehicle, into the LV. Operant conditioning, intake
of peanut butter, and chow consumption were measured as
described above.
Statistical analysis
All the data are presented as mean ± standard error of
the mean (SEM). Statistical significance was analyzed
using Student’s t test or one- and two-way ANOVA,
when appropriate, with Sidak’s or Holm-Sidak’s post hoc
tests (GraphPad Software, Inc., San Diego, CA). p values
lower than 0.05 were considered statistically significant.
Results
Effect of central Ex4 treatment on reward and food intake
in non-deprived males and females
To investigate potential differences in the effects of
central Ex4 treatment between males and females, rats
of both sexes were tested using a progressive ratio
reinforcement schedule after administration of Ex4 (0.01
or 0.03 μg/μL) or vehicle. Two-way repeated measures
ANOVA revealed a significant reduction in sucrose re-
wards earned, and lever presses for sucrose, at both
doses of Ex4 in female, but not male, rats (Holm-Sidak’s
multiple comparisons test, p < 0.0001; Fig. 1a, c). The
main effect of drug treatment was significant for both
rewards earned and number of lever presses for rewards
(F(2, 108) = 19.25, p < 0.0001; F(2, 108) = 15.91, p < 0.0001).
The main effect of sex on rewards earned and lever
presses was not significant (F(1, 108) = 1.790, p > 0.05;
F(1, 108) = 3.717, p > 0.05, respectively). Importantly,
there was a significant interaction between these two
factors (F(2, 108) = 10.46, p < 0.0001; F(2, 108) = 9.195,
p < 0.001). Data displayed as sucrose rewards earned and
active lever presses in percent of vehicle value revealed
significant differences for both parameters at both doses
of Ex4 between males and females (p < 0.05, Fig. 1b;
p < 0.05, Fig. 1d). Two-way ANOVA also revealed a
significant effect of sex (F(1, 108) = 25.56, p < 0.0001;
F(1, 108) = 17.02, p < 0.0001) and a significant interaction
between sex and treatment (F(2,108) = 7.610, p < 0.001;
F(2,108) = 4.424, p < 0.05).
Central GLP-1R stimulation led to a significant de-
crease in peanut butter consumption compared to con-
trols in both sexes (two-way ANOVA, Holm-Sidak’s
multiple comparisons test, p < 0.001 and p < 0.0001 for
females for the low and high dose of Ex4, respectively,
and p < 0.0001 for males for both doses of Ex4; Fig. 1e).
Two-way repeated measures ANOVA indicated that the
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main effect of sex on peanut butter consumption was not
significant (F(1, 108) = 2.088, p > 0.1). The effect of drug
treatment, however, was significant (F(2, 108) = 36.38,
p < 0.0001) though there was not a significant inter-
action between these two factors (F(2, 108) = 0.2951,
p > 0.1). Data expressed as percent of vehicle value
revealed a significant effect of drug treatment (F(2, 108) =
130.1, p < 0.0001), but not the effect of sex (F(1, 108) =
0.4864, p > 0.1; Fig. 1f) or interaction between these
parameters (F(2, 108) = 3.026, p > 0.05).
To investigate if 1 h peanut butter consumption is in-
fluenced by the experimental setup (the timing of the
Fig. 1 In non-deprived animals, central GLP-1R stimulation specifically decreases food-motivated behavior in females but not males. Ex4 injection
into the LV significantly reduced sucrose rewards earned (a), and active lever presses for reward (c) in female but not male subjects. Sucrose
rewards (b) and active lever presses (d) were also significantly lower in females compared to males after Ex4 treatment, at both doses, analyzed
as percent relative to vehicle value. Central GLP-1R agonist treatment significantly reduced peanut butter consumption in both males and females
(e), with no significant differences between the two sexes (f). Chow consumption was reduced in males and females after Ex4 treatment (g); no
significant differences were present between sexes at either dose of the agonist (h). Chow and peanut butter consumption are displayed in
grams. Data are expressed as mean ± SEM. n = 20 (females) and 18 (males) per treatment group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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test relative to injections or the fact that it is preceded
by the operant task), an additional group of males
received Ex4 injections (0.3 μg/μL) or vehicle, in a non-
deprived state, and peanut butter consumption was mea-
sured 20 min after injection for 60 min (the same time
point as operant conditioning testing was conducted).
One-hour peanut butter consumption was significantly
reduced in Ex4-treated male subjects compared to con-
trols (Student’s t test, p < 0.05, data not shown) at this
time point. The size of the effect was comparable to the
effect obtained when testing was conducted after PR, in-
dicating that 1 h intake after PR testing was not affected
by the experimental design.
In addition to peanut butter, Ex4 treatment led to a sig-
nificant dose-dependent reduction in chow intake after
24 h, in both male and female rats (two-way ANOVA,
Holm-Sidak’s multiple comparisons test, p < 0.0001 for
both doses of Ex4, in males and females; Fig. 1g). The
main effect of drug treatment was significant (two-way
ANOVA, F(2, 108) = 118.5, p < 0.0001). Two-way repeated
measures ANOVA also revealed a significant difference
between males and females in both the main effect of sex
(F(1, 108) = 21.01, p < 0.0001) as well as interaction between
sex and drug treatment (F(2, 108) = 9.590, p < 0.001).
Comparison of chow consumption relative to vehicle
revealed a significant effect of treatment (F(2, 108) = 149.5,
p < 0.0001; Fig. 1h), but not sex (F(1, 108) = 1.698, p > 0.1),
and there was no significant interaction between these
two factors (F(2, 108) = 1.051, p > 0.1).
Effect of central Ex4 treatment on reward and food intake
in food-restricted males and females
Due to the absence of effect of Ex4 on food-motivated
behavior in non-food deprived males, an effect which
has previously been established for fasted males, add-
itional experiments in a food-restricted state were neces-
sary to validate the experimental setup and to investigate
potential differences in the action of Ex4 between sexes
in different hunger states. Operant conditioning testing
as well as food intake measurements were therefore con-
ducted in overnight food restricted animals using only
the higher concentration of Ex4. Under these conditions,
Ex4 significantly decreased the amount of sucrose re-
wards earned in both males and females (Holm-Sidak’s
multiple comparisons test, p < 0.0001 and p < 0.05 for fe-
males and males, respectively; Fig. 2a). While the main
effect of drug treatment was significant (two-way
ANOVA, F(1, 34) = 38.41, p < 0.0001), the main effect of
sex was not (F(1, 34) = 1.219, p > 0.1). Importantly, there
was also a significant interaction between these two fac-
tors (F(1, 34) = 4.447, p < 0.05). Though significant in both
groups, females had a larger reduction in rewards earned
than males (sucrose rewards earned as percent of vehicle
value, p < 0.01; Fig. 2b). In the restricted condition, lever
pressing for sucrose rewards reached significance in the
female group after analysis using two-way ANOVA ana-
lysis (p < 0.001; Fig. 2c). Though the effect of treatment
was significant (F(1, 34) = 21.66, p < 0.0001), there was no
significant effect of sex (F(1, 34) = 1.943, p > 0.1) or
interaction of sex and drug treatment (F(1, 34) = 2.725,
p > 0.1). Additionally, a significant difference was present
between active lever press counts for restricted males
and females (presses in percent of vehicle, p < 0.01;
Fig. 2d).
In restricted animals, Ex4 treatment led to a significant
reduction in 1 h peanut butter consumption in both
sexes (two-way ANOVA, Holm-Sidak’s multiple compar-
isons test, p < 0.001 for males and females; Fig. 2e). The
main effect of drug treatment was significant (two-way
ANOVA, F(1, 34) = 44.26, p < 0.0001). The main effect of
sex was non-significant (F(1, 34) = 1.545, p > 0.1). There
was no significant interaction between these two factors
(F(1, 34) = 0.00183, p > 0.1). There was, however, a differ-
ence in peanut butter consumption between male and
female Ex4-treated groups when analyzed as percent
peanut butter consumed relative to the amount con-
sumed after vehicle injection (p < 0.05; Fig. 2f ).
Ex4 treatment also led to a significant reduction in 24 h
chow consumption, compared to controls, in both re-
stricted males and females (two-way ANOVA, Holm-
Sidak’s multiple comparisons test, p < 0.001 and p < 0.0001
for females and males, respectively; Fig. 2g). Two-way
ANOVA revealed significance in all measures, including
the main effect of sex (F(1, 34) = 18.46, p < 0.001), the main
effect of drug treatment (F(1, 34) = 85.50, p < 0.0001),
and the interaction between these two measures
(F(1, 34) = 10.14, p < 0.01). However, no differences
were found between Ex4-treated males and females when
displayed as percent chow consumed compared to vehicle
(Fig. 2h).
Effect of estrogen blockade on the actions of Ex4 on
reward in food-restricted rats
To explore the impact of estrogens on the actions of
Ex4, the estrogen antagonist ICI was administered cen-
trally along with Ex4 into fasted male and female rats.
Two-way repeated measures ANOVA revealed a signifi-
cant difference in the main effect of sex (F(3, 98) = 14.71,
p < 0.001) and effect of drug treatment (F(3, 98) = 14.43,
p < 0.0001). A significant interaction between the two
factors was also detected (F(3, 98) = 4.014, p < 0.01).
Pretreatment with ICI attenuated the Ex4-induced food
reward suppression in female rats. After the combined
treatment, the amount of sucrose rewards earned was
therefore no longer statistically significant compared to
controls (Fig. 3c). Interestingly, similar effects of the com-
bined treatment on sucrose rewards earned were also
present in males (Fig. 3a). For lever presses, two-way
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Fig. 2 Ex4 treatment in overnight food-restricted rats leads to a larger reduction in food-motivated behavior in females than males. After overnight
food restriction, central Ex4 treatment reduced sucrose rewards earned in both males and females (a), an effect that was larger in females (b). Active
lever presses were significantly reduced by Ex4 treatment in female subjects; a trend for reduction was present in male subjects but it did not reach
statistical significance (c). Lever presses after Ex4 treatment in males and females analyzed as percent of vehicle treatment also revealed a significantly
larger reduction in female subjects (d). Peanut butter consumption was significantly reduced in both sexes (e) with a slightly larger
response to Ex4 in females (f). Twenty-four hour chow consumption was reduced in both males and females after GLP-1R agonist injection (g); no
significant differences were found in chow intake between the two sexes (h). Chow and peanut butter consumption are displayed in grams. Data are
expressed as mean ± SEM. n = 10 (females) and 9 (males) per treatment group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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ANOVA indicated a significant effect of sex (F(1, 98) =
25.87, p < 0.0001) and effect of drug treatment (F(3, 98) =
13.87, p < 0.0001). Importantly, there was also a significant
interaction between the two factors (F(3, 98) = 6.792,
p < 0.001). ICI treatment in females led to an attenuation
of the reduction of active lever presses for sucrose after
Fig. 3 Central estrogen blockade attenuates the effects of Ex4 on food-motivated behavior. Concurrent administration of the selective estrogen
antagonist ICI and Ex4 attenuated the reduction in sucrose rewards earned in females (c) and males (a) compared to Ex4 treatment alone, although
this effect did not reach significance. Reduction of active lever presses for sucrose was also attenuated in both sexes after ICI treatment (b, d). The
number of sucrose rewards earned for males and females combined was reduced after central Ex4 injection (e); this effect was attenuated after ICI
treatment. Combined results for males and females also demonstrate a significant reduction in lever presses for sucrose after central GLP-1R stimulation;
attenuation by the ICI treatment did not reach statistical significance (f). Data are expressed as mean ± SEM. n= 10 (females) and 18 (males) per treatment
group. *p < 0.05, **p< 0.01, ****p < 0.0001
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central GLP-1R stimulation (Fig. 3d). In males, the re-
duced amount of active lever presses for sucrose did not
reach statistical significance after Ex4 treatment, although
interestingly, combination of Ex4 with the antagonist
treatment did lead to an increase in the amount of lever
presses compared to Ex4 treatment alone (Fig. 3b). When
results of males and females are combined due to similar
trend in response pattern, a significant difference in re-
wards earned (one-way ANOVA, F(3, 102) = 9.633, p < 0.05;
Fig. 3e), but not active lever presses for sucrose (Fig. 3f),
between Ex4- and Ex4/ICI-treated rats is detected. ICI
treatment alone did not have any significant effects on
reward-related behavior in this experiment. One male rat
and three female rats did not finish the study due to dis-
lodged or blocked cannula.
Two-way repeated measures ANOVA indicated that
the main effect of sex (F(1, 63) = 0.8913, p > 0.1) was not
significant. Drug treatment (F(3, 63) = 4.682, p < 0.01) was
significant. A significant interaction between these two
factors was not found (F(3, 63) = 0.3939, p > 0.1). Treat-
ment with Ex4 alone, or in combination with the estro-
gen antagonist ICI, led to a significant reduction in
peanut butter consumption after 1 h in females (one-
way ANOVA, F(3, 33) = 4.242, p < 0.05; Fig. 4c), but not in
males (F(3, 30) = 1.142, p > 0.1; Fig. 4a). Chow consump-
tion was significantly different, both regarding the dif-
ferences in the effect of sex (F(1, 97) = 17.73, p < 0.0001)
and the main effect of drug treatment (F(3, 97) = 1.197,
p < 0.001). A significant interaction between these two
factors was not found (F(3, 97) = 0.6991, p > 0.1). Twenty-
four hour chow consumption was reduced after Ex4 treat-
ment in both male and female subjects (one-way ANOVA,
F(3, 66) = 4.139, p < 0.05; Fig. 4b, F(3, 31) = 9.230, p < 0.001;
Fig. 4d, for males and females, respectively). In contrast to
peanut butter consumption, ICI treatment attenuated
Ex4-induced food intake reduction in females, but not in
males, resulting in an increased amount of chow intake
consumed during the 24-h period (Fig. 4b, d).
Effects of central administration of the ERα-antagonist
MPPd on male and female food-motivated behavior after
Ex4 treatment
For sucrose rewards earned, two-way ANOVA re-
vealed a significant difference in the main effect of
sex (Holm-Sidak’s multiple comparisons test, F(1, 56) =
7.319, p < 0.01) and effect of drug treatment (F(3, 56) =
13.98, p < 0.0001). A significant interaction between these
two factors was not found (F(3, 56) = 0.5209, p > 0.1). As
shown previously, Ex4 significantly decreased the amount
of sucrose rewards earned in both male and female
rodents in the operant conditioning task (one-way
ANOVA, F(3, 28) = 4.750, p < 0.5; Fig. 5a, F(3, 28) = 10.04,
p < 0.001; Fig. 5c, for males and females, respectively).
Coinciding treatment with MPPd attenuated the effects of
Ex4 in both sexes (Fig. 5a, c). Two-way repeated measures
ANOVA revealed that the main effect of sex (F(1, 56) =
9.483, p < 0.01) and drug treatment (F(3, 56) = 10.36,
p < 0.0001) were significant for active lever presses. There
was, however, no interaction between these two factors
(F(3, 56) = 1.777, p > 0.1). Active lever presses for sucrose
were significantly decreased in females after Ex4 treatment
(one-way ANOVA, F(3, 28) = 7.328, p < 0.01; Fig. 5d), but
not in males (Fig. 5b). The effects of Ex4 on lever presses
were also attenuated after MPPd treatment in females and
an increase in presses was also present in males, though
this increase was not significant (Fig. 5d, b). Combined re-
sults for males and females showed a significant increase
in sucrose rewards earned after MPPd/Ex4 treatment
compared to Ex4 treatment alone (one-way ANOVA, F(3,
60) = 12.92, p < 0.05; Fig. 5e). The attenuation of MPPd/
Ex4 administration on active lever presses in males and
females combined, however, did not reach significance (5F).
Two-way repeated measures ANOVA indicated that
the main effect of sex was not significant (F(1, 56) = 1.413,
p > 0.1) for 1-h peanut butter consumption. The main
effect of drug treatment was significant (F(3, 56) = 20.13,
p < 0.0001). A significant interaction between these two
factors was not found (F(3, 56) = 0.7364, p > 0.1). MPPd
injection did not affect the action of Ex4 on peanut but-
ter consumption which remained significantly reduced
compared to vehicle in both males and females (one-way
ANOVA, F(3, 28) = 10.21, p < 0.01; Fig. 6a, F(3, 28) = 10.74,
p < 0.001; Fig. 6c, for males and females, respectively).
Two-way repeated measures ANOVA revealed that the
main effect of sex (F(1, 56) = 16.94, p < 0.001) and drug
treatment (F(3, 56) = 21.27, p < 0.0001) were both signifi-
cant for the 24-h food consumption. There was no inter-
action between these two factors (F(3, 56) = 0.3711, p >
0.1). Furthermore, the 24-h food intake was also un-
affected after combined Ex4 and MPPd treatment com-
pared to Ex4 alone and was still significantly reduced
compared to controls (one-way ANOVA, F(3, 28) =
9.905, p < 0.001; Fig. 6b and F(3, 28) = 12.83, p <
0.0001; Fig. 6d, for males and females, respectively). Two
male and two female rats did not finish the study due to
dislodged or blocked cannula.
Discussion
Preclinical research unraveling the neural basis of feed-
ing behavior is almost exclusively conducted in male
subjects, although recent evidence suggests females and
males may regulate feeding behavior differently [4–6].
Likewise, reward-mediated behavior may be differentially
regulated between men and women due to the impact of
sex hormones [40, 41]. GLP-1 agonists have previously
been shown to affect food intake and food-reward be-
havior [27, 29, 42, 43]. The current study provides
evidence that Ex4, the long-lasting GLP-1 analog, may
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have differential effects on food-reward in male and
female subjects. Moreover, we demonstrate that signal-
ing via central ER is necessary for the full impact of Ex4
on food reward. More specifically, signaling at the ERα
may be crucial, since selective ERα-antagonist, MPPd,
attenuated Ex4-induced food reward suppression.
Central GLP-1R agonist injection potently reduced
food-motivated behavior in females and males in a sex-
dependent manner in a progressive ratio operant condi-
tioning task. The progressive ratio operant conditioning
task, used here to analyze reward behavior, measures the
motivation to obtain a food reward. Food-reward behav-
ior is typically divided into two components: liking and
wanting, where liking is typically associated with the im-
mediate experience the moment a palatable food is con-
sumed, while wanting is associated with reward seeking
Fig. 4 Effect of central estrogen blockade on the actions of Ex4 on peanut butter consumption or chow intake is not divergent between the
sexes. No significant changes in peanut butter consumption were observed in males (a), but a significant reduction in consumption was noted in
females after injection of Ex4 or Ex4 and ICI (c). Ex4 reduced chow intake in both males and females (b, d). This reduction was attenuated by
simultaneous ICI treatment only in females. Chow and peanut butter consumption are displayed in grams. Data are expressed as mean ± SEM.
n = 10 (females) and 9 (males) per treatment group for peanut butter measurement and n = 10 (females) and 18 (males) per treatment group for
chow intake. *p < 0.05, ***p < 0.001
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Fig. 5 (See legend on next page.)
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Fig. 5 Central injection of the ERα-antagonist MPPd attenuated the effects of Ex4 on food-motivated behavior. As expected, central administration of Ex4
led to a reduction in sucrose rewards earned in females (c) and males (a). Ex4 no longer significantly reduced sucrose rewards earned after administration
of the specific ERα-antagonist MPPd. Additionally, Ex4 treatment reduced lever presses for sucrose earned in females (d) and produced a trend for
reduction in males (b), an effect which was also attenuated by co-treatment with MPPd. Compilation of female and male data revealed a significant
reduction in sucrose rewards earned (e) and active lever presses (f) after EX4 treatment that was attenuated after combined MPP/Ex4 treatment. Data
are expressed as mean ± SEM. n = 7–9 for males and females. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 6 MPPd treatment did not attenuate the effects of central Ex4 treatment on food intake. Central injection with the GLP-1R agonist Ex4
significantly reduced peanut butter intake and chow intake in males (a, b) and females (c, d). The reduction was still present after treatment with
the ERα-antagonist MPPd. Chow and peanut butter consumption are displayed in grams. Data are expressed as mean ± SEM. n = 7–9 for males
and females. **p < 0.01, ***p < 0.001
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and an increased motivation to obtain rewarding foods
[23]. Here, we show that the wanting component of the
food-reward suppressing effects of Ex4 displays differen-
tial sensitivity in male and female rats. The actions of
Ex4 on food reward were also accompanied by a reduc-
tion in palatable food intake in females and males com-
pared to controls. However, peanut butter consumption
response to Ex4 was not significantly different between
male and female subjects. Progressive ratio test and pal-
atable food intake may to some extent represent the two
different aspects of food reward, where operant condi-
tioning mainly measures wanting, while peanut butter
intake better reflects the liking aspect of food reward.
The differences in sensitivity to Ex4 treatment between
sexes, therefore, seem to be specific to food-motivated
behavior. Though, it is important to note that consump-
tion of peanut butter is not a “pure” test of liking as it
allows for ingesting ad libitum amounts of the palatable
food; thus, an interaction with satiation signaling cannot
be discounted.
Our data clearly indicate differences in the sensitivity
to the food reward impact of Ex4 between females and
males. Interestingly, only females showed a significant
reduction in active lever presses, and sucrose rewards
earned, in the non-food deprived state after Ex4 treat-
ment. Yet, Ex4 has previously been shown to reduce
food-motivated behavior and reduce the intake of palat-
able foods in males [27, 44]. However, considering that
the preceding studies were conducted in rats that were
food-restricted during training, and typically also testing
in the progressive ratio task, in contrast to this experi-
ment, the absence of reward reduction in males may in-
dicate that Ex4 effect on food reward may be dependent
on feeding state. A recent report indicates that a single
overnight fast can attenuate GLP-1’s suppressive effect
on food intake. [45]. Here, we show similar results for
the GLP-1 agonist, Ex4, as unrestricted access to chow
resulted in a more potent reduction in chow intake after
GLP-1R agonist treatment. For reward behavior, the
interaction with fasting differs: overnight food restriction
led to a significant reduction in sucrose rewards earned
in male subjects after Ex4 administration. This effect
was still less potent than in females, further indicating a
higher sensitivity to Ex4 in female subjects. Baseline
measures for reward slightly differed between sexes, with
females receiving a larger quantity of rewards after ve-
hicle treatment. The differential baseline values may
cause some difficulty when comparing the effects of Ex4
in each sex since the higher baseline values displayed in
females may make small reductions in reward caused by
the drug more apparent. However, Ex4 treatment still re-
duced sucrose rewards earned in the food-restricted fe-
males to a larger extent than in food-restricted males,
even though here the baseline values of rewards earned
are not significantly different between the sexes. This
further supports the hypothesis that females are more
greatly affected by Ex4 treatment than their male
counterparts.
Sex differences in reward were not accompanied by
differences in overall food intake, indicating a potential
selectivity of the sex differences to reward. The clear im-
pact of Ex4 treatment on food intake suggests that the
drug was in fact also effective in males, as expected
based on previous studies with this agonist. However,
the long-term interaction of estrogens with GLP-1 in
women, including potential resulting sex differences in
body weight, requires further investigation. Our results
clearly suggest that when food availability is limited by
the amount of work/effort the animal has to put in to
obtain the food, Ex4 is much more efficient at reducing
this type of behavior in females. Since food is rarely
freely available to animals in nature, this effort-based
eating behavior is likely very relevant to natural eating
behavior. Surprisingly, only a few studies have looked at
potential differences in food reward regulation between
sexes in humans, though a recent study revealed differ-
ential connectivity in areas of the brain regulating re-
ward between men and women which may indicate that
food-reward behavior is differently regulated between
sexes [46]. Recently, several studies investigated the
effects of GLP-1R agonists on food intake and reward,
and activation of intake or reward-controlling CNS areas
in humans [47–49]; however, sex or gender interaction
was not the focus, and therefore, sex was either not
reported or the effect of sex not analyzed.
While the ability of estrogens to increase the potency
of Ex4 in both sexes is unexpected, it is in line with one
previous study indicating that co-administration of a
GLP-1 and estrogen agonist in a conjugated form, that
activates cells expressing estrogen receptors and GLP-
1R, or GLP-1R alone, reduces food intake and body
weight at doses of the hormones that are ineffective
alone [50]. Importantly, the reduction was comparable
in both sexes, suggesting that females and males benefit
from the enhancing effects of estrogens on GLP-1 ac-
tion. These data combined with current findings suggest
that estrogens’ signaling is sufficient to enhance food
intake in both sexes but does not seem necessary for the
anorexic effect of Ex4.
Estrogen receptors and GLP-1R are co-localized in
areas involved in reward behavior regulation such as the
VTA and the NAc [26, 51]. To our knowledge, little is
known about the role of estrogens in food reward,
though estradiol treatment in ovariectomized females
was previously shown to reduce the intake of palatable,
high-fat/high-sugar foods, in addition to reducing intake
of standard food [52]. The role of GLP-1R activation in
reward, however, is well-supported by recent literature
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[27, 29, 44], though studies investigating the food-
reward-mediated effects of GLP-1 have previously been
conducted exclusively in males [27, 31, 53, 54]. Nonethe-
less, estrogens have been shown to cause functional
changes in GABAergic neurons in the VTA and
dopaminergic terminals within the striatum [55, 56], and
estrogen treatment enhances striatal dopamine release
[55, 57–61]. Furthermore, estrogens induce increased
dopaminergic sensitivity to cocaine in ovariectomized
rats [61]. In addition, administration of estradiol during
the follicular phase increases the subjective effects of
amphetamine [62]. Levels of dopamine, its metabolites
and synthesizing enzymes, and amphetamine-induced
dopamine release vary as a function of the ovarian cycle
stage [57, 63]. Women progress faster to cocaine
dependence and display a higher incidence of relapse;
female rats also display a higher preference for cocaine
rewards, potentially due to the effects of estrogens
[40, 41]. In contrast, gonadectomy and sex hormone
treatments in males do not have a large impact on
cocaine-reinforced behaviors [64, 65]. Thus, while the
food reward impact of estrogens is unknown, the litera-
ture at least suggests its impact on drug reward. Past
studies focus on the rewarding effects of drugs of abuse
where estrogens mainly enhance reward in contrast to the
current results where estrogens reduced food reward by
enhancing effects exerted by GLP-1. Interestingly, it has
previously been reported that women report higher levels
of craving to rewarding foods, such as chocolate; these
cravings were reported to be most persistent during the
periods of the menstrual cycle characterized by low circu-
lating levels of estrogens [66] indicating that estrogens
may indeed reduce food reward, in contrast to their effects
on drug reward.
Current experiments utilizing ICI, a nonselective ER
antagonist, revealed that estrogens may increase the sen-
sitivity to Ex4 effects on reward. Estrogens’ effects on
food intake may be due to its ability to modulate the ac-
tivity of endogenous hormones [4, 5]. Thus, surprisingly,
the impact of estrogens on the anorexic action in the
case of insulin is opposite to that previously seen for
leptin and currently revealed for Ex4. Collectively, these
studies illustrate estrogen’s ability to modulate feeding
behavior by acting on appetite-regulating hormones.
Therefore, we hypothesized that estrogens may also play
a role in the differential sensitivity displayed by males
and females after Ex4 treatment. As hypothesized, cen-
tral treatment with the ERα (Esr1) and ERβ (Esr2) recep-
tor antagonist, ICI, attenuated the food reward effects of
Ex4 in females, but surprisingly, food-reward behavior in
males was also attenuated by ER blockade. Past literature
suggests that ERα is involved in homeostatic feeding
and weight regulation, and deletion of ERα leads to
obesity in both sexes in mice [67, 68]. In addition,
administration of estradiol reduces food intake and pre-
vents weight gain in wild-type, but not in ovariectomized
transgenic mice lacking ERα, further indicating a role for
ERα in homeostatic feeding [69, 70]. Previous studies
have mostly failed to find a connection between ERβ and
feeding behavior [69, 70]. In contrast, selective activation
of ERβ receptor was even shown to increase cocaine-
seeking behavior, an effect that was not seen after ERα
receptor stimulation, indicating that ERβ may affect
reward-related behavior [71]. Thus, ERβ was an unlikely
interaction target. Consistent with this idea, the selective
ERα-antagonist MPPd was sufficient to attenuate the ef-
fects of Ex4 on reward, in both males and females, indi-
cating that signaling via the ERα may be necessary for
Ex4 impact on food-reward behavior. Though it is im-
portant to note that while MPPd is classified as an ERα
antagonist and has been shown to antagonize estrogen-
regulated genes in vitro and attenuate estrous-related
decreases in food intake [72, 73], it has also been sug-
gested to have estrogen-like activity since it increased
uterine weight in rodents and reduced food intake in
OVX rats [73]. Our data do not eliminate the possible
involvement of ERβ, or other ER, such as GPR30. It is
also possible that other gonadal steroids may be behind
these differences. Testosterone, for example, regulates
insulin sensitivity [74, 75]. However, in contrast to ovari-
ectomy, orchiectomy decreases daily food intake and
body weight by decreasing meal frequency, an effect
which can be reversed by testosterone treatment [76, 77].
Potential effects of testosterone on Ex4 actions on food re-
ward are yet to be investigated. Importantly, substances
other than sex steroids may also be involved.
Although females have higher estrogen levels than
males, males also possess a certain level of circulating
estrogens due to the conversion of testosterone to estro-
gen, by the enzyme aromatase, in the reproductive tract,
bone, and adipose tissue [78]. Since premenopausal fe-
males have much higher levels of circulating estrogens,
the increased impact of Ex4 in females shown here may
result from these elevated levels of estrogens. However,
since estrogens can enhance the action of GLP-1 on
food intake in males [50] and blockade of ER signaling
reduces the impact of GLP-1R activation on food reward
in males, even low levels of estrogens in males may be
sufficient to increase the sensitivity to GLP-1. Moreover,
the estrogen synthesis enzyme aromatase is also present
in the brain, mainly in neurons in the hypothalamus and
limbic system [79]. In addition, the anorexigenic effects
of estradiol have previously been attributed to its actions
within the CNS as only central but not peripheral block-
ade with ICI increases food intake [38]. Thus, it is pos-
sible that the small amounts of estrogens synthesized by
the male brain are also sufficient to play an important
role in the reward effects of GLP-1. It is even possible
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that brain-synthesized estrogens may function as a po-
tential downstream mediator of GLP-1 effects, an idea
ripe for future studies.
The current study provides novel evidence for the
effects of the synthetic GLP-1R agonist Ex4 on food-
motivated behavior in females and its interaction with
central estrogen signaling, but it also has some limita-
tions. Here, for reasons described above, only central
Ex4 application was used in contrast to the peripheral
administration utilized during clinical treatment with
these agonists. However, both GLP-1 and Ex4 have been
shown to cross the blood-brain barrier [35, 80], and
feeding or reward impact of Ex4 is mediated by CNS
GLP-1R, indicating that GLP-1 agonists are likely to re-
sult in sex differences even after peripheral injection. In
addition, the potential food-reward suppressing effects
of endogenously produced GLP-1 may differ from those
found here for Ex4; thus, the results here are more
directly relevant to the clinically used GLP-1 analog, and
the relevance to endogenous GLP-1 should be a topic
for future investigation.
Conclusions
These data indicate that there are sex differences in the
sensitivity to the food reward effects of Ex4. Moreover,
signaling through the ERα is essential for the reward-
reducing impact of Ex4. Synthetic GLP-1 analogs are
widely used in the clinic as a treatment for type-2
diabetes, and one was also recently approved as a
supplement for weight-management [81]. Although
these drugs are prescribed to individuals of both sexes,
preclinical studies have almost exclusively been done in
male subjects, a concern which is present throughout
many scientific fields. Moreover, these drugs have the
ability to cross the blood-brain barrier and exert the ef-
fects evaluated here through their actions on the CNS.
Data presented here may indicate a higher sensitivity to
these substances in women. If our findings will be repli-
cated in a future clinical study, then physicians prescrib-
ing this medication may need to consider establishing
alternative doses for female patients taking these drugs.
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Lateral hypothalamic GLP-1 receptors are critical for the
control of food reinforcement, ingestive behavior and
body weight
L López-Ferreras1, JE Richard1, EE Noble2, K Eerola1, RH Anderberg1, K Olandersson1, L Taing1, SE Kanoski2, MR Hayes3 and
KP Skibicka1,4
Increased motivation for highly rewarding food is a major contributing factor to obesity. Most of the literature focuses on the
mesolimbic nuclei as the core of reward behavior regulation. However, the lateral hypothalamus (LH) is also a key reward-control
locus in the brain. Here we hypothesize that manipulating glucagon-like peptide-1 receptor (GLP-1R) activity selectively in the LH
can profoundly affect food reward behavior, ultimately leading to obesity. Progressive ratio operant responding for sucrose was
examined in male and female rats, following GLP-1R activation and pharmacological or genetic GLP-1R blockade in the LH.
Ingestive behavior and metabolic parameters, as well as molecular and efferent targets, of the LH GLP-1R activation were also
evaluated. Food motivation was reduced by activation of LH GLP-1R. Conversely, acute pharmacological blockade of LH GLP-1R
increased food motivation but only in male rats. GLP-1R activation also induced a robust reduction in food intake and body weight.
Chronic knockdown of LH GLP-1R induced by intraparenchymal delivery of an adeno-associated virus-short hairpin RNA construct
was sufficient to markedly and persistently elevate ingestive behavior and body weight and ultimately resulted in a doubling of fat
mass in males and females. Interestingly, increased food reinforcement was again found only in males. Our data identify the LH
GLP-1R as an indispensable element of normal food reinforcement, food intake and body weight regulation. These findings also
show, for we believe the first time, that brain GLP-1R manipulation can result in a robust and chronic body weight gain. The broader
implications of these findings are that the LH differs between females and males in its ability to control motivated and ingestive
behaviors.
Molecular Psychiatry (2018) 23, 1157–1168; doi:10.1038/mp.2017.187; published online 12 September 2017
INTRODUCTION
Obesity and associated metabolic diseases are continuing to
increase worldwide while safe and effective obesity treatments
remain elusive. As food intake and body weight are controlled by
the central nervous system (CNS), understanding the complex CNS
mechanisms that regulate energy homeostasis is essential for the
discovery of successful antiobesity therapeutics.
The lateral hypothalamus (LH) is historically known as a critical
‘feeding center’ and a powerful coordinator of the drive to eat,
drink and move. The key role of this nucleus in feeding control is
illustrated perhaps most robustly by a profound aphagia induced
by bilateral lesions of the LH.1–4 Conversely, stimulation of the LH
induces eating, even in satiated rats.5 This nucleus is also
suggested to be the interface between the homeostatic and
hedonic control of feeding behavior. Rats will eagerly press a lever
to stimulate their LH, suggesting that LH activation itself is
rewarding.6–8
Food can be a very potent rewarding stimulus. Food consump-
tion and reward are controlled by partly divergent and partly
overlapping brain nuclei: areas that respond to hormonal and
metabolic signals that are derived from the periphery and
elsewhere in the brain.9,10 The mesolimbic neurocircuitry,
especially the ventral tegmental area (VTA) and its dopaminergic
projections to the nucleus accumbens (NAc), have garnered much
of the attention on neural control of food reward.11–13 However,
the LH is in fact the most potent self-stimulation center in the
brain, and given that hungry/food-restricted rats self-stimulate
even more than fed rats, an interaction between the metabolic
status and reward may require processing by this brain
nucleus,7,14 although it is also possible that stimulation of the
median forebrain bundle, which connects the VTA to the NAc and
runs through the LH, may contribute to the reinforcing effects of
the intracranial self-stimulation studies.15 The LH is innervated by
the hindbrain glucagon-like peptide-1 (GLP-1) neurons and GLP-1
receptors (GLP-1R) are expressed in the LH.16 A potential reward
impact of this communication is largely unexplored.
GLP-1 is an anorexigenic peptide that is produced both in the
peripheral L-cells of the gastrointestinal tract and in the brain,
primarily by neurons located in the nucleus of the solitary tract
(NTS).16 These neurons project to widespread, but discrete,
GLP-1R-expressing brain areas.16 Analogs of GLP-1 are currently
approved for treatment of type 2 diabetes and obesity.17
Administration of GLP-1 or the GLP-1R agonist, exendin-4 (Ex4),
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into the CNS reduces food intake and body weight, actions
historically attributed to the hypothalamic and brainstem GLP-1R-
expressing targets.18–21 More recently, central GLP-1 signaling has
been linked to food (see Kanoski et al.21 and Skibicka22 for
reviews) and drug reinforcement.23–25 Despite the reliable and
potent inhibitory effects of pharmacological activation of GLP-1R
on feeding and body weight—paradoxically, pharmacological
blockade of central GLP-1R, and especially knockout studies of
whole-body or neuronal GLP-1R, produce only minor changes in
feeding or body weight.26–28 Collectively, this phenomenon has
led to an ever-increasing view that GLP-1R is only sufficient, but
not critical, for body weight control. Here, utilizing a knockdown
model of LH GLP-1R, we wanted to challenge that view and
propose that central, and specifically LH, GLP-1R activation is
indispensable to control of ingestive and food reward behaviors
and ultimately body fat mass. We further wanted to examine
behavioral, molecular and efferent targets of LH GLP-1R activation.
Moreover, conceivable sex differences, as well as potential sources
of differential female responses, including estrous cycle, were
assessed.
MATERIALS AND METHODS
Animals
Male and female Sprague-Dawley rats (5 weeks of age at arrival, Charles
River, Sulzfeld, Germany) were housed in a 12-h light/dark cycle (light on at
0700 hours) in individual cages with ad libitum access to chow (Teklad
Global 16% Protein Rodent Diet (2016), Envigo, Huntingdon, UK) and
water, unless otherwise stated. All studies were carried out with ethical
permissions from the Animal Welfare Committee of the University of
Gothenburg, in accordance with legal requirements of the European
Community (Decree 86/609/EEC). All efforts were made to minimize
suffering.
Drugs
Ex4 and the GLP-1R antagonist exendin-9 (Ex9) were purchased from Tocris
(Bristol, UK), dissolved in artificial cerebrospinal fluid (Tocris; used as
vehicle) and stored as aliquots at − 20 °C.
Brain cannulation
Guide cannulas were implanted into the LH as previously described29 (for
details, see Supplementary Information). With the chosen coordinates, our
manipulations/injections consistently reached the central, lateral and
dorsal LH. Injections may have also reached the zona incerta; however,
unlike the LH, this area does not express GLP-1R16 (Supplementary
Figure S1).
Operant conditioning
The operant conditioning procedure is used to assess the motivation to
obtain a reward, in this case food reward in the form of a sucrose pellet
(45 mg TestDiet, Richmond, IN, USA). Training and testing were conducted
as described previously30,31 and in Supplementary Information. All operant
response testing was performed under the progressive ratio (PR) schedule.
Effects of pharmacological LH GLP-1R activation or blockade on
food intake, body weight, locomotor activity and food-motivated
behavior
To test the effects of GLP-1R activation, 11-week-old rats were injected
with Ex4 (0.05 or 0.15 μg) or vehicle (artificial cerebrospinal fluid), and
operant conditioning response was tested 20 min after injection.
Additionally impact of the estrous cycle on LH GLP-1R activation was
evaluated in a separate group of 8-week-old females (see Supplementary
Information). For experiments examining the effect of GLP-1R blockade,
11-week-old rats were first fasted overnight, then given a chow meal for
20 min and injected with Ex9 (10 μg) immediately after the meal. This
design was modified from Hayes et al.32 and used to elicit endogenous
GLP-1 release to a controlled meal. Rats were tested in the operant
conditioning task 10 min after injection. Food seeking was assessed as the
number of head pokes into the feeding chamber during the 60 min
operant session. Chow intake was measured 1 and 24 h after the operant
testing sessions. Each treatment was counterbalanced where each
condition was separated by a 4-day period. Locomotor activity
was measured using horizontal infrared beams in the operant chambers
(Med-Associates, Georgia, VT, USA).
GLP-1R knockdown
To knockdown the expression of the GLP-1R in the LH, a short hairpin RNA
(shRNA) targeting GLP-1R transcripts was used (for details, see Schimdt
et al.24). Preliminary in vitro studies demonstrated ~ 88% knockdown of
GLP-1R expression in a rat neuronal cell line transfected with this shRNA.24
To knockdown GLP-1R expression in vivo, this shRNA sequence was cloned
and packaged into an adeno-associated virus (AAV) (serotype 1; titer =
5.22e12) in collaboration with the Viral Core at the University of
Pennsylvania. This construct was previously shown to reduce GLP-1R
expression in vivo in the rat VTA by 50%.24 A green fluorescent protein
(GFP)-expressing AAV (titer = 5.0e12) was used as a control.
To determine the functional significance of endogenous GLP-1R
signaling in the LH, rats were surgically implanted with LH-directed guide
cannulae as described above. Once rats achieved stable sucrose-motivated
behavior on PR (at 9 weeks of age), AAV-expressing GFP (AAV-GFP) or the
GLP-1R shRNA (AAV-GLP-1R-shRNA) was infused bilaterally into the LH
(0.5 μl per hemisphere during 5 min). Microinjectors were left in place for
10 min after infusion to allow for diffusion away from the injection site.
Rats chosen for each treatment group were matched for body weight, food
intake and food reinforcement parameters on PR.
Body weight and food intake were measured daily after AAV construct
infusion, except for days where fasting or food restriction was applied.
Motivation to self-administer sucrose was assessed using a PR schedule 3,
7 and 10 days after AAV injections. On day 7, rats were food restricted
overnight to determine whether the contribution of LH GLP-1R signaling to
food-motivated behavior is altered by fasting.
Three weeks after viral injections, two experiments were performed that
required food restriction: fasting blood glucose measurements and
subsequent oral glucose tolerance test (intraperitoneal glucose tolerance
test; for details, see Supplementary Information), and a fasting/refeeding
experiment.
Four weeks after AAV injection, adipose tissue was weighed and the
brains were collected. Brains were dissected and the LH, NAc and NTS were
collected to assess GLP-1R expression using quantitative real-time PCR (for
details, see Supplementary Information). An LH-containing coronal section
(10 μm) was collected from each brain to verify correct placement of AAV
injections by visualizing GFP fluorescence (see Figure 4 for a representative
placement).
A second smaller group of rats (n=20, 10 males and 10 females, 13-
week old) was included after the first study to determine whether there are
sex differences in the effects of LH GLP-1R knockdown and to follow food
intake and body weight daily without the interruptions for testing that
required overnight restriction carried out in the first group of rats. In
addition, another group of female rats (n= 16) was tested to further
evaluate the necessity of LH GLP-1R in younger females whose body
weight gain is more rapid compared with the 13-week-old females; these
rats were 9 weeks at the time of AAV-shRNA infusion.
Viral tract tracing and in situ hybridization
Injections of cholera toxin subunit B and in situ hybridization were
performed as previously described.33 For detailed methods, see
Supplementary Information.
Impact of Ex4 or feeding on LH gene expression
Hypothalamic neuronal cells, immortalized from four 8-week-old male
mice were used to evaluate the impact of GLP-1R activation on LH
neuropeptides in neurons. In order to determine whether the genes found
to be altered in the immortalized hypothalamic cell line were also
expressed in the LH in vivo and altered by ingestion of fat, chow or sucrose,
rats were exposed to respective diets for 1 h per day for 1 week on an
every other day schedule. Brains were collected, and the LH was dissected
immediately after the last feeding session. Gene expression was then
analyzed (see Supplementary Information and Supplementary Table for
details). In each feeding group, there was one animal that ate o0.5 g of
food; these rats were eliminated from final gene analysis.
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Figure 1. Behavioral, molecular and neuroanatomical consequences of glucagon-like peptide-1 receptor (GLP-1R) activation in the lateral
hypothalamus (LH) in male rats. Activation of GLP-1R in the LH reduces food reinforcement and food intake. Intra-LH GLP-1 analogue,
exendin-4 (Ex4), microinjection reduced the amount of sucrose rewards earned (a) and the number of lever presses for the rewards (b) in a
progressive ratio schedule, without changing activity at the inactive lever (c) in male rats. Food ingestion is also affected, as illustrated by a
potent reduction in 1 (d) and 24 h (e) chow intake. Data are expressed as mean± s.e.m. n= 14–15 (male rats). Moreover, GLP-1R-expressing LH
neurons were found to project to the mesolimbic ventral tegmental area (VTA), a likely neuroanatomical target area for reinforcement control
exerted by LH GLP-1R. Representative images showing GLP-1R on LH neurons that project to the VTA. Cholera toxin subunit B (CTB)
conjugated to AlexaFluor 488 was injected into the VTA (f, g). Back-labeled cells were present in the rostral LH region dorsal to the fornix (h)
where the majority of the LH GLP-1R-containing neurons are localized. Images of GLP-1R in situ hybridization (red; i), back-labeled CTB-positive
neurons from the VTA (green; j) and 4,6-diamidino-2-phenylindole (DAPI) nuclear counterstain (blue; k) at × 20 magnification. A merged image
showing co-localization of GLP-1R and CTB in the LH (white arrows; l) and a confocal image taken at × 40 magnification of a double-labeled
GLP-1R and CTB-positive neuron with DAPI counterstain (m). Intra-LH Ex4 infusion produced a marked increase in anorexic interleukins 1 (IL1)
and 6 (IL6) and also reduced orexigenic LH neuropeptide expression (melanin-concentrated hormone (MCH)) in male rats (n). n= 14–22 (male
rats). GLP-1R activation with Ex4 increased IL6 expression (o) in hypothalamic neuronal cell culture. In order to determine whether
endogenous GLP-1 release also leads to similar changes within the LH, three groups of rats were allowed to eat chow, sugar or lard for 1 h.
Lard meal did not alter any of the genes measured; however, a consumption of sucrose water increased LH IL6 expression (p). Data were
normalized to the housekeeping gene beta-actin and are expressed as mean± s.e.m.. n= 7–9 (male rats). ARC: arcuate nucleus of the
hypothalamus; DMH: dorsomedial hypothalamus; VMH: ventromedial hypothalamus; NT: neurotensin; ORX: orexin; IL6R: IL6 receptor; Cart:
cocaine- and amphetamine-related peptide. *Po0.05, **Po0.01,***Po0.001, ****Po0.0001 compared with vehicle (artificial cerebrospinal
fluid).
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Statistical analysis
All the data are presented as mean± s.e.m. Statistical significance was
analyzed using t-test or one- or two- way analysis of variance with Holm–
Sidak’s multiple comparison tests, when appropriate (GraphPad Software,
San Diego, CA, USA). P-values o0.05 were considered statistically significant.
Further information on methods is available in Supplementary
Information.
RESULTS
Acute LH-targeted GLP-1R activation is sufficient to reduce food
reinforcement and ingestive behavior and affect LH neuropeptide
expression
Intra-LH Ex4 microinjection induced a robust reduction in food-
motivated behavior, as indicated by the reduced number of
sucrose rewards earned (F(2,26) = 12.59; P= 0.0001; Figure 1a) and
reduced number of lever presses emitted for the sucrose rewards
(F(2,26) = 8.727; P= 0.0013; Figure 1b), without changes in inactive
lever pressing (F(2,26) = 0.7931; P= 0.4631; Figure 1c) in male rats.
Notably, in situ hybridization combined with viral tract tracing
analyses revealed GLP-1R mRNA in ~ 55.3% of LH cells that project
to the VTA, a region that has a well-established role in mediating
food reward11–13 (Figures 1f–m). The suppression of food intake
was also very potent (F(2,26) = 11.10; Po0.0005; Figure 1d), with
Ex4-injected rats consuming only 15% of the amount they ate
while injected with vehicle. At 24 h, food intake (F(2,26) = 14.49;
Po0.0001; Figure 1e) and body weight were still significantly
suppressed (Supplementary Figure S2A) by intra-LH Ex4. Both the
0.05 and 0.15 μg doses significantly suppressed reinforcement,
intake and body weight relative to intra-LH vehicle injection.
In order to determine which of the LH food and reward-
regulating neurochemicals are affected by LH-targeted GLP-1R
activation, Ex4 was microinjected into the LH of male rats, and
gene expression of candidate genes was measured. Marked, 10-
fold induction of anorexic interleukins 1 (IL1) and 6 (IL6) was
found, along with a reduction in melanin-concentrating hormone
(MCH) (Figure 1n). Both ILs were previously shown to mediate
anorexic and weight loss effects of GLP-1 analogs.34 We further
showed that Ex4 induces IL6 in a hypothalamic neuronal cell
culture, indicating that LH neurons could be one potential source
of the Ex4-induced ILs (Figure 1o). Interestingly, we found that
consumption of a sucrose solution, but not lard or chow meal,
leads to LH IL6 induction (Figure 1p).
The same treatment produced a slightly less potent reinforce-
ment and intake suppression in female rats, with the amount of
sucrose rewards earned suppressed only by the higher Ex4 dose (F
(2,74) = 2.81; P=0.06; Figure 2a). Active lever pressing did not reach
significance (F(2,74) = 2.72; P=0.07; Figure 2b). One hour chow intake
was also suppressed by the higher dose of Ex4 (F(2,76) = 15.43;
P=0.07; Figure 2d), yet 24 h chow intake was reduced by both
doses (F(2,76) = 29.51; Po0.0001; Figure 2e). Changes in 24 h weight
gained were detected only for the higher dose (Supplementary
Figure S2B). To test whether the estrous cycle stage affects
behavioral impact of intra-LH Ex4 treatment, females were tested
specifically in the estrus and metestrus/diestrus phases with the
higher dose of Ex4 (0.15 μg), which was earlier found to be effective
in females. Females in the estrus phase but not in metestrus/
diestrus responded with reduced food reinforcement to the LH
GLP-1R activation (rewards earned: t19 = 2.7, Po0.05; active lever:
t19 = 2.3, Po0.05; Figures 2f–i). Although 1 and 24 h chow intake
were reduced by the drug in all phases (Figures 2n and p), the drug
effect was more potent in females in the estrus phase (1 h: t19= 2.2,
Po0.05; 24 h: t19 = 2.5, Po0.05; Figures 2o and q). The effect size
seen was similar between males and females in estrus, yet
significantly different when males and females in metestrus/
diestrus were compared (Supplementary Figure S5). This cycle-
dictated divergent behavioral impact of Ex4 was mirrored by Ex4-
induced molecular changes in the LH, where a marked induction of
anorexic IL1 and IL6 and conversely a reduction of the orexigenic
neuropeptide, orexin, was found only in the estrus-phase females
(Figure 2r). Reduction of MCH was the only drug-induced change
detected in all phases of the cycle. In metestrus/diestrus, females
show no changes in ILs compared with the 10-fold induction of
each IL1 and IL6 in males (Supplementary Figure S6A). Molecular
changes in the LH are similar between males and females in estrus,
though males still display a more potent IL induction
(Supplementary Figure S6B).
Acute LH-targeted GLP-1R blockade is sufficient to increase food
reinforcement but not intake in male rats
Acute pharmacological blockade of LH GLP-1R by bilateral
microinjection of Ex9 led to increased food rewards earned
(t9 = 2.739, Po0.05, t13= 1.21, P=0.701, t22 = 2.16, Po0.05 for
males, females, and percentage of vehicle comparison between
males and females, respectively), lever presses for sucrose (t9 = 3.59,
P=0.005, t13= 1.344, P=0.201, t22 = 2.44, Po0.05) and food-seeking
behavior (t9 = 2.66, Po0.05, t13= 0.756, P=0.463, t22 = 1.85, P=0.07)
in male but not in female rats (Figures 3a–h) without changes in
horizontal activity (Figures 3m and n). This treatment was, however,
not sufficient to increase 1 h (t9 = 0.96, P=0.36, t13= 0.903, P=0.383,
t22= 0.52, P=0.61) or 24 h food intake (t7 = 0.91, P=0.39, t13= 1.054,
P=0.311, t20= 0.01, P=0.98) (Figures 3i–l). As previous experiments
indicated that LH GLP-1R activation in females is only effective in
the estrus phase, an additional group of rats was tested only in the
estrus phase. However, even here female rats failed to increase food
reinforcement or intake after bilateral LH microinjections of Ex9
(Supplementary Figure S7).
Chronic LH-targeted GLP-1R silencing leads to increased weight
gain, food intake and food reinforcement
To determine whether endogenous GLP-1R signaling in the LH is
necessary for control of body weight, food intake and motivation
Figure 2. Behavioral and molecular consequences of glucagon-like peptide-1 receptor (GLP-1R) activation in the lateral hypothalamus (LH), as
well as their interactions with the estrous cycle, in female rats. In females only the higher dose of exendin-4 (Ex4) reduced the amount of
sucrose rewards earned (a) and resulted in a trend to reduce the number of lever presses for the rewards (b) in a progressive ratio schedule,
without changing activity at the inactive lever (c). Food ingestion was also affected in female rats but only by the higher dose of Ex4, as
illustrated by a reduction in 1 (d) and 24 h (e) chow intake (n= 9–37). LH GLP-1R activation in females has divergent behavioral and molecular
impact in different estrus cycle phases. Intra-LH Ex4 reduced the effort to obtain a reward (f–i) in a sucrose-motivated progressive ratio task in
females in the estrus phase (E) but not metestrus or diestrus (MD) phase of their cycle. Performance on the inactive lever or locomotor activity
during the task was not altered by Ex4 in any of the cycle phases (j–m). Although Ex4 potently reduced ingestive behavior in all females
irrespective of the cycle phase, the reduction was enhanced for females in E (n–q). Data are expressed as mean± s.e.m. For each measured
parameter, raw values and values calculated as the percentage of vehicle response are presented in order to minimize the impact of baseline
differences across the two cycle groups. n= 10–11. Behavioral differences were mirrored by similarly divergent gene expression changes
induced by intra-LH Ex4 application, where a potent induction of interleukins was only detected in females in E, and a reduction in orexin or
neurotensin expression was only present in E (r). A reduced expression of melanin-concentrating hormone (MCH) was the only mRNA change
preserved in MD phases. Data were normalized to the housekeeping gene beta-actin and are expressed as mean± s.e.m. n= 19: vehicle in E,
n= 20: Ex4 in E, n= 8: vehicle in MD, n= 8: Ex4 in MD. *Po0.05, **Po0.01,***Po0.001, ****Po0.0001.
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for food reinforcement, AAV-GFP or AAV-GLP-1R-shRNA were
administered bilaterally directly into the LH. This resulted in
approximately 50% and 80% reduction (males/younger females
and older females, respectively) in the GLP-1R transcript
expression in rats infected with AAV-GLP-1R-shRNA when
compared with controls (Figure 4n, Supplementary Figures S8A
and B). This treatment was sufficient to disturb normal body
weight and food intake regulation in 9-week-old male rats, as
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AAV-GLP-1R-shRNA rats gained significantly more weight (F
(23,644) = 10.69; Po0.0001, two-way repeated-measures analysis
of variance) and ate more chow than control rats (F(18,435) = 4.583;
Po0.0001) (Figures 4a and b). Elevated food intake and weight
gain were detected in the third week after the treatment and the
differences persisted until the termination of the study at 4 weeks.
At that point, the weight of both fat pads measured, gonadal and
inguinal white adipose tissue (GWAT: t27 = 2.86, Po0.01 and IWAT:
t27 = 2.93, Po0.01), was also significantly higher (Figure 4d). LH
GLP-1R knockdown also resulted in a much higher food intake and
weight gain upon refeeding (1 h: t27 = 3.62, Po0.01; 24 h:
t27 = 3.49, Po0.01; weight: t27 = 3.07, Po0.01; Figure 4e), and a
slightly higher blood glucose level during an intraperitoneal
glucose tolerance test (area under the curve t33 = 1.82, P= 0.07;
Figure 4c).
Knockdown of GLP-1R in the LH significantly increased food
reinforcement in ad libitum-fed male rats, as indicated by
increased number of rewards earned and more lever presses
emitted during the PR operant test by rats infused with intra-LH
AAV-GLP-1R-shRNA compared with AAV-GFP controls (Figures 4f
and g), with the rates of pressing the active lever nearly doubling
on both testing occasions. Food seeking was also potently
elevated by the treatment (Figure 4h). These changes were not
associated with nonspecific changes in locomotor activity
(Figure 4i). An identical pattern of effects was detected in fasted
rats (Figures 4j–m).
When comparing males and females, in the second experi-
mental group, a significant increase in food intake was detected in
male rats already by the end of the second week (cumulative
intake: F(20, 160) = 9.95 Po0.0001; non-cumulative intake:
F(21,168) = 4.48 Po0.0001; Figures 5a and d), and body weight
gain reached significance 1 week after the onset of hyperphagia
(F(22,176) = 7.57 Po0.0001; at day 19, Figure 5g). Interestingly,
females did not show a consistent hyperphagia or weight gain
(Figures 5b, e and h). The weight of the adipose tissue depots,
examined 3 weeks after initiation of the knockdown of GLP-1R in
the LH, doubled in males (GWAT: t7 = 2.2, Po0.05 and IWAT:
t7 = 2.6, Po0.05, Figure 5j), but remained unchanged in females
(GWAT: t7 = 0.4, P= 0.34 and IWAT: t7 = 0.6, P= 0.3, Figure 5k).
Despite the large increase in fat mass and food intake, fasting
blood glucose (t7 = 0.3, P= 0.4) levels remained unchanged in male
rats. Likewise, female fasting blood glucose levels were unaltered
(t6 = 1.6, P= 0.08; Figure 5m). In stark contrast to males, females
did not show any changes in food-motivated or food-seeking
behaviors (Supplementary Figure S9). Both males and females
were adult (13 weeks of age) at the time of AAV infusion, and
while males continued to gain weight during the entire 3-week
period postinfusion, females at this age reached a weight plateau
after the first 2 weeks of the study. To test whether the tapering
growth rate in females is masking a potential impact of the GLP-1R
knockdown, younger females (week 9, young adult) were tested.
Surprisingly, these females displayed a drastically different
response from the older females, where food intake (cumulative:
F(27,378) = 15.18, Po0.0001, non-cumulative: F(25,350) = 3.244,
Po0.0001, Figures 5c and f) and body weight (F(26,364) = 18.26,
Po0.0001, Figure 5i) were massively impacted by the GLP-1R loss
in the LH. The striking weight gain was likely due to fat gain, as at
the end of the study the adipose tissue of these females nearly
tripled (GWAT: t13 = 5.9, Po0.0001 and IWAT: t14 = 4.7, Po0.001,
Figure 5l). Despite the profound impact of the LH GLP-1R
knockdown on chow intake and adipose mass gain, we
surprisingly found no effect on food reinforcement
(Supplementary Figure S10). In an effort to not miss a potential
late-developing effect in these young females or an effect only
evident in the estrus phase, we additionally tested both
parameters during week 4 and still found no effect
(Supplementary Figure S10) of the LH GLP-1R knockdown on
food motivation. Based on baseline daily feed efficiency
calculations, we did not find any energy expenditure disturbances
in either sex (Supplementary Figures S11A–C); however, we did
find trends or a significant increase in feed efficiency after an
overnight fast and upon re-feeding (Supplementary Figures S11D–
F), indicating that LH GLP-1R may be necessary for energy
expenditure regulation in some physiological contexts.
To test whether the reduction in GLP-1R in the LH elicits
potentially adaptive counter-regulatory responses within the
central GLP-1 system, GLP-1R expression was measured in the
NAc (core and shell included), where GLP-1 also exerts food
reinforcement-suppressing effects.31,35 GLP-1R expression was
increased more than twofold in the NAc of male rats in response
to LH GLP-1R loss. Interestingly, this compensatory effect was not
seen in any of the female groups (Figure 5o). This counter-
regulation seems site-selective, as, for example, the NTS GLP-1R
remained unaltered (Figure 5p). Finally, we also tested whether
the hindbrain preproglucagon gene, a precursor of GLP-1, was
altered in all GLP-1R knockdown groups irrespective of altered
physiology or behavior. We found that expression of this gene was
increased (Figure 5n), consistent with the brain GLP-1 system
attempting to compensate for the loss of the LH node, indicating
an interesting, and previously unexplored, capacity for adaptive
compensatory plasticity within the brain GLP-1 system.
DISCUSSION
Although much is known about distinct populations of LH
neurons, the metabolically relevant inputs to the LH are less
clear. Here we show that the LH is a key brain area that mediates
weight loss and the reward inhibitory effects of exogenous GLP-1R
activation. Importantly, our data also demonstrate that the LH is a
crucial site for motivated and ingestive behavior suppression
driven by endogenously released GLP-1. With these results, LH
emerges as one of the most important sites to date for
endogenous GLP-1R activation, especially considering the size
and robustness of the hyperphagia, weight gain and hypermoti-
vation when GLP-1R in the LH are blocked and/or reduced.
Although local LH GLP-1R activation was sufficient to reduce
weight and reinforcement in both sexes, the effect of LH GLP-1R
blockade was sex divergent, with the LH-GLP-1R signaling found
to be crucial for motivated behavior control in males but
disposable in females. Thus the female and male LH differs in its
ability to control motivated behavior. The principal finding from
these studies is that GLP-1R in the LH is required for normal body
weight homeostasis and food reward control. This finding
contrasts with conclusions drawn from studies carried out on
GLP-1R knockout mice (for example, Finan et al.,26 Scrocchi et al.27
and Sisley et al.28), where little to no necessary contribution of CNS
GLP-1R was demonstrated. Thus LH emerges as one of the most
critical sites for the endogenous GLP-1 effect on energy balance
and reinforcement.
In the context of food reward, the present data suggest that
GLP-1, within the LH, inhibits motivation for palatable food. The
effect of exogenous local LH Ex4 microinjection was fairly potent
with a 30% reduction in the amount of effort the rats chose to
expend for food reward. The VTA may be one of the
neuroanatomical targets underlying this effect, as we found that
more than half of the LH GLP-1R-expressing neurons project to the
VTA. However, it is the impact of the endogenous GLP-1 in this
area that is most striking, as when the GLP-1 signal is reduced
acutely, male rats expend twice as much effort for the sucrose
reward, indicating the crucial role of the endogenous GLP-1 in
curbing food reward regulation in males. Compared with the LH, a
smaller contribution was recently found with acute pharmacolo-
gical blockade of GLP-1R in the dorsal part of the lateral septum36
and with GLP-1R knockdown in the NTS.37 In the ventral
hippocampus, GLP-1R knockdown increases operant responding
for food reward in non-restricted male rats (while not influencing
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Figure 3. Acute pharmacological blockade of lateral hypothalamus (LH) glucagon-like peptide-1 receptor (GLP-1R) increases food
reinforcement but not intake. Intra-LH microinjection of GLP-1R antagonist, Exendin 9 (Ex9; 10 μg) increased the amount of sucrose rewards
earned (a, b) and the number of lever presses for the rewards (c, d) in a progressive ratio schedule, without changing activity at the inactive
lever (e, f) in male rats. Similarly food-seeking (number of entries into a food dispenser) was significantly increased by this treatment in male
rats (g, h). None of these parameters were altered in female rats. Food ingestion measured as 1 (i, j) and 24 h (k, l) chow intake were
unaffected in either sex. Locomotor activity was also not significantly altered (m, n). Data are expressed as mean± s.e.m. n= 8–10 (male rats:
m) and n= 14 (female rats: f). *Po0.05, **Po0.01, #P= 0.07.
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chow intake).33 The impact of acute blockade of the GLP-1R in the
LH is further supported by the enhanced food motivation
detected after GLP-1R knockdown in the LH. It is of interest that
the potently elevated food motivation is detected in both ad
libitum-fed as well as food-restricted/re-fed male rats. This
suggests that the detected food reward deregulation
is robust and persists through different physiological/metabolic
states.
The most striking result of GLP-1R knockdown in the LH was the
persistent and potent hyperphagia: 450% increase in daily chow
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consumption was detected, starting 2 weeks after the knockdown.
This hyperphagia likely contributes to the massive increase in
body fat, where the amount of fat detected in both fat depots
examined (IWAT and GWAT) doubled in males and tripled in
younger females. This is perhaps the most potent collection of
effects on reward behavior and metabolism of a single nucleus
and one receptor-encoding gene change detected to date. These
data demonstrate the important contribution of the LH GLP-1R to
homeostatic physiology and behavior. Interestingly, whole-body,
or CNS-specific, GLP-1R knockout in a mouse did not result in
sizable change in body weight, fat mass or hyperphagia.26–28
There could be many reasons for this discrepancy; developmental
compensation or species difference (mouse vs rat) are two
possible explanations. Importantly, the combinations of generally
weak effects of the pharmacological blockade of the GLP-1R along
with little impact of the GLP-1R knockout led to a long-standing
conclusion that, while GLP-1R analogs are an attractive pharma-
ceutical treatment option, the endogenous GLP-1 system is not
necessary or critical for body weight and behavior regulation. Thus
current results contradict this view and show that CNS GLP-1R, at
least at the level of the LH, is necessary for normal body weight
maintenance. Of note, we found that, while acute stimulation of
GLP-1R in LH was highly effective at food intake and body weight
gain suppression, acute blockade was not sufficient to alter chow
intake or body weight. This may suggest that acutely other
GLP-1R-expressing sites are able to compensate for the loss of
GLP-1R signaling, compensation that proves insufficient when LH
GLP-1R is silenced in a chronic manner. Although our data also
indicate that, following chronic LH GLP-1R silencing, the brain
attempts to compensate for the reduced anorexic signal in the LH
by potently increasing GLP-1R expression in the NAc only in males
and preproglucagon in the NTS of both sexes. This is clearly not
sufficient to rescue the reward and metabolic phenotype in males,
although we can hypothesize that simultaneous GLP-1R knock-
down in both of these sites may produce an even more
pronounced reward phenotype in males. We did not find any
compensation in receptors from another GLP-1R-expressing
site,37–39 the NTS, in either sex or age.
Several studies revealed that peripheral hormones, ghrelin or
leptin, affect food intake through actions on the LH orexin or
neurotensin neurons.40–43 Leptin and GLP-1 are known to interact,
and both have been shown to reduce food intake, body fat, body
weight and food reward, although the impact of reduced GLP-1R
signaling in the LH observed in the current study is quite distinct
from that reported after LH leptin receptor knockdown.44 Leptin
receptor knockdown does not change food intake or weight in
chow-fed rats, and a high-fat challenge is necessary to bring out
the disturbed metabolic phenotype, which is transient. This
contrasts with the robust, and long-lasting, weight and intake
elevation found here after GLP-1R knockdown. Importantly, leptin
receptor knockdown did not yield changes in food-motivated
behavior, while potent and lasting upregulation of food motiva-
tion was found here after GLP-1R knockdown, at least in males.
Collectively, these data suggest that, while there may be some
overlap in the cellular and molecular targets of leptin and GLP-1 in
the LH, GLP-1 seems to stimulate a broader, at least functionally,
fraction of LH cells. Interestingly, the VTA proved to be the key
target site for food intake and reward effect of leptin.45–47 For
GLP-1, while many studies suggest that VTA GLP-1R are sufficient
to inhibit food intake and motivation,31,48 no data to date exist to
show that they are necessary for these behaviors.
A number of genetically and functionally distinct cell popula-
tions reside in the LH,49 although the neuropeptides or
neurotransmitters affected by GLP-1R activation remain unknown.
Acuna-Goycolea and van den Pol50 reported a possible link
between GLP-1 and the LH orexin neurons, where GLP-1
depolarizes orexin neurons and increases their spike frequency
ex vivo. In our study, LH GLP-1R activation reduced orexin
expression but only in females. Nevertheless, a more potent
molecular effect of LH GLP-1R activation was to increase IL1 and
IL6 in both males and females and also in a male-derived
hypothalamic cell line. These ILs are not only clearly anorexic and
weight reducing but are also already clearly indicated as
mediators of anorexic and weight-loss effects of GLP-1.34
Interestingly, our data also indicate that IL6 expression levels are
increased by food intake, as sucrose meal, but not fat or chow
meal, increased the levels of IL6 in the LH. Of note, the
hypothalamic cell line was derived from males, thus it is
possible, based on our in vivo results, that had this cell line
been derived from females a smaller IL6 induction would be
expected, as a 5-fold increase was found in the female LH
compared with a 10-fold increase in IL6 mRNA in male LH.
Expression of MCH, an orexigenic LH neuropeptide, was reduced
by LH GLP-1R activation in both males and females, which could
contribute to both the reinforcement and adiposity effects of LH
GLP-1R activation.
Sex differences were noted in response to GLP-1R activation but
especially in the response to GLP-1R blockade or silencing.
Females showed a similar but somewhat less potent feeding and
intake inhibition after LH-targeting Ex4 microinjections, results
consistent with LH GLP-1R expression which was 10-fold higher in
adult males compared with females, an age-dependent sex
difference. This is somewhat surprising as we have previously
shown that females show a more potent feeding and food
motivation inhibition after intracerebroventricular Ex4 injections.51
However, our more recent data indicate that the LH is not a neural
substrate mediating this enhanced reward response.29 In stark
contrast to the effects found in males, the LH does not seem to be
a critical site for GLP-1 control of motivated behavior in females, as
both the acute pharmacological and chronic genetic GLP-1R
inhibition in the LH did not alter food motivation in female rats.
Thus female brains may more readily compensate for the reduced
LH GLP-1 signal. The molecular signature of LH GLP-1R activation
was also partly sex divergent, with ILs and MCH affected in both
sexes, while reduced expression of orexin and neurotensin
detectable only in females, selectively in their estrus phase. In
Figure 4. Glucagon-like peptide-1 receptor (GLP-1R) in the lateral hypothalamus (LH) are necessary for normal body weight, food intake and
food reinforcement control. Decreased GLP-1R expression in the LH promoted weight gain (a) and hyperphagia (b), along with small
impairments in glucose tolerance (c). Knockdown of GLP-1R in the LH led to increased fat mass in gonadal and inguinal adipose tissues (GWAT
and IWAT, respectively; d). The hyperphagia and increased body weight gain persisted even after food deprivation/refeeding procedure (e).
Data are expressed as mean± s.e.m. n= 14–15 (male rats). Knockdown of GLP-1R in the LH resulted in an increased amount of sucrose rewards
earned (f) and increased number of lever presses for the rewards (g) in a progressive ratio schedule. In addition, food-seeking (number of
entries into a food dispenser) behavior was increased (h) without concurrent changes in locomotor activity (i). Similar potentiation of food
reinforcement and seeking behaviors was detected in highly motivated (fasted) rats (j–l), again without significant changes in locomotor
activity (m). Data are expressed as mean± s.e.m. n= 19–20 (9-week-old male rats). Four weeks after adeno-associated virus (AAV) construct
injections, GLP-1R expression was reduced by ~ 50% in the LH of rats treated with AAV-GLP-1R-shRNA (short hairpin RNA) compared with
controls (n). Coronal brain section depicting LH-targeted infusions of control and AAV-GLP-1R-shRNA (o). Nuclear stain, DAPI (4,6-diamidino-2-
phenylindole), is shown in blue. Panels (p and q) show green fluorescent protein-expressing cells in the LH. *Po0.05, **Po0.01,***Po0.001,
****Po0.0001; #Po0.1. DMH, dorsomedial hypothalamus; KD, knockdown; VMH, ventromedial hypothalamus.
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fact, the estrus phase had a surprisingly potent effect on both
molecular and behavioral outcomes of LH GLP-1R activation,
which were nearly completely attenuated in females in cycle
phases associated with low estrogen signaling.
Our data demonstrate that, contrary to previous findings,
GLP-1R in the brain, and specifically in the LH, are indispensable
for the regulation of body weight and body fat in males and
females. Likewise, they are essential to curb food reward behavior
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in males. Considering the robust and persistent changes obtained
with this single gene manipulation in the LH, this nucleus has a
tremendous potential to contribute both to the development of
obesity and possibly to identifying strategies to control
overeating.
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